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ABSTRACT 
A biomarker is a characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes or pharmacological responses to a 
therapeutic intervention. The aim of this project was to deal with the identification of 
potential biomarker candidates from experimental data comparing samples displaying 
divergent physiological traits. Chapter 1 introduces the topic and the aims of the project. The 
primary aim was to identify the ideal statistical analysis methods and data pre- and post-
treatment options to use for potential biomarker identification from proteomic datasets. The 
product of this work was a statistical analysis pipeline for identifying potential biomarker 
candidates from proteomic experimental data. Proteomic data often suffers from missing 
values, so methods to deal with these were also evaluated in this project. 
Chapter 2 outlines the data sets that were used as well as presenting an overview of the 
“Biomarker Hunter” pipeline software solution created in this project. Chapter 3 evaluates the 
appropriate univariate statistical methods to use for biomarker identification and the results of 
biomarker identification using these techniques. Chapter 4 evaluates options for data pre- and 
post-processing. Chapter 5 suggests the use of missing value imputation as well as offering a 
novel clustering algorithm to deal with missing values. The software pipeline also offers 
multivariate statistical methods, which are evaluated in Chapter 6. Chapter 7 provides some 
business context for both biomarker discovery and the statistical analysis software available 
for the purpose of proteomic biomarker discovery.  
As well as providing a software pipeline for the identification of biomarkers, the project 
aimed to identify a suggested strategy for statistical analysis of proteomic experimental data. 
Strong conclusions regarding the ideal statistical approach could only be made if the list of 
actual, validated biomarkers were available. Unfortunately this information was not available, 
but in the absence of this a strategy was suggested based on the available information from 
both the available literature and the author’s interpretation of the results from this study. In 
terms of data pre-processing, this strategy involved not averaging technical replicates, and 
using total abundance normalisation to reduce technical variation. A novel clustering 
algorithm was suggested to reduce the presence of missing values prior to existing methods 
of missing value imputation. Following statistical analysis multiple testing correction 
methods should be implemented to reduce the number of false positives. 
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1 Introduction and Background 
This chapter provides the background knowledge to allow the understanding of the constantly 
evolving field of biomarker discovery from proteomic experimental data. The chapter begins 
with an introductory overview of proteomics and biomarkers in drug discovery along with the 
advantages these areas of study bring to the pharmaceutical and health industries. As 
proteomics studies biological systems on a protein or peptide level an introduction to proteins 
and protein chemistry is also presented. Following this there is an introduction to the various 
techniques used in the fast moving area of proteomics. This includes a description of the 
analysis techniques currently used in this industry including both mass spectrometry and gel-
based technologies. Data from these techniques is subsequently analysed using statistical 
methods, so an introduction to statistics in biomarker discovery will be presented. Finally an 
overview of the original project aims discusses the nature of study that was conducted over 
the four year EngD period. 
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1.1 Introduction to Biomarker Discovery and Proteomics 
1.1.1 Biomarker Discovery 
The definition of a “biomarker” as agreed by the National Institute of Health (NIH) is “a 
characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes or pharmacological  responses to a therapeutic intervention” 
(Atkinson & Lesko, 2001).  
A biomarker may be a metabolite, protein or a feature on an image from gel-based 
techniques. Study in this field is focused on searching for these biological measures that are 
indicative of differences in biological state. The study of biomarkers is essential for a better 
understanding of biological systems, to allow the understanding of different biological 
processes through the identification of the biomarkers responsible for different states (e.g. 
diseases), and the discovery of biomarkers involvement in specific metabolic pathways, as 
well the subsequent identification of biomarker targets in drug and biomarker discovery 
(Stoughton & Friend, 2005). Biomarkers can be described as any biological parameter 
(genes, metabolites or proteins) which can be objectively measured, and can be used to 
indicate a particular biological (physiological or pathological) state (e.g. in drug discovery 
these would be substances which indicate diseased states or responses to therapeutic 
treatments).  
This study focuses more specifically on the discovery of medical biomarkers and the 
discovery of biomarkers which are indicative of the effect of a specific drug. It aims to 
revolutionise the diagnosis, treatment and prevention stages of diseases by potentially 
speeding up and controlling the drug discovery process. The main objective of biomarker 
discovery, for any diseases or disorders, is to facilitate the development of clinically viable 
biomarkers that can be used for diagnostic or prognostic applications. For this to be achieved 
these markers need to be clinically reliable and robust with a high diagnostic accuracy in a 
significant number of patients, irrespective of geographical barriers and other confounding 
factors (Pepe et al, 2001). 
In medical biomarker discovery these may be indicators for diagnosis, where the changes in 
abundance or chemical modification of proteins or peptides in samples (e.g. blood, urine, 
tissue) can be used to detect a diseased state. Alternatively they may be indicators of disease 
progression or in an ideal world an indicator of risk or susceptibility to a disease (e.g. the 
biomarker to recognise susceptibility to heart disease is cholesterol). 
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Researchers in drug discovery look for specific markers, or groups of markers, which fall into 
the following categories: 
 Diagnostic biomarkers: Identified to detect diseases, preferably at an earlier stage 
than existing techniques. 
 Prognostic biomarkers: Indicate how a disease may develop in a patient regardless of 
any treatments. 
 Predictive biomarkers: Predict the effectiveness of treatments within a patient. 
 Pharmacodynamic biomarker: Reveals the size, if any, of a biological response to a 
treatment. 
 Therapeutic biomarkers: Give information on possible new pathways for drug action. 
In drug discovery biomarkers may be substances which can be introduced into organisms to 
examine biological functions or health related phenomena. For example rubidium chloride 
has been used as a radioactive isotope for the evaluation of heart muscle perfusion (Karley et 
al, 2011). They can be used to help extract disease targets or pathways to validate drug 
activity mechanisms. In drug design biomarkers may indicate alterations in protein 
expression which are implicated in disease progress or disease susceptibility to administered 
treatments. 
Biomarker discovery is made possible due to advances in technology and better awareness of 
the human genome allowing more practical and affordable research. Most biological states 
and responses involve multiple proteins. Due to this it is essential to determine groups (or 
patterns) of biomarkers rather than individual biomarkers (Thayer, 2003). Detection of 
biomarkers can be summarised in the following series of steps which are all dependent on the 
previous step: 
1. Collection of relevant samples and experimental design. 
2. High throughput analysis of samples. 
3. Using computational and statistical methods to obtain useful biomarkers. 
Studies in this field are usually typified by small sample sizes, and subsequent verification is 
then conducted on a larger number of samples. To protect the study from methodological and 
analytical bias, different technologies should be used for the discovery and validation stages 
(Matta et al, 2008).  
There are a number of important hierarchical steps to be considered when demonstrating the 
clinical interest of a biomarker (Ray et al, 2010). These steps are: 
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1. Demonstrate that the biomarker is significantly modified in the diseased sample group 
compared to the control group. 
2. Asses the diagnostic properties of the biomarker. 
3. Comparing the diagnostic properties of the marker to existing tests available. 
4. Demonstrate that the diagnostic properties of the biomarker increase the physicians’ 
ability to make a decision. This can be tricky because the timing of diagnosis may be 
essential, but it may not be easy to identify. For example a particular treatment may 
be more accurate however other treatments may allow for earlier diagnosis. An 
example of this was seen when procalcitonin was suggested as a diagnostic biomarker 
for susceptibility to nose infections following cardiac surgery. Previously 
procalcitonin was determined to have a lower accuracy in the diagnosis of 
postoperative infection following cardiac surgery compared to the existing physicians 
approach so it was rejected. However later studies confirmed that the use of 
procalcitonin allowed for earlier diagnosis of infections (Jebali et al, 2007). 
5. Assess the usefulness of the biomarker, which needs to be distinguished to the quality 
of the diagnostic information provided. This involves both the characteristics of the 
test itself and the characteristics of the clinical context. Characteristics of the test may 
involve consideration of the cost, invasiveness, technical difficulties and speed. 
Characteristics of the clinical context include prevalence of the disease, consequences 
of outcome, cost and the consequences of therapeutic options.  
6. Demonstrate that measurement of the biomarkers affect the outcome. This is done 
using intervention studies, which are lacking for many novel biomarkers (Lokuge et 
al, 2010). 
 
1.1.1.1 The Capabilities of Biomarker Discovery 
The advantage of identifying a biomarker, or more likely a panel of biomarkers, is based on 
the premise that it will lead to the development of a sensitive and reliable assay that is easily 
readable. That ability, developed and validated in a platform, leads to the capability to 
develop an assay that is able to detect the biomarkers (i.e. proteins) at extremely low 
concentrations (Larner, 2008), To ensure long-term and widespread success the assay 
platform needs to be as non-invasive as possible. The ultimate goal, following the 
development of an assay kit, is to translate this assay into a user friendly, handheld point-of-
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care (POC) device which is able to monitor this panel of markers in body fluids such as blood 
or urine with minimal invasive procedures. 
There is an ongoing need to minimise the risk of serious adverse events following drug 
approval, as well as in clinical trials. The project sponsor is involved in the discovery of 
novel early stage biomarkers involved in diseases within model organisms such as rats or 
zebrafish embryos. These biomarkers are then subsequently translated to higher species such 
as humans and then validated. This leads to: 
 The earlier diagnosis of diseases in patients. 
 The monitoring of physiological responses in a systematic way. 
 The determination of the mechanisms which drugs use to deliver their effect. 
 The reduction in time and cost of the drug development process, due to the reduced 
cost and time of clinical trials (Higgs et al, 2005). 
 Decreased attrition rates within developmental candidates. This is because increased 
biological efficacy allows for lower doses which may lead to fewer drugs failing 
during testing stages due to associated toxicities (Thayer, 2003).  
 
1.1.1.2 The Challenges of Biomarker Discovery 
Despite recent developments there are relatively few novel biomarkers which have been 
translated to clinical uses. Although advances have been made in the field of proteomics, the 
discovery of biomarkers still remains one of the most challenging aspects and often further 
analysis is required to fully characterise the significant proteins and understand the 
phenotypic role of these potential biomarkers (Kreunin et al, 2007). These issues lie not only 
in technological advances but also in the discovery, translation and validation phases of using 
these markers to bring the drugs to patients. The lack of convincing biomarker experiments 
are not necessarily due to limitations with the technology but in the difficulty of elucidating 
useful clinical information from identified biomarkers (Listgarten & Emili, 2005). Reasons 
for this may include: 
 Cost and time dependent techniques make validation of biomarkers complex (Codrea 
et al, 2007). 
 Although a considerable amount of progress has been made in standardising the 
methodology and reporting of randomised trials, little has been accomplished 
concerning the assessment of diagnostic and prognostic biomarkers (Ray et al, 2010). 
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 Identification and modification of biomarkers in drug discovery does not guarantee 
increased survival in patients (Morgan, 2011). 
 There is a desperate need to have drastic advances in the current methods used for 
proteomic screening (Cho & Diamandis, 2011) especially with regards to biomarker 
identification using blood and urine as opposed to muscle (Listgarten & Emili, 2005). 
This allows for non-invasive diagnostic tests for diseases, as opposed to requiring 
tissue samples. 
 Muscle tissue is preferred as a base for biomarker research. However, this does not 
allow for a non-invasive test to be able to diagnose individuals suffering from earlier 
stages of the disease, predict possible associated risks, or detect patients who are not 
responding to the treatment (Etzioni et al, 2003). Hence currently drug discovery 
targets are focused on symptoms rather than the cause of the disease (Thayer, 2003). 
 Due to the immaturity of the field there are still no established benchmarks and 
standard methods (Sciclips, 2011). 
 When developing targeted therapies, not all drugs work on all patients and there is not 
much hope of therapies that can be universally effective (Thayer, 2003). 
 Blood samples contain large amounts of albumin and other high abundance proteins, 
which can screen low abundance proteins and may hinder the ability to identify those 
which may be relevant to the study. This has been addressed by using immuno-
affinity technologies such as cyclic abundant protein immunodepletion (CAPI) based 
on antibody technologies (APAF, 2006). 
 For biomarker studies to have an impact on the drug development process the time 
taken by the discovery and implementation should be short (i.e. less than 18 months) 
(Amir-Aslani & Mangematin, 2009). 
 As with all bioinformatics techniques, “garbage-in garbage-out” means that the results 
deduced from these methods are only as good as the samples used, regardless of how 
accurate the technology and statistical methods are. 
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1.1.2 Introduction to Proteins 
As stated before a biomarker can be any measurable biological medium indicative of 
physiological change. This study however is focused on protein biomarkers, in particular 
those that indicate a diseased state. The reason for the focus on proteomic study is because of 
the available types of biomarkers, proteins offer more promise because the proteome of an 
organism is far larger than, for example, the metabolome. This is particularly true if protein 
variants are considered. Proteins should therefore provide higher sensitivity than other types 
of markers. In the medical field, protein biomarkers are of great importance because it is 
relatively easier to produce diagnostic tests for a specific protein marker, which makes 
translation of the discovered markers easier to put into practice.  
This section gives an introduction to the area of protein science including the structure and 
formation of proteins, as well as an explanation of post translational modifications (PTMs). 
PTMs offer a plethora of candidates for biomarker detection that complement discoveries 
using strictly proteomic or genomic platforms (Krueger & Srivastava, 2006). Proteins are 
biochemical compounds which are comprised of one or more polypeptides. A polypeptide 
can be described as a linear chain of amino acids which are bonded together by peptide 
bonds. Protein chemistry is the area of science which relates to:  
 The obtaining and purifying of proteins 
 Investigation of protein structure and function  
 The controlling and engineering of proteins 
This area of research contributes in a number of industries in a wide variety of applications 
including clinical and pharmaceutical research.  One of the most ambitious experiments in 
protein chemistry is the study of how the structure of a protein affects its function. Much of 
the research in this field rely on physical measurements (usually spectroscopic) and/or 
chemical protocols (usually covalent modification). Physical measurements may also include 
diffraction, thermal or spectrometry methods as well as in-silico computer modelling. 
1.1.2.1 Structure of Proteins 
Proteins are large molecules, composed of one or more chains of amino acids, otherwise 
known as polypeptides. The primary sites of biological protein synthesis are ribosomes. 
Ribosomes are organelles existing in cells and are made up primarily from ribosomal 
ribonucleic acid (rRNA) and are essentially the building catalyst of proteins. They catalyse 
protein translation using the messenger ribonucleic acid (mRNA), in the nucleus, as a 
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template and subsequently form proteins from individual amino acids. Amino acids are 
linked to each other via amide bonds forming peptide chains (Figure 1). Folding of these 
peptides may occur when peptides are linked together via disulphide bridges as in Figure 2. 
Disulphide bonds play an important role in many facets of proteins. However disulphide 
bonds are not essential for protein folding and many cysteines cannot form disulphide bonds. 
Many proteins do not contain any disulphide bonds, as there are many non-covalent forces 
involved in the stabilisation of protein folds and the guiding of folding pathways. These non-
covalent forces include hydrogen bonding, ionic interactions, Van der Waals forces as well as 
hydrophobic packing. Generally extracellular proteins often have several disulphide bonds, as 
opposed to extracellular proteins which usually lack them (Beeby et al, 2005). 
The orders in which these amino acids are linked determine the eventual shape and function 
of the protein. The sequence of amino acids in a protein is defined by the sequence of a gene, 
which is programmed in the genetic code. Once formed these proteins automatically fold into 
their predetermined shape. Proteins may also form stable protein complexes with other 
proteins, in order to work together and achieve particular functions. 
 
 
Figure 1 - The formation of a peptide chain by linking amino acids using amide bonds. 
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Figure 2 – The formation of a disulphide bridge between cysteines. 
Proteins consist of a number of amino acids, linked in a linear sequence. Figure 3 shows the 
chemical structure of an amino acid. It consists of a carbon atom with four bonds. Three of 
these bonds are identical in all proteins, i.e. the hydrogen (H) atom, the amino group (NH
2
), 
and carboxylic acid (CO
2
H). When multiple amino acids combine to make a polypeptide 
chain, the peptide bonds are formed between amino group and the carboxylic group of 
adjacent amino acid residues. The fourth bond is referred to as the side chain, and essentially 
determines the structure and specific properties (e.g. hydrophobicity, size, aromaticity, 
charge, etc) of the amino acid. This group will determine the interactions between the atoms 
and molecules. However proteins are not just made up of amino acids, as water, metal ions, 
carbohydrates, lipids, phorphyrin rings and cofactors must also be considered. 
 
Figure 3 - The basic structure of an amino acid. 
There are 20 different side chains, hence 20 different amino acids from which proteins can be 
made. Each of these are represented by either a single letter or a three letter abbreviation (e.g. 
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Alanine can be denoted as either A or Ala). The overall structure of the protein is defined by 
the constituent amino acids as well as the peptide bonds and disulphide bridges, which 
connect the amino acids together. The primary structure of a protein is simply the linear 
sequence of amino acids in a polypeptide chain as shown in Figure 4. Proteins however carry 
out their functions in the body by three-dimensional (3D) tertiary and quaternary interactions 
between different substrates. The tertiary structure of a protein determines its eventual 
function in the cell. The structures arise when particular amino acids in a chain fold in order 
to create domains with specific structures. These domains may either be used as modules for 
larger structures or provide specific catalytic or binding sites. 
 
 
Figure 4 - The structure of proteins (Branden & Tooze, 1991).  
 
1.1.2.2 Formation of Proteins 
The overall formation of proteins from DNA (Deoxyribonucleic acid), situated in the nucleus, 
can be outlined as the transcription of DNA to RNA, followed by translation of this RNA 
(Ribonucleic acid) into the relevant protein (Figure 5).  
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Figure 5 - An outline of the process of protein formation following transcription of DNA 
into RNA and subsequent translation (www.nobelprize.org). 
DNA is a nucleic acid consisting of thousands of genes, which contains the genetic 
instructions for the development and functioning of all living organisms (except RNA 
viruses). A protein-coding gene is a segment of chromosomal DNA which directs the 
synthesis of a protein. DNA is contained in, and never leaves the nucleus of a eukaryotic cell. 
Instead the genes (genetic code) are copied (transcribed) into RNA, and subsequently 
translated into proteins in the cytoplasm. It is a double-stranded polymer made up of four 
simple nucleotide building blocks (i.e. Adenine (A), Thymine (T), Guanine (G) and Cytosine 
(C)), and provides the instructions on how to build a protein molecule (Figure 6). A gene is a 
defined as a sequence of DNA containing the genetic information, which influences the 
phenotype of the organism.    
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Figure 6 - The structure of DNA. The nucleotide building blocks comprise of a 
phosphate group, a deoxyribose sugar and one of four nitrogen bases. The two strands 
of complementary DNA are held together by hydrogen bonds, forming a double helix 
structure (Paszek, 2007). 
The sequence of bases within a strand of DNA defines the messenger RNA (mRNA) 
sequence, which consequently defines one or more protein sequences. Like DNA, RNA is 
also a complex nucleic acid. It is used in cells to assist with the synthesis of proteins. The link 
between the nucleotide sequences of genes and the resultant amino acid sequences of the 
proteins are defined by the rules of protein translation, otherwise known as the genetic code. 
The genetic code consists of codons which are formed from a sequence of three of the 
nucleotides mentioned above (e.g. ACG, CTT).  
During transcription the codons of a gene are copied into mRNA (Figure 7). This is achieved 
by RNA polymerase and the necessary transcription elongation factors travelling along the 
DNA template. The RNA polymerase synthesises an RNA strand complementary to one of 
two DNA strands. This polymerises the ribonucleotides into an RNA copy of the gene. This 
continues until the end of the gene, when the RNA polymerase falls of the DNA template in a 
process called transcription termination. This process is otherwise known as RNA synthesis. 
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Transcription is very important, as it is the process which helps mediate the expression of the 
genetic material contained within the DNA. The product of RNA transcription subsequently 
transfers the information from the DNA into the functional protein.  
 
 
Figure 7 - The process of protein transcription within the cell nucleus from which DNA 
is copied into RNA (www.nobelprize.org). 
Before RNA can be translated into a protein, it must undergo three major modifications prior 
to leaving the nucleus. These modifications are 1) Capping, 2) Poly(A)-tail and 3) Splicing. 
Capping involves attaching a special nucleotide to the end of the mRNA, which is necessary 
for the initiation of protein synthesis as well as serving as stabilisation.  Poly (A)-tail uses a 
special enzyme which attaches a chain of 150-200 adenine nucleotides to the pre-mRNA 
directly following transcription. This also adds to the stability and lengthens the lifetime of an 
mRNA molecule. Splicing involves removing the non-coding sequences; called introns, from 
the pre-mRNA to create mRNA, which only contains the coding sequences of a protein.  
Following this a ribosome decodes the RNA copy by reading the RNA sequence by base-
pairing the mRNA to transfer RNA (tRNA), which is used by organisms to bridge the four-
letter genetic code of mRNA into the amino sequence of the protein. This process is known 
as protein translation, and occurs outside the nucleus (Figure 8). This process involves a large 
number of protein factors that facilitate binding of mRNA and tRNA to the ribosome. The 
major role of the ribosome is to catalyse the coupling of amino acids into proteins according 
to the mRNA sequence. The role of the tRNA is to bring the amino acids to the ribosome. 
These amino acid chains, otherwise known as polypeptides fold into an active protein.  
Translation can be outlined in three distinct steps: 1) initiation, 2) elongation and 3) 
termination. Initiation involves the forming of an initiation complex within which the 
ribosome binds to the start site on the mRNA, while the initiator tRNA is bound to the 
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ribosome with the initiator codon. In elongation, amino acids join to the budding polypeptide 
chain. This is repeated until the termination codon is reached. This codon signals the last 
stage of protein translation, in which the ready-made protein is released from the ribosome.  
 
Figure 8 - The process of protein translation, outlined in the three steps 1) Initiation, 2) 
Elongation and 3) Termination (www.nobelprize.org). 
1.1.2.3 Functions of Proteins 
Proteins are essential building blocks for all living organisms and they facilitate biological 
functions in those organisms.  They regulate a variety of actions in living organisms, 
including replication of genetic code as well as the transportation of oxygen. Some examples 
of the functions of these proteins are shown in Figure 9. They are responsible for the 
regulation of cells and additionally determining the characteristics of an organism.  
Some proteins are enzymes which act as catalysts for biochemical reactions, and are essential 
for metabolism. The reason that proteins make good catalysts lies in their high specificity 
(Koshland, 1958). An example of a protein enzyme is pepsin which degrades dietary proteins 
in the stomach. There are a number of industrial uses for protein enzymes such as in the 
textile, detergent, pharmaceutical and food industries. However not all proteins are enzymes.   
Some proteins have structural or mechanic functions which are responsible for maintaining 
the shape of a cell, and serve as building blocks of the cells and tissues. Keratin is a structural 
protein found in hair. There are also proteins known as receptor proteins which receive some 
sort of stimuli prior to initiating a response in the cell. Rhodopsin is a receptor protein which 
lies in the retina of the eye and is used to detect light. Signalling proteins exist in order to 
transfer signals between or within cells. Insulin is a signalling protein, which is used to 
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control blood sugar levels in blood. Other examples of proteins include gene regulatory 
proteins, as well as transport proteins, which transport molecules or ions around the body. 
 
Figure 9 – Examples of the functions of proteins (www.nobelprize.org). 
1.1.2.4 Protein Isoforms 
There are occasions when the same protein may take up different forms. These different 
forms of the same protein are called protein isoforms. These may be made from related 
genes, or may be produced by the same gene by alternative splicing. Some isoforms are 
caused by single-nucleotide polymorphisms (SNPs), which are variations in the DNA 
sequence that occur when a single nucleotide in the genome differs between members of a 
biological species or between paired chromosomes in humans. 
Due to protein isoforms it is possible to create categorically divergent proteins from the same 
gene, which increases the diversity of the proteome. The occurrence of protein isoforms 
partially explains why there have been a small number of coding regions, or genes, have been 
identified by the Human Genome Project (Powledge, 2000). These isoforms can be identified 
using microarray technology as well as complementary DNA (cDNA) libraries. 
1.1.2.5 Post-Translational Modifications (PTMs) 
Most of the proteins that are translated from mRNA undergo chemical modifications before 
becoming functional within the various cells of the body. Sometimes during synthesis, or 
shortly after, the amino acid residues in a protein can be chemically altered by these post-
translational modifications (PTMs). These modifications regulate how a particular protein 
sequence will act within the organism. These PTMs alter the physical and chemical properties 
via extra-translational processes and play an essential role in maintaining the uniformity, or 
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homogeneity, in the composition of a protein. Additionally they assist in using identical 
proteins within different cell types for different cellular functions. 
The result of these modifications may affect the folding, stability, activity and therefore 
ultimately the function of the protein. This may involve very complex systems of enzymes 
and the resultant modifications cannot be predicted from the DNA sequence. Examples of 
PTMs include, but are not limited to, glycosylation, sulfation or hydroxylation. Mass 
spectrometry can be used in the identification of PTMs. This is possible because these PTMs 
usually lead to a change in the molecular weight, which is often predictable.  
When studying diseased conditions, the expression of proteins is very important. PTMs play 
a significant role in modifying the end product of expression, as well as contributing towards 
biological processes and diseased conditions. The amino terminal sequences are removed by 
the proteolytic cleavage when the proteins cross the membranes. These terminal sequences 
target the proteins for their transportation to their point of action within the cell. 
1.1.2.6 Differential Expression 
A complete copy of an organism’s genome is contained in each cell of the organism. These 
cells may be of many different types and states, such as blood, nerve or skin cells etc. The 
difference between these cells is dependent on the differential gene expression. Differential 
gene expression is defined as how much each gene is expressed, as well as when and where it 
is expressed. The genetic information within a DNA molecule is expressed during both the 
DNA to RNA transcription stage as well as the protein translation stage. Different types of 
cells synthesise different sets of proteins at different times. At any given time only a fraction 
of our genes are expressed (Blau, 1992). It is projected that around 40% of the genome is 
expressed at any given stage (Ma et al, 2008). Gene expression is important in studying 
diseases as for many diseases specific patterns of expression are associated with different 
phenotypes. 
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1.1.3 Proteomics 
The term proteome is derived from the words PROTEin and genOME and can be described 
as the total protein composition of an organism, biological system or sample. Proteomics 
aims to identify, and possibly quantify, proteins in a biological system. This is a broad field 
of study and has different connotations to different aspects (Hubbard & Jones, 2010). Studies 
in this area often aim to quantify differential protein levels from complex biological samples 
in order to determine and understand specific markers of biological states to determine 
biological action, efficacy and toxicities (Higgs et al, 2005). It involves studying protein 
structures and functions on a large scale.  This may also include any modifications made to 
the complement of proteins. Studies are based on the assumption that the proteome holds the 
key to understanding biological mechanisms. Studying protein function allows researchers to 
correlate these differences in proteomic structure to any phenotypic occurrences and allows 
determination of relationships between these events and relevant protein levels. It is expected 
that studies in this field will yield a potential in novel drug development in the future. The 
main applications of proteomics can be outlined as: 
 Separation and Identification of proteins and their post-translational modifications 
(PTMs) from a biological sample giving rise to information relating to the sample 
 Analysis of differential protein expression associated with a specific phenotype (e.g. a 
diseased state)  
 Characterisation of proteins by exploration of their function  
 Discovering the protein interaction networks 
The mass analysis of peptides and proteins has been made possible by the use of techniques 
such as Electrospray Ionisation (ESI), Matrix Assisted Laser Desorption Ionisation (MALDI) 
or Desorption/Ionisation on Silicon (DIOS). It is these techniques ability to promote the 
proteins non-destructive vaporisation/ ionisation, through the removal of protons in an 
unambiguous order (Trauger et al, 2002). As well as molecular weight determination, these 
techniques are used for the purpose of protein identification (Sherman & Kinter, 2000) and 
protein PTMs (Mann & Neubauer, 1999).  
The determination of the complete and routine protein sequence is yet to be realised 
(Mathivanan et al, 2012), however it is possible to use proteolytic peptide fragments 
combined with data searching algorithms to identify proteins (Trauger et al, 2002). This can 
be done by enzymatic or chemical digestion of proteins, usually using Trypsin, combined 
with mass spectrometry techniques. This is followed by the mass analysis of the peptides and 
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database searching techniques. In complex samples, before the proteins are digested into their 
constituent peptides, the proteins may be separated into less complex protein mixtures. These 
can be separated using 2D Gel electrophoresis or chromatography based methods.  
1.1.3.1 Top-Down and Bottom-Up Proteomics 
Top-down proteomics involves separating intact proteins from biological samples using 
traditional separation techniques such as liquid chromatography (LC) and 2D gel 
electrophoresis (2DGE). This is followed by differential expression analysis using spectrum 
analysis or gel imaging platforms (Dalmasso et al, 2009). Spots or fractions which are 
thought to contain biomarkers are identified using mass spectrometry (MS). As the proteins 
are separated intact they reflect PTMs and intact protein masses. Other advantages of this 
approach include simplified sample preparation and the elimination of the time-consuming 
process of protein digestion needed for bottom-up methods. Unlike the bottom-up approach, 
which involves more specific and limited sample sets, the starting point for top-down 
proteomics can be hundreds of different complex biological samples (Figure 10).  
Although the more complex studies such as relative and absolute quantification of proteins is 
becoming more common, the mainstay of proteomic study continues to be bottom-up protein 
identification. Bottom-up proteomics refers to studies in which the information about the 
constituent proteins of a biological sample is reconstructed from individually identified 
fragment peptides. It can be defined as an attempt to identify all the expressed proteins 
present in cells, tissues and organisms or the differential analysis of biological systems 
reacting upon physiological changes such as diseases. This accounts for much of the protein 
research undertaken in MS laboratories today (Lamond et al, 2012). The objective of these 
studies is to identify as many of the protein components of a biological sample as possible.  
Bottom-up MS is facilitated by the proteolytic digestion of proteins, which is typically done 
using trypsin. This is usually followed by separation of the resultant peptides using one or 
more dimensions of liquid chromatography. The multiple LC eluents are then individually 
analysed by MS. The resultant sequence data is then used to determine the original protein 
composition of the sample. Due to the advances in the field of mass spectrometry, such as the 
resolution, accuracy, fragmentation technology and speed, the bottom-up analysis can 
identify more proteins within a complex sample than ever before (Lamond et al, 2012). 
While the top-down approach has limited sensitivity, the shotgun bottom-up approach is a 
highly sensitive method. The limitations of these methods however lie in the poor 
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reproducibility as well as the large number of missing data that is typical of these methods. In 
most cases the techniques have a very low throughput, leading to lower statistical power 
(Dalmasso et al, 2009). 
 
Figure 10 - The overview of general bottom-up and top-down proteomics profiling 
workflows (Dalmasso et al, 2009). 
1.1.3.2 The Use of Trypsin 
Trypsin is a proteolytic enzyme found in the digestive system of most vertebrates, where it 
hydrolyses proteins so that they can be broken down into smaller peptides. Trypsin belongs to 
the serine protease family, which are enzymes which cleave peptide bonds in proteins. This 
process is called trypsin proteolysis or trypsination (Figure 11). Trypsin is produced in the 
pancreas in its inactive form, known as proenzyme trypsinogen. It cleaves peptide chains 
mainly at the carboxyl side of the amino acids lysine or arginine. This cleavage does not take 
place if either the arginine or lysine residue is followed by a proline residue. 
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Figure 11 - Trypsin and water break down a polypeptide chain into smaller peptide 
fragments (Moyna, 1999). 
Trypsin is considered an endopeptidase, which means that it cleaves peptides within the 
polypeptide chain, as opposed to the end terminals of the chain leading to orderly and 
unambiguous cleavage of proteins. Because of this property it is often used in studies for the 
determination of the amino acid sequence of proteins. Trypsin continues to be used for the 
development of cell and tissue culture protocols (Yang et al, 2009). It is also used for protein 
identification through peptide sequencing techniques (Schuchert-Shi & Hauser, 2009). 
Trypsin is the favoured enzyme for techniques such as peptide mass fingerprinting, as it is 
relatively cheap and effectively generates peptides which are usually 8-10 amino acids long 
(Thiede et al, 2005). This size of peptide is more suited for analysis using mass spectrometry 
techniques.   
1.1.3.3 The Capabilities of Proteomics in Biomarker Discovery 
Proteomics has allowed the previously divergent areas of biomarker and drug discovery to 
converge. The study of proteomics has brought progression in the field of targeted drugs to 
treat certain diseases by creating drugs which inactivate any proteins which have been 
implicated in a particular disease. Genomic and proteomic data can be used to determine 
proteins, which are related to the diseased state, to be used as possible targets for future 
drugs. The 3D structure of these proteins can help develop compounds that may interfere 
with the function of the proteins, and hence interfere with the disease process (King, 2011).  
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1.1.3.4 The Constraints of Proteomics in Biomarker Discovery 
High-throughput peptide identification may be relatively straightforward, but identifying 
post-translational modifications (PTMs) is more challenging. Due to the existence of PTMs 
protein levels may be inaccurately measured in the samples because of the increase in number 
of possible matches and hence false assignments (Mallick & Kuster, 2010). Additionally 
alternative PTM or alternative splicing can cause a single gene to give rise to multiple 
proteins. Sometimes complexes may be created between proteins or RNA molecules, which 
are expressed only when complexes are formed (Phillips, 2008).  
Developments in this field have to take place in tight integration with the developments in 
LC-MS or gel-based technologies, which is currently a very rapidly evolving field (Bertsch et 
al, 2011). Due to this the actual clinical impact of these technologies in drug and disease 
research has been limited (Gad, 2009). For example some human disease genes such as sickle 
cell anaemia and cystic fibrosis have been identified for over 20 years, though the 
development of suitable therapies has been much slower than expected (Green & Guyer, 
2011). A study from the National Cancer Institute has been cited as a classic example of the 
failure of biomarker discovery (Cramer et al, 2011). In this study the researchers tested more 
than 35 ovarian biomarkers that were claimed in previous studies to be better than CA125, 
which is a well established ovarian cancer biomarker. Following the analysis of hundreds of 
tissue samples, the researchers found that none of the biomarkers were better than CA125. 
Proteomic study is considered more complex than genomic study, because unlike the genome 
the proteome is subject to changes due to post-translational modifications and the fact that 
certain proteins are made under different conditions (e.g. time, light, stress of physiological 
change). This is the case, especially in biomarker studies, which requires a large number of 
samples for increased confidence in the results. This leads to an increased complexity.  
Previously the detection of proteins which exist in a low abundance posed a great challenge 
in proteomic studies (Lipp, 2006). Although there have been advances in the form of targeted 
selected reaction monitoring (SRM) techniques (Hossain et al, 2011). SRM techniques 
present researchers with the added advantage of increased sensitivity and quantification 
compared with other, more traditional, MS-based techniques. These techniques are able to 
detect more low abundance proteins by reducing the background chemical noise to a low 
level, thus increasing the signal-noise ratio. These increased signals also improve the 
reproducibility of measurements. 
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There is a challenge in juggling the necessity to develop and adopt new technologies and 
focusing on the biological or clinical goals of the research (Lipp, 2006).The approval as well 
as the impact of these automated techniques is limited by the ability to efficiently handle and 
analyze the large volume of data produced by these methods. This is the inevitable flip-side 
of automation (Bertsch et al, 2011). 
Certain publications provide results from proteomic biomarker experiments and make 
conclusions using data generated from one or two biological samples. The small number of 
experiments is usually due to the time and cost which is required for these experiments. This 
however is not a sufficient number of experiments to base conclusions upon. Due to 
experimental variation it is unlikely that these studies will realise their full potential 
(Bantscheff & Kuster, 2007). 
 
1.1.4 Future of Biomarker Discovery 
The pharmaceutical industry currently aims to develop high-throughput screening methods to 
find potential drug candidates in large compound libraries (Angelino & Yang, 2012). More 
progress may be achieved in this field if the discovery process is made more effective 
(ECHRD, 2010), so multiple biomarkers can be identified, validated and accepted on the 
same patient samples (Cottingham, 2006). It is also suggested that research in this field 
should be focused on tissue samples rather than blood samples which are more complex to 
analyse. As well as the complexity, there may be a high abundance of relevant biomarkers 
directly at the disease site which are not transferred to the blood in such large quantities.  The 
counter argument is that biomarkers found in muscle tissue do not allow for non-invasive 
checks for diagnosis; however once the biomarkers are detected in their differentiated 
concentrations at disease sites, they can be checked for in blood samples (assuming that these 
biomarkers are transferred to the blood at all). It should be noted that not all the biology of 
these may be fully understood so care needs to be taken when using different sample types.  
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1.2 Introduction to Proteomic Techniques Used in Biomarker Discovery  
Proteomics is a field which is currently still evolving rapidly due to the rate of emergence of 
new technologies. The chief aim of biomarker discovery is to identify differentially expressed 
proteins (Wu et al, 2009). A number of platforms exist for the analysis of proteins, some of 
which will be discussed in detail in this thesis. Often these technologies are used in 
combination with each other such as LC-MS, where the LC stage is used to separate the 
sample into smaller, less complex portions and subsequently MS is used to identify the 
composition of the samples. Liquid chromatography separates ions or molecules in a solvent 
based on differences in absorption, ion exchange, partitioning or size.   These processes have 
their own disadvantages but when used in complement they can be used to obtain a fair 
representative coverage of the proteome over a wide dynamic range.   
This allows the comparison of samples from healthy individuals against samples from 
patients suffering from disease. Samples from a single patient can also be collected at 
different stages of the disease to monitor progress or reaction to treatment. 
There are various technical disciplines that are currently used in proteomics of which Mass 
Spectrometry is one of the many possibilities (Palagi et al, 2005):  
• Separation techniques 
 2-DE gels: Provide pI and molecular weight of proteins  
 LC alone: Only determines Retention Time (not very accurate)  
• Identification techniques 
 Protein Sequencing: much better predictor, but very time consuming  
 LC-MS/MS: Does not consider low abundance proteins (X Li et al, 
2005) 
 
The following sections describe the available proteomic technologies, used in this field, along 
with the strengths and limitations of each technique. The techniques described are: 
 2D gel electrophoresis (2DGE) 
 Mass spectrometry (MS) 
 Isobaric Tagging for Relative and Absolute Quantification (iTRAQ) 
 Label-free techniques 
 Liquid Chromatography – Mass Spectrometry (LC-MS) 
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1.2.1 2D Gel Electrophoresis Based Techniques 
2D Gel experiments are commonly used in biomarker discovery for the analysis of large 
amounts of proteins to identify biologically relevant changes (Grove et al, 2008). Proteins of 
interest to researchers can be studied using two-dimensional gel electrophoresis, which 
involves separating proteins in orthogonal directions. This method allows the visualisation of 
even small differences in proteins because modified proteins are separated from the 
unmodified forms. 
1.2.1.1 The Technology of Gel-Based Proteomics 
Gel technology involves separating proteins from a biological sample (such as blood or 
muscle tissue) on a SDS-polyacrylamide gel (SDS-PAGE). Two distinct steps are used for 
separation, one which separates proteins based on pH, and secondly based on molecular 
weight (Figure 12).  
 
Figure 12 – A description of how proteins are separated using 2D Gel electrophoresis. 
Peptides move horizontally based on their pH and vertically based on their molecular 
weight (www.whatislife.com). 
The gels are then stained to reveal clusters of spots. A spot in a 2D gel may represent either a 
protein or isoforms of a protein. It should not be assumed that a spot represents an individual 
protein as this is not always the case. Occasionally spots may belong to an alignment due to 
an error, which are also known as noise spots (Peres et al, 2008). Some spots may also 
represent more than one protein, which may lie very closely in the 2D space of a gel. These 
gels can then be used to compare with other gels from different samples. The intensity of 
each spot gives an indication of the relative abundance of the protein that exists in the 
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sample. Following the separation of proteins in the two-dimensional space the spots, which 
are of interest, may be extracted from the gel. Trypsin, or another suitable protease, is then 
used to digest the protein into its peptide constituents, some of which are unique to each 
protein. These mixtures are then analysed using MS. The gel-based techniques offer powerful 
visualisation allowing researchers to spot differentially expressed, or post-translational 
modified protein spots (Loh & Cao, 2008). 
1.2.1.2 The Capabilities of Gel-Based Proteomics 
Regardless of the fact that 2D gel electrophoresis is not an ultra-modern technology; it 
provides a well defined and robust technology for biomarker discovery when combined with 
Mass Spectrometry (MS).  This is due to its extremely high-resolving power for complex 
protein mixtures (Loh & Cao, 2008). An important consideration often ignored by enthusiasts 
of shotgun mass spectrometry is that although 2D gels only visualise proteins in a sample 
present in higher abundances, it does not mean that the proteins identified from gels are 
unrepresentative of the biological processes within the sample. More proteins identified, does 
not necessarily lead to a better understanding. It is still regarded as one of the most powerful 
tools in the field of proteomic research (Geng et al, 2011). Thousands of spots can be 
resolved on a single 2D gel and when coupled with MS can assist with detection of proteins 
within a large range of isoelectric points and molecular weights. The method provides both 
qualitative and quantitative information. Whilst 2D gel techniques are useful for the 
separation of proteins and quantification of protein levels they do require additional 
identification techniques further downstream, such as MS analysis. 
1.2.1.3 The Constraints of Gel-Based Proteomics 
The reproducibility of results from gel experiments is low; therefore comparison between 
different gels is difficult due to variation in gel composition and run conditions (Lipp, 2006). 
Because of this it is essential that experimental conditions are standardised as much as 
possible and reported accurately to be able to minimise or at least account for experimental 
differences. Advances in gel-based techniques have also been developed to provide greater 
reproducibility between runs (Loh & Cao, 2008). These advances include the introduction of 
gels with a narrow pH gradient range as well as the use of radioactive labelling, such as 
DIGE techniques. 
Traditional gel-based biomarker discovery methods involve comparing gels against each 
other. However, the low reproducibility of gels can make this difficult, as spots relating to the 
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same protein may travel to different locations on the gel and therefore can increase the 
occurrences of false positives and false negatives.   
This problem has been addressed by certain researchers by using a technique referred to as 
difference gel electrophoresis (DIGE) (Alban et al, 2003). DIGE involves labelling of the two 
samples using distinct cyanide dyes which fluoresce at different wavelengths (Figure 13). 
The two samples are then separated on the same 2D gel so that proteins from each sample run 
identically so they occupy the same gel volume. This reduces the inter-gel experimental 
variation between samples as identical proteins separate to the same coordinates. These 
proteins can then be visualised and quantified by altering excitation and emission optics in 
order to ensure a direct spatial correlation and hence comparable protein identity. In addition, 
the creation of a “total sample” preparation labelled with the third dye gives a between-gel 
comparator and underpins accurate normalisation. This allows for better comparison of 
samples using the 2D gel technique and eases the complex task of revealing biological 
variation. 
 
Figure 13 - 2D DIGE technique. Cy2, Cy3, Cy5:- fluorescent dyes. Samples are dyed 
and then combined prior to gel electrophoresis. Following this images are generated 
using different fluorescence wavelengths (Fitzgerald, 2002). 
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Additional issues with gel-based techniques arise from the fact that certain characteristics of 
proteins are often poorly represented by gel-based methods. These characteristics include the 
poor representation of proteins at: 
 Extremes of isoelectric points, i.e. very acidic or vey basic proteins. This can be 
addressed by splitting samples up over various isoelectric point ranges and analysing 
smaller, less complex samples. 
 Hydrophobic proteins. 
 Extremely high or low molecular weights. 
 Low abundance proteins, creating a biased view of the proteome skewed towards 
proteins which exist in higher concentrations. This can be addressed by albumin 
depletion or by immunoaffinity chromatography which simplifies complex samples 
by binding high abundance proteins to a column.  
 There is an inability to profile, quantify and compare large numbers of samples 
therefore limiting the statistical power of proteomic analysis (Levin et al, 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page | 28  © Cranfield University, 2011 
 
1.2.2 Mass Spectrometry (MS) Based Techniques 
Although gel-based techniques are an established platform for these experiments, the use of 
Mass Spectrometry (MS) based techniques is growing in this field (Schulz-Trieglaff et al, 
2008). The previous research in this area has been focused on high throughput Mass 
Spectrometry based profiling of blood and tissue samples (Johann et al, 2004).  
1.2.2.1 The Technology of Mass Spectrometry (MS) Based Proteomics 
The output from a MS experiment is a mass spectrum plot which displays the mass-to-charge 
ratio (m/z) against the intensity of the signal which is correlated to the intensity of the peptide 
(Figure 14). Proteins are cleaved using trypsin to make them a suitable size for MS analysis. 
The spectra are often referred to as the mass fingerprint of the peptide composition of the 
samples. These can be compared against spectra generated in silico that are available in 
primary sequence databases to be able to identify the proteins contained within the sample. 
 
Figure 14 - Mass Spectrometry-based proteomics. Proteins are fractionated by trypsin 
digestion. Chromatography and mass spectrometry is then used to quantify the peptides 
(Blonder et al, 2007). 
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1.2.2.2 The Capabilities of Mass Spectrometry (MS) Based Proteomics 
One of the primary reasons for the use of Mass Spectrometry in proteomic biomarker 
discovery is the larger potential the technique has for complete automation (Malmstrom et al, 
2011). Protein mass spectrometry has been established as an indispensible choice for analysis 
in proteomics studies to identify relevant molecular patterns (Stanley et al, 2004), due to its 
adaptability, sensitivity and precision (Hanash, 2004). Currently it is widely used in this field 
(Colaert et al, 2011). It is preferred for these studies because of the techniques sensitivity, 
selectivity, accuracy, speed and output (Chen & Pramanik, 2009). As well as the choice of 
using MS for proteomic analysis, further choices need to be made regarding the growing 
options for ionisation and ion separation available in MS (Figure 15). Using MS following 
gel analysis is another technique which allows the detection of proteins which have a lower 
abundance which is a likely range for cancer biomarkers (Cottingham, 2006). An example of 
the use of mass spectrometry in proteomics is the technology of multidimensional protein 
identification technology (MudPIT). This is an unbiased method for rapid and large-scale 
proteome analysis (Washburn et al, 2001). This method involves multidimensional liquid 
chromatography followed by tandem mass spectrometry. This technology is paired with the 
use of database searching which utilizes the SEQUEST algorithm to comprehensively 
identify proteins in samples in a rapid and sensitive process (Link et al, 1999). 
 
Figure 15 – The simplified schematic of a mass spectrometer showing examples of 
various ionisation, analyser and detector options (Ashcroft, 2012). 
1.2.2.3 The Constraints of Mass Spectrometry (MS) Based Proteomics 
An issue with MS is that some peptides cannot be ionised, meaning they cannot be detected 
using this technique. Additionally blood samples are often very complex and produce very 
noisy spectra. Unless very accurate MS technology is used, results may be too inaccurate to 
confidently identify clinical biomarkers. This has been addressed through processes of 
sample fractionation to simplify more complex samples; however this takes time and 
decreases the throughput of studies.  
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1.2.3 Isobaric Tagging for Relative and Absolute Quantification (iTRAQ) 
This method is based on protein sequence tags and aims to provide a quick, sensitive and 
accurate technology to assist in biomarker discovery (Ross et al, 2004). Isobaric tagging has 
recently become very popular in proteomic profiling (Simon, 2011). Coupled with liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), iTRAQ has revolutionised the 
field of biomarker discovery and identification (Zieske, 2006). iTRAQ is a non gel-based 
approach to quantitatively study protein expression, and is currently commercially available 
(Applied-Biosystems, 2006).  
1.2.3.1 The Technology of iTRAQ 
This technique allows the analysis of up to eight samples in a single run. The iTRAQ 
technique involves digesting the complex samples into smaller less complex ones by the 
process of reduction, alkylation and then Trypsin digestion (Figure 16). The digested samples 
are then chemically reacted with different iTRAQ reagents which contain stable isotopes. The 
reagents attach at the N-terminus of the digested peptides. The two peptide mixtures can now 
be combined, followed by separation using nano-liquid chromatography and subsequent 
analysis by tandem Mass Spectrometry methods. The peptides are tagged. The tags can be 
identified by detection of their unique low molecular mass reporter ions the peptides can be 
linked to their samples (Figure 17). Determining the intensity of the reporter ions also allows 
for quantification of the relevant peptides. For each reporter ion peak range, the total area is 
calculated by summing the areas between ion peak pairs using trapezoid approximation for 
calculating the area under a curve. 
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Figure 16 – The iTRAQ workflow. Up to eight samples are digested and then tagged. 
The samples are then combined and quantified using LC-MS. 
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Figure 17 - An example of iTRAQ spectra. The reporter ion peak is comprised of 
multiple ions (Zieske, 2006). 
 
1.2.3.2 The Capabilities of iTRAQ 
iTRAQ can be employed with existing techniques to identify proteomic compositions of 
samples to assist in biomarker discovery. When coupled with Matrix Assisted Laser 
Desorption Ionisation – Tandem Time of Flight (MALDI-TOF/TOF) MS techniques, iTRAQ 
provides both quantitative and qualitative data. It has been used in previous studies to identify 
potential biomarkers by determining differentially expressed proteins in head-and-neck/oral 
cutaneous squamous cell carcinomas (HNOCSCCs) against non-cancerous head-and neck 
tissues (Matta et al, 2008). 
Studies suggest that quantification of proteins and peptides using iTRAQ can be further 
enhanced by combining the technique with electron transfer dissociation (ETD) (Phanstiel et 
al, 2008). ETD provides the possibility to determine peptide sequences with post-translational 
modifications (PTMs), because of its ability to retain labile PTMs (Cook & Jackson, 2011).  
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1.2.3.3 The Constraints of iTRAQ 
iTRAQ can occasionally lead to false conclusions due to the false positive identification of 
proteins (Bantscheff & Kuster, 2007). Current data analysis techniques for iTRAQ struggle to 
report reliable relative protein abundance estimates due to problems of precision and 
accuracy (Karp et al, 2010). 
The technique relies heavily on full coverage of the proteome of the species being studied. 
This is not always the case depending on the species being investigated. Additionally the 
method is very powerful and ideally suited for biomarker discovery but is not able to handle 
tens or hundreds of samples, which is normally typical for biomarker studies, in a single run 
(Matta et al, 2008). There are ways around this by the inclusion of a control sample which is 
used in every run of multiple analyses, to allow normalisation of technical variance. 
 
1.2.4 Label-Free Based Techniques 
Current approaches of quantitative proteomics have mainly been based on implementing 
isotopic labelling; however another preferred alternative is the label-free approach (Yan & 
Chen, 2005). Although Isotope labelling and fluorescent labelling techniques have been 
widely used in quantitative proteomics research, researchers are increasingly turning to label-
free shotgun proteomics techniques for faster, cleaner, and simpler results (Zhu et al, 
2010). Label-free approaches look for discriminating peak patterns in mass spectra, without 
regard to their identity (Lai, Wang & Witzmann, 2013). 
1.2.4.1 The Technology of Label-Free Based Techniques 
Label-free techniques involve protein separation and comparison using two-dimensional 
polyacrylamide gel electrophoresis (2D-PAGE), followed by MS or tandem mass 
spectrometry (MS/MS) identification. It is a classical method for quantitative analysis of 
protein mixtures.   
1.2.4.2 The Capabilities of Label-Free Based Proteomics 
MS based label-free quantitative proteomics falls into two general categories. Those that 
measure changes in chromatographic ion intensities, such as peptide peak areas or peak 
heights, and those that involve the spectral counting of identified proteins. An advantage of 
the label-free approach is the reduction in cost, because the employment of stable isotopes is 
very costly, and it is not a simple process. Reviews of the differences between labelled 
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techniques, such as iTRAQ, and the label-free approach suggest that the total analysis time is 
reduced by 50% and experimental requirements are significantly reduced (Patel et al, 2009).  
There are however other technical advantages as well as simply a reduction in cost and time, 
as opposed to techniques that involve labelling. Evidence suggests that the dynamic range of 
quantification is higher with label-free techniques (Bantscheff et al, 2007). This allows 
researchers to measure significant variations within complex mixtures or even across the 
whole proteome, using a single experiment. Additionally when using the label-free approach 
there is only one sample to analyse by MS as opposed to 30-60 fractions which would need to 
be analysed when using techniques like iTRAQ. Research also suggests that the sequence 
coverage provided by label-free approaches is over four times greater than the coverage 
provided by iTRAQ (Patel et al, 2009). 
1.2.4.3 The Constraints of Label-Free Based Proteomics 
There is however also disadvantages of the label-free approach: 
 Although label-free techniques offer a higher dynamic range, for spectral counting 
this comes at the cost of unclear linearity and relatively poor accuracy (Patel et al, 
2009) 
 Quantitation of peptides or proteins is often affected by changes in peptide 
chromatography conditions.  
 There is an uneven dispersion of peptides throughout multi-dimensional separations.   
 Slight variances in the chromatography step can lead to irreproducible peptide 
separations (Leptos et al, 2006).  
 
1.2.5 Liquid Chromatography – Mass Spectrometry (LC-MS) 
Quantitative Liquid chromatography coupled with Mass Spectrometry (referred to as LC-MS) 
is being increasingly used in the differential profiling of biological samples (Katajamaa et al, 
2006). The combination of the methods allows high accuracy protein profile comparisons 
between different sets of biological samples (Kreunin et al, 2007).  
1.2.5.1 The Technology of LC-MS Techniques 
The liquid chromatography stage deals with the 2-dimensional physical separation of proteins 
within a sample. This is achieved by separating proteins dependent on their pI (Isoelectric 
point) and also by the size of the peptides in mass. The protein elutions are then analyzed 
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using the mass analysis capabilities of MS. It exploits the ability of MS to be able to identify 
and precisely quantify a large number of proteins (thousands) from complex biological 
samples.  The MS stage allows the acquisition of an accurate and reproducible protein 
molecular weight. 
1.2.5.2 The Strengths of LC-MS Based Proteomics 
Liquid Chromatography – Mass Spectrometry (LC-MS) methods are commonly used in 
proteomic studies (Peng & Gygi, 2001) at the biomarker discovery phase of drug discovery 
(Kawase et al, 2009). This technique has been used to identify potential biomarkers which 
identify breast tumour metastasis (Kreunin et al, 2007) as well as the discovery of potential 
Down’s syndrome biomarkers in maternal serum (Nagalla et al, 2007). The use of these 
techniques is not limited to proteomic research and more recently are also being implemented 
in the metabolomics field (Katajamaa et al, 2006).    
1.2.5.3 The Constraints of LC-MS Based Proteomics 
As with any technique, LC-MS is by no means without its limitations and boundaries 
including issues with the analysis of data (Bellew et al, 2006). One issue is that not all of the 
peptides present in a complex mixture are currently ionised and detected by MS; therefore the 
amino acid sequence is not fully accounted for (Listgarten & Emili, 2005). Additionally the 
dynamic range of some Mass Spectrometers is limited so low levels of peptides in a mixture 
might not be detected because they are not distinguishable from the background noise.  
Other limitations of this technique include: 
 Some peptides may be under represented or absent in mass spectra of complex 
mixtures of peptides.  
 Some modified peptides are unstable and may decay during ionisation or mass 
analysis therefore escaping detection.  
 Unlike MALDI, ESI used with LC-MS applies multiple charges to peptides which 
need to be determined in order to determine the mass of a peptide.   
 The comparison of peptides across experiments involves alignment in two dimensions 
rather than just one. This additional dimension of retention time varies in a non-linear 
way.  
 There may be deviations in the elution times across different experiments.  
 Ambiguity can occur when there is an overlap in the time and m/z spaces.  
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 Signal intensities can be affected by differences in overall sample composition.  
These limitations become more apparent as the amount of protein available for analysis is 
reduced due to the use of gel spots from 2-D PAGE. Signals from modified peptides, such as 
phospho-peptides or glycopeptides, are often not present from the mass spectra of peptide 
mixtures (Knochenmuss, 1998). To add to the complication, the modification on a given site 
is sometimes only partial. The result of this is that the corresponding unmodified peptide is 
observed instead of the modified peptide. This leads to the dangers of failure to recognise, 
and account for the presence of a modified peptide peak. Furthermore the influences of the 
experimental conditions on the PMF spectra are also a limiting factor to the successive use of 
MS for proteomic profiling for determination of biomarkers (Bellew et al, 2006).  
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1.3 The Use of Statistical Analysis in Proteomic Biomarker Discovery 
1.3.1 Biomarker Discovery Workflows 
Organisations involved in biomarker discovery, such as the sponsor company Oxford 
BioTherapeutics (OBT) use a range of both MS and 2D gel methods in their biomarker 
experiments. Figure 18 illustrates the work process flow used by these companies for their 
biomarker discovery projects. Datasets from some of these analyses (gel or MS based) were 
provided by OBT as part of their biomarker research. The focus of this EngD lies mainly 
within the statistical analysis step. Once the required statistical analysis is completed the 
results were provided to the company in the format described later in this thesis. Any further 
analysis (MRM/SRM) required to validate these biomarkers was then conducted.  
 
Figure 18 - The biomarker discovery work process flow. Collected samples are analysed 
and data files are created, ready for statistical analysis using software created for this 
EngD Project. 
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1.3.2 Experimental Design of Biomarker Discovery 
An aspect of proteomics studies is the discovery of biomarkers indicative of physiological 
differences (e.g. diseases or responses to treatments in biological systems). Experiments in 
this field aim to identify a correlation between abundances of proteins within a sample, and 
the biological conditions of sample groups. Use of differential analysis of protein expression 
levels has developed rapidly over recent years (Keselman et al, 2011).  
A factor that decides whether these experiments result in successful scientific discoveries is 
the quality of the experimental design. A good experiment suggests a “fair test” is conducted 
including only the variance that the experiment is trying to capture (i.e. the differences in 
biological states compared). However there may be biological and technical variation within 
the samples in the groups, which are not involved in the divergences seen in biological states. 
The effect of these variations can be reduced by using replicate samples (Molloy et al, 2003). 
As well as standardisation of sample and analysis protocols, there needs to be standardisation 
in the application of the statistical tests used throughout the study. 
A topic of frequent debates about experimental design in biomarker proteomics is the use of 
these replicates. These experiments usually contain two types of replicates including 
biological and technical replicates. Biological replicates are individual biological samples 
which are independent of each other, whereas technical replicates are multiple labelled repeat 
technical runs of the same biological sample. The purpose of including biological replicates is 
to control for biological diversity between samples (Altman, 2005). These are considered 
superior to technical replicates because they are often more informative. However biological 
replicates are often more difficult to obtain, and budgets may restrict the number of biological 
samples available for analysis. Technical replicates can however also be useful as they 
account for the technical variability within an experiment (Patterson et al, 2006). Technical 
variation may occur from differences in the experiment, such as in sample preparation and 
separation. 
Biological replicates are necessary in biomarker discovery experiments in order to draw 
conclusions about the differences between groups. As a general rule, the more biological 
replicates used, the better the statistical confidence (Ekefjard, 2010). If only one biological 
replicate in the groups are being compared, it is not possible to draw meaningful conclusions 
about differences between the samples. Technical replicates are not however useless as they 
allow the experiment to account for errors in the measuring techniques. Running multiple 
runs on the same biological samples is useful for reducing differences arising from the 
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running conditions. Technical replicates also result in a cost benefit as the number of samples 
is increased at a lower cost (Altman, 2005).  
1.3.3 Statistical Analysis Methods  
The proteomic experiments of interest for this study are those that aim to identify correlations 
and differences in the abundances of proteins between samples exhibiting divergent 
biological conditions.  
There are a number of statistical methods that can be employed for the use of proteomic 
biomarker discovery experiments. The relevant techniques will be discussed in later chapters 
in greater detail. Table 1 identifies the optimum statistical strategy that should be employed, 
depending on the nature of the question that needs to be answered.  
 
Table 1 - Ideal statistical methods for proteomics questions (Bantscheff & Kuster, 2007). 
Testing For? Question Optimum testing method 
Variances in protein 
abundance between sample 
groups (Different biological 
conditions) 
Do any proteins act 
significantly differently in 
various biological 
conditions? 
Multiple Hypothesis Testing 
Do any proteins show time-
dependent change? 
Analysis of Variance 
(ANOVA) 
Defining the class of an 
unknown sample 
Classification techniques 
such as PLS-DA 
Relationships between 
proteins and samples 
Which (if any) proteins are 
dependent on each other? 
Cluster Analysis such as 
HCA. 
Which (if any) proteins are 
responsible for variances 
between samples? 
Principal Component 
Analysis (PCA) 
As well as the statistical analysis techniques there is a choice of data pre-processing and post-
processing options that can be conducted on the data. There are a number of current 
algorithms available for this. The choice of statistical analysis and data processing techniques 
will inevitably have an effect on the biomarkers identified from these experiments. The best 
statistical approach to deal with data from these proteomic biomarker studies remains an area 
of ambiguity and interest (Blanchet et al, 2011), and forms the core focus of this project. 
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1.3.4 Errors in Hypothesis Testing  
When conducting statistical hypothesis tests, the result is a p-value (described in detail in 
Chapter 2) indicating the probability of each feature (peptide or protein) fulfilling the null 
hypotheses for the tests. The null hypothesis for these significance tests is that there is no 
difference between the samples being compared (i.e. null hypothesis suggests the feature is 
not a potential biomarker candidate). Potential biomarkers are indicated by a p-value of lower 
than the significance level of 0.05 (i.e. rejection of the null hypothesis that there are no 
differences between the samples). It is possible, however that the null hypothesis of no true 
difference is true and that the large difference between sample means occurred by chance.  
If this is the case, then the conclusion that the feature identified as a potential biomarker is in 
error. This type of error is called a Type I error or a false positive error. More generally, a 
Type I error occurs when a significance test results in the rejection of a true null hypothesis. 
The Type I error rate is affected by significance level used (0.05 for this study which is the 
generally accepted significance level in statistical significance testing (Butzen, 2011)). 
Lowering the significance level decreases the Type I error rate. It might seem that the 
significance level is the probability of a Type I error, but actually the significance level is the 
probability of a Type I error given that the null hypothesis is true.  
Another type of error seen in significance testing is failing to reject a false null hypothesis, 
called a Type II error or a false negative error. This is not a great cause for concern in 
proteomic biomarker studies where the number of features is generally large. When a 
statistical test rejects the null hypothesis, it suggests that the data doesn’t display strong 
evidence that the null hypothesis is false. It does not support the conclusion that the null 
hypothesis is true (i.e. the test is inconclusive). A Type II error occurs if the null hypothesis is 
false (i.e. there is a significant difference between the groups).  
Because of these errors it is better to use the p-value as an indication of the weight of 
evidence against the null hypothesis, rather than as part of a decision rule for making a reject 
or do-not-reject decision. In this study the Type I (false positive) errors are of greater concern 
than the Type II (false negative) errors. This is because the validation of biomarkers is an 
expensive process, so resources should not be wasted on non-markers. As there is generally a 
large number of features (therefore many statistical tests) it is not a great problem if some 
potential biomarkers are identified as non-markers. 
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1.3.5 Power Analysis 
For the successful discovery of biomarkers, it is important to address a correctly formulated 
clinical research question where power analysis is essential (Karp et al, 2007). Therefore all 
biomarker studies should have included an a priori calculation of the number of samples that 
need to be included in the study. The power of a test is its ability to correctly reject the null 
hypothesis of the statistical test (i.e. the ability to detect an effect, if an effect exists). The 
exact statistical power considerations that are relevant for interpreting a biomarker study 
depend on the nature of the study but generally focus on demonstrating that the sensitivity 
and/or specificity of a biomarker is superior to a stated value. The statistical power in a 
proteomic biomarker study depends on specific factors including: 
 Variance in protein expression 
 The size of the change in protein expression 
 The number of replicates 
 The significance level used 
For greater statistical power in an experiment, the number of replicates must be sufficient 
enough to distinguish between true differences and random effects (Zhou et al, 2012). Using 
too few replicates can lead to an underpowered study which will not identify changes in 
protein expression with statistical significance. Using too many replicates leads to an 
unnecessary waste of time and resources. This issue is frequently overlooked by researchers 
(Bachmann et al, 2006). Most researchers in quantitative proteomics rely solely on the 
estimation of p-values and a significance threshold (Karp et al, 2007), but this approach does 
not account for the effect of multiple testing which is described in more detail later in this 
thesis in Section 4.2.1. A measure of significance in terms of the false discovery rate (FDR) 
is then calculated to return a q-value. A q-value is used to maintain the power by allowing the 
researcher to achieve an acceptable level of false positives or false negatives. 
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1.4 Project Aims 
1.4.1 Identification of the Suggested Statistical Analysis Methods for Biomarker 
Discovery 
The overall objective is to identify a recommended statistical approach for the identification 
of features (peptides or proteins) which are differentially expressed between divergent groups 
of samples. This will allow the identification of peptides or proteins which are responsible for 
the divergent traits displayed between sample groups. 
As stated earlier there are a number of statistical methods that can be employed for the use of 
proteomic studies and biomarker experiments. At present no one correct method or answer is 
defined for biomarker discovery but it is through development of the combination of all these 
technologies that the biomarker field will thrive (Haleem et al, 2011). Although there has 
been advances in this area there is ambiguity regarding the best statistical approach, including 
the pre-processing and post-processing options to deal with data from these proteomic 
biomarker studies (Blanchet et al, 2011). 
Along with the development of a software pipeline to be discussed in Section 1.4.2, the 
various methods available for statistical analysis as well as data pre- and post-processing will 
be investigated and reviewed. These methods will be made available using the software 
pipeline. Following the use of this pipeline on actual proteomic data from biomarker 
experiments the recommended methods of data treatment and statistical analysis will be 
presented. 
 
1.4.2 An R Toolkit for Biomarker Discovery from Proteomic Data  
Software and algorithms available for the statistical analysis of data created from biomarker 
experiments remains a subject of interest in proteomics (Zhu et al, 2010). One of the required 
outcomes of this project is the development of a reliable pipeline software solution for the 
identification of biomarkers through the use of statistical analysis of experimental datasets.  
Although there are currently software platforms that exist in order to conduct statistical 
analysis on biomarker data (e.g. Marker View) these often are limited in their range of 
statistical tests. Currently the commercial options available for this analysis usually provide 
black-box analysis tools which often cannot be modified and it is often difficult to understand 
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the inner workings of the software. These tools do not allow OBT to use their expertise and 
modify the analysis workflow to their or their clients’ individual requirements.  
Often the existing software is not able to deal with or analyse the sheer amount of data 
created from these experiments. These issues can only be overcome by new developments in 
algorithms, data management and software engineering (Malmstrom et al, 2011). Only then 
can the full potential of these studies be realised. It is very important that these software 
projects are developed alongside tight integration with the method developments in 
technologies used such as Mass Spectrometry based or gel-based methods. 
The software pipeline developed for this project will allow users to conduct high-throughput 
statistical analysis in order to identify biomarkers from datasets obtained from biomarker 
experiments. The toolkit developed through this EngD project was named Biomarker Hunter. 
This pipeline software will aim to identify peptides or proteins which are differentially 
expressed following various treatments in order to identify the effects these treatments may 
have on these markers. It will conduct a range of both multivariate and univariate statistical 
techniques in order to identify features of interest between different groups of samples.  
The use for this pipeline will be to evaluate the various statistical methods described in 
section 1.4.1 in a high throughout manner. The advantage this software provides to biomarker 
companies such as OBT is the ability to produce higher quality results for their clients, which 
will lead to higher client confidence. This will add value to the biomarker experiments 
conducted by these companies. Currently OBT use the GeneSpring MS software for the 
univariate analysis and do very little in terms of multivariate analysis. The idea behind the 
pipeline is to conduct univariate analysis, as well as providing multivariate analysis options.  
 
1.4.3 Identification of Suitable Methods for Dealing with Missing Values in 
Proteomic Data 
Statistical techniques usually require, and work best with, complete datasets. Proteomic 
datasets are often incomplete due to numerous issues including identification, technical range 
and sensitivity of the proteomic technologies employed for quantitative analysis. Methods of 
dealing with these missing values prior to statistical analysis still remain a key issue in 
proteomic analysis (F. Li et al, 2011). Proteomic data from biomarker experiments can 
generally contain about 50% of missing values (Bantscheff & Kuster, 2007). If these values 
are just ignored, the loss of information can induce a considerable bias to the dataset.  
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Reasons for missing values in proteomic data may be either biological or technical. 
Biological reasons may represent a protein that is truly missing from a particular sample or 
those features which are present but at a level that is below the detection level of the analysis 
tool. Although the biological implication of these two cases is different, it is often not 
possible to differentiate between them. A proteomic feature refers to an experimental 
parameter which relates to a peptide or a protein. These may be in the form of a gel spot or 
peak on mass spectra. 
Examples of technical causes of missing values in gel-based data include inaccuracies 
encountered during the electrophoresis process (Albrecht et al, 2010). These include: 
 pH variations in the running buffer 
 Incomplete or over-focusing in the first dimension 
 Poor transfer from first to second dimension 
 Different run times in the second dimension 
 Gel variations in staining  
 Local differences in protein migration on gels (This may be caused by incomplete 
polymerisation or air bubbles in the gel) 
 Differences in image analysis (e.g. high background noise, poor resolution of spots or 
poor detection and separation of nearby spots) 
A recent study showed that the occurrence of missing values in gels does not correlate with 
the spot locations; however feature intensity is a function of the percentage of missing values 
(Miecznikowski et al, 2010). Values which are present in high abundances in other sample 
groups are more likely to be detectable than those present at lower levels. Therefore the more 
abundant a protein is, the lower the chance that the protein will be below detection level in 
another sample group (Wood et al, 2004). This also applies to MS (F. Li et al, 2011). 
The consequence of missing values is that they can have a significant effect on the 
conclusions that are drawn from the data. Values that are missing due to biological reasons 
are important for analysis as they provide an insight into the differences between the samples. 
Missing values caused due to technical variations are not of biological interest but need to be 
avoided. It is important to identify the causes for missing values so that they can be treated 
differently. This may be determined by identifying whether there is a systemic relationship in 
the number of missing values between the experimental groups. Random distribution of the 
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missing values suggests that the reason for the missing values is technical. Non-random 
distributions lead to the suggestion that the missing values are biological (Cardillo, 2008). 
This project will address this issue of dealing with missing values in proteomic data. Features 
below the detection value may be replaced with zeroes or another arbitrary low threshold 
value. This may be acceptable if the values are missing because a feature’s abundance being 
below the detection value, or those that are truly not present. However this is not acceptable 
for values that are missing for other reasons such as other technical reasons. There are 
additional imputation methods than can replace missing values based on a model created 
using the existing data, for these purposes. Existing methods of imputation will be researched 
and implemented in an appropriate manner. 
Additionally many values may not be present due to the incorrect mismatching of features. 
This occurs when an individual peptide or protein is identified as different features between 
samples. To deal with these missing values, the creation of a novel algorithm for the 
reduction of missing values will also be implemented and reviewed. This will aim to address 
the issues of features (peptides or proteins) that have incorrectly been identified into two or 
more separate features. This will be achieved through the creation of a clustering algorithm, 
“ClusterFix”, to re-cluster the original dataset. This novel algorithm as well as the existing 
missing value imputation techniques will be the focus of Chapter 5. 
 
1.4.4 Researching the Business Opportunities for Biomarkers and Statistical 
Analysis Software 
As this is an EngD research project it is important to consider the business and economic 
aspects of this research area. This will be discussed in Chapter 7. This chapter will outline the 
business opportunities that will be presented through quicker, more efficient discovery of 
biomarkers. It will discuss the clinical impact that biomarkers aim to deliver both in terms of 
health benefits to patients and economic benefits to organisations such as healthcare 
providers and drug manufacturers. This chapter will also consider the competition in the 
industry by presenting a SWOT analysis and a review of competitive software that exists in 
the industry. 
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2 Materials and Methods 
This chapter discusses the resources that were used throughout this project. The first section 
discusses the datasets that were provided by the sponsor company OBT, on which the 
statistical analysis was conducted. Firstly an outline of the types of data that will be analysed 
using the pipeline software will be discussed. Then a list of the actual proteomic datasets 
provided for this project will be presented. Following this, an overview of the pipeline 
software, Biomarker Hunter, will be described. 
2.1 Data from Proteomic Biomarker Data 
Oxford BioTherapeutics (OBT) provides data from experiments which consist of groups of 
samples. This data is usually in the form of pivot tables, which is a method of summarizing 
large amounts of data and presenting it in an easy-to-read format. These datasets are 
generally .csv files with each row representing a feature (e.g. a peptide), and each column 
representing a different sample. Features are often referred to as Molecular Cluster Indexes 
(MCIs) or Protein Cluster Indexes (PCIs). The datasets may previously have been normalised 
using the GeneSpring MS or similar software using log transformations. 
The benefit of using the datasets provided by the sponsoring company is that these are large 
in terms of the number of samples and are generally of high quality, as the company was at 
the time providing proteomics as a service and has high quality control standards. Crucially, 
it was also expected that the studies from which these datasets came would progress to the 
validation stage, where potential markers found during the statistical analysis would be 
validated experimentally using targeted proteomics (SRM). Unfortunately, only one of the 
three studies did actually reach the validation stage and for commercial reasons it has not 
been possible to ascertain what the biomarkers were in that study. 
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2.1.1 Dataset 1 – Circadian Variation  
Data from this experiment aims to identify whether circadian rhythm or “body clock” has an 
effect on the protein expression of DMSO (Dimethyl sulfoxide) treated Zebrafish Embryos 
(ZFEs). The circadian clock regulates various physiological processes. It is unknown how 
circadian clock controls physiological rhythmicity. As most living organisms display 
circadian rhythm to some extent, to adapt to daily environmental changes, it is important to 
be aware of its effects on future studies. Most circadian clocks are close to 24 hours. 
To determine whether time of sample collection affects the levels of proteins detected by 
comparing five independent biological replicates at each of two time points using 2D gel 
analysis. The circadian rhythm is investigated using five pools of DMSO treated ZFE (A-E) 
with two samples from each pool, one collected at 0900 hours and another at 1200 hours. The 
2D gel results from these tests were analysed to identify any differentially expressed proteins. 
Table 2 shows the samples that were analysed and their reference numbers which were used 
in the output diagrams from the study. Since gel-based analysis is conducted on proteins 
rather than peptides, the features (proteins) for this study are often referred to as Molecular 
Cluster Indexes (MCIs). Each sample contained 1,678 MCIs or features. This dataset differs 
from the others as it does not contain any missing values. This is because specific 2D gel 
spots were chosen and analysed for this study. Figure 19 shows the range of intensities 
contained within the dataset, showing the majority of proteins within the lower intensity 
range between 0 and 1 million.  
Table 2 – An experimental outline for circadian rhythm study, including the sample 
names. Five samples were collected at two different time points and analysed using 2D 
gel technology. 
Pool  Time point 09:00 12:00 
A A9 A12 
B B9 B12 
C C9 C12 
D D9 D12 
E E9 E12 
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Figure 19 - A histogram showing the number of features (proteins) within specific 
intensity ranges for Dataset 1. 
This data was specifically created to determine whether there were any changes in protein 
expression between the samples collected at 9 am as opposed to those collected at noon. This 
was achieved by conducting the multivariate analysis techniques to identify if the time of 
collection had a significant impact on the expression of proteins between these two groups. 
2.1.2 Dataset 2 – Project 9549 Label-Free Analysis (OBT) 
This dataset is obtained from label free MS analysis, consisting of 31 samples run in 
duplicate giving a total of 62 experiments. The samples are split into four groups being 
compared (named 1, 2, 3 and 4). There are eight samples in groups 1, 2 and 4 and seven 
samples in group 3. Since there were duplicate runs conducted there are two readings 
(technical replicates) for each sample. One of the sample groups is a control group whereas 
the other three groups are various doses of treatment. This experiment is done for a highly 
sensitive project, therefore the nature of the sample groups have to be kept confidential. This 
data involves study at the peptide level so the features (peptides) for this study are often 
referred to as Peptide Cluster Indexes (PCIs). Table 3 illustrates the experimental outline for 
this data set. For each sample there are a total of 8,892 features that have been identified. This 
shows that for each group there are 16 total samples except for group 3 which has 14.   
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Table 3 - Experimental outline for Dataset 2 – Project 9549 Label-Free Analysis. X 
represents a dataset being available for each sample. 
Group/Sample 
Sample 
1 
Sample 
2 
Sample 
3 
Sample 
4 
Sample 
5 
Sample 
6 
Sample 
7 
Sample 
8 
Group 1 - Run 1 X X X X X X X X 
Group 1 - Run 2 X X X X X X X X 
Group 2 - Run 1 X X X X X X X X 
Group 2 - Run 2 X X X X X X X X 
Group 3 - Run 1 X X X X X X X  N/A 
Group 3 - Run 2 X X X X X X X  N/A 
Group 4 - Run 1 X X X X X X X X 
Group 4 - Run 2 X X X X X X X X 
The data has already been normalised. The dataset contains the natural logarithms of the 
normalised data with one row per feature and a column for each experiment. This data suffers 
from a large proportion of missing values (i.e. 327772 values, which accounts for over 60% 
of the dataset). Missing values have been replaced by the value 0.01.  The natural logs of the 
values are given as these are what the statistical analysis is to be carried out on.  Therefore a 
value of ln(0.01) = -4.60517 indicates the value is missing. Figure 20 shows the number of 
features within specific intensity ranges. Analysis of this dataset involves comparing the 
peptide expression between the four groups using both multivariate and univariate statistical 
techniques. Table 4 shows how the four groups were compared for univariate analysis. 
 
Figure 20 - A histogram showing the number of features (peptides) within specific 
intensity ranges for Dataset 2. 
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Table 4 - A table showing how the samples were pooled in four groups. The cells 
marked with an X show how the groups were compared with each other. 
Groups 1 2 3 4 
1 
 
   
2 X 
  
  
3 X X 
 
  
4 X X X   
 
2.1.3 Dataset 3 – Xenograft Pre-Clinical Project (OBT) 
This study involves the analysis of plasma aiming to investigate the influence of compound 
administration on protein expression. It is based on the mouse Xenograft model (Richmond & 
Su, 2008). It aims to identify proteins which are differentially expressed in Xenograft mice 
which have undergone treatment of a compound administered at different dose levels. This 
will allow development of an assay to monitor the efficacy of drug treatment.  
20 different biological samples were analysed using state of the art LC-MS comparative 
peptide profiling methods. Each sample underwent a replicate run, to include technical 
replicates, so there will be 40 samples in total (Table 5). For each sample there are a total of 
94,727 features that have been identified for analysis. Although there are a large number of 
features, this data suffers from a large proportion of missing values (over 90%). There is a 
need to identify and validate a set of differentially expressed peptides between these samples. 
This data involves study at the peptide level so the features (peptides) for this study are 
referred to as Peptide Cluster Indexes (PCIs).  
The biological samples consist of: 
 5 mice (biological replicates) treated with dose A(1) 
 5 mice (biological replicates) treated with dose B(2) 
 5 mice (biological replicates) treated with dose C(3) 
 5 untreated mice (biological replicates) (Vehicle)(4) 
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Table 5 - Experimental outline for Dataset 3 – Xenograft Pre-Clinical trial. X represents 
a dataset being available for each sample. 
Group/Sample 
Sample 
1 
Sample 
2 
Sample 
3 
Sample 
4 
Sample 
5 
Group A(1) - Run 1 X X X X X 
Group A(1) - Run 2 X X X X X 
Group B(2) - Run 1 X X X X X 
Group B(2) - Run 2 X X X X X 
Group C(3) - Run 1 X X X X X 
Group C(3) - Run 2 X X X X X 
Group D(4) - Run 1 X X X X X 
Group D(4) - Run 2 X X X X X 
 
Figure 21 shows the number of features within specific intensity ranges for this dataset. This 
shows that the majority of values fall within the lower intensity range below 25 million. This 
graph however was not very informative so Figure 22 shows a breakdown of the features 
within this lower intensity range (0-25). The four groups were compared in the same manner 
as Dataset 2, as shown previously in Table 4.  
 
Figure 21 - A histogram showing the number of features (peptides) within specific 
intensity ranges for Dataset 3. 
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Figure 22 - A histogram showing the number of features (peptides) between zero and 25 
within specific intensity ranges for Dataset 3. 
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2.2 Design and Implementation of the Biomarker Hunter Pipeline 
This section discusses the creation of the pipeline software that will be used to identify 
biomarkers from the proteomic biomarker experimental data described in section 2.1. The full 
R script is presented in Appendix A as well as a copy of the program and user manual 
(Appendix D) provided on the supplemental CD ROM for this thesis. The key features of this 
software include: 
 Support of different proteomic workflows (e.g. gel, LC-MS and iTRAQ) 
 Traceability of statistical analysis and data pre- and post-processing methods 
 Support for multiple groups of samples 
 Extensive range of univariate and multivariate statistical techniques in a high 
throughput manner 
 Various data pre- and post processing options 
 A novel method of dealing with missing values 
The statistical programming platform R has been chosen as the platform in which to create 
the pipeline (www.r-project.org). R is an open-source environment which enables statistical 
computing and visualisation. As it is free software it is preferred as university and perhaps 
small enterprises do not always have budgets to spend on the commercial alternatives such as 
MATLAB licences. Free software also brings advantages for the distribution of this software 
as commercial licenses may create a barrier to the use of the pipeline. R also contains many 
pre-written packages for various algorithms which lead to easier programming. 
Firstly an overview of the pipeline will be presented. There are four stages of analysis that 
comprise the pipeline: 
 Data Pre-Processing 
 Statistical Analysis 
 Data Post-Processing  
 Results Presentation 
Figure 23 shows the flow of data through the software pipeline. Firstly quantitative data from 
gel-based or MS based experiments is pre-treated using various options, to ensure the data is 
suited for the subsequent statistical analysis. Once the statistical analysis is conducted the 
data may need to be processed prior to presenting the resulting list of biomarkers. 
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Figure 23 - An overview of the Biomarker Hunter Pipeline. It shows the flow of data 
from 1) The original datasets being pre-treated for statistical analysis 2) The statistical 
analysis conducted and subsequently 3) The output of results (i.e. potential biomarkers). 
 
The following sections describe the various sections of the pipeline from pre-processing the 
data, to statistical hypothesis testing, and then subsequent post- hoc testing, multiple testing 
correction and finally creating the output files.  
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2.2.1 Data Pre-Processing 
The process of the pipeline from data importation to preparing the data into groups prior to 
statistical analysis, described above, is illustrated in Figure 24. The accepted file format for 
this pipeline is .csv files. The first row contains the column headings. The first column 
identifies the feature (e.g. MCIs or PCIs) that is being analysed as shown in Table 6. 
Additional columns may also be present for LC-MS data, for the mass and retention times.  
 
Figure 24 - Flowchart describing data pre-processing steps prior to statistical analysis 
 
Table 6 - An outline of a dataset that can be analysed using Biomarker Hunter, using 
data from MS or gel-based techniques. This example shows one control sample and 
three various doses of treatment (The mass and retention time columns are optional). 
 
Before any analysis is conducted the features of the dataset need to be extracted from the data 
file and arranged in a form suitable to carry out the relevant analysis. Due to differing 
laboratory conventions, in order to class any missing values as such, the user is prompted for 
the syntax that has been used to denote missing values (i.e. 0, 0.0, NA, N/A). 
In order to identify the samples and group them the user is presented with two options. This 
can be achieved either manually, using command line prompts, or with the use of grouping 
data in the form of a separate .csv file. A grouping file (.csv) consists of two columns 
specifying the group name and their respective column numbers (Table 7).  
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Table 7 - An example of a grouping list, that can be used to split the samples into their 
corresponding groups. Column 1 - respective group name Column 2 column number  
 
Firstly the raw data needs to be sorted into its relevant sample groups for calculation of the 
group statistics and subsequent statistical hypothesis testing. Following this the user will be 
presented with data pre-treatment options which will be discussed in the following sections. 
Biomarker Hunter provides options for normalisation and dealing with technical replicates 
and missing values. 
2.2.1.1 Normalisation 
The pipeline offers an option for normalisation of technical variances between the samples if 
the data requires it. The software offers Total Intensity Normalisation which is explained in 
detail in section 4.1.1. It involves the division of the abundance values by the sum of all 
values within the sample. 
2.2.1.2 Averaging of Technical Replicates 
There are two options with regards to the management of technical replicates. These can 
either be treated as individual samples (i.e. not averaging the dataset) or can be averaged 
prior to analysis. The advantages and disadvantages of these options form the focus of section 
4.1.2. 
2.2.1.3 Missing Value Treatment 
Additionally the user will be presented with options to deal with the missing values in the 
proteomic datasets. This includes both options for missing value imputation as well as the 
novel clustering algorithm “ClusterFix”. These options for the treatment of missing values, 
and their effects on statistical analysis, are the focus of Chapter 5. 
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2.2.2 Statistical Analysis  
This section describes the various analysis methods offered in Biomarker Hunter to identify 
potential biomarkers from proteomic data. The software conducts a range of statistical tests 
that can be used to identify the differences within and between groups of samples. The 
analysis portion of the pipeline conducts a range of analyses including univariate analysis, 
multivariate analysis as well as additional calculations (i.e. means, feature presence and fold 
changes) that help in the identification of biomarkers and provide insight into the data. 
 
2.2.2.1 Univariate Analysis 
Once the groups have been defined, the statistical tests described in Figure 25 are conducted. 
These statistical hypothesis tests will be described in detail in Chapter 3 along with the 
methodologies, advantages and limitations of each technique.  
Each of these tests return a p-value, indicating the probability of each feature (peptide or 
protein) fulfilling the null hypotheses for the tests. There are two overall types of univariate 
analysis conducted in Biomarker Hunter. These are pair-wise and group-wise analysis. For 
pair-wise analysis a p-value is returned for each group comparison. For example if there are 
four groups being compared (i.e. groups 1-4) there will be six p-values returned (i.e. Grp 1 
vs. Grp 2, Grp 1 vs. Grp 3, Grp 1 vs. Grp 4, Grp 2 vs. Grp 3, Grp 2 vs. Grp 4, Grp 3 vs. Grp 
4) as shown in Figure 26. When group-wise analysis (i.e. ANOVA and Kruskal-Wallis) is 
conducted one p-value is returned for the whole analysis regardless of the number of groups 
being compared. This p-value represents the probability that there are statistically significant 
differences between all the groups being analysed. Post-hoc analysis can be conducted to 
identify which groups the differences lie between. These post-hoc tests return a p-value for 
each group comparison as with the pair-wise analysis. 
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Figure 25 - An outline of the univariate hypothesis tests implemented for Biomarker 
Hunter showing the parametric and non-parametric alternatives for both one-way and 
group-wise analysis 
For the group-wise methods (i.e. Welch ANOVA and Kruskal-Wallis) the null hypothesis for 
the tests is that all groups being compared come from the same sample (i.e. a non-marker). 
The ANOVA post-hoc Tukey analysis p-values show the probability of each individual group 
being from the same population as each other group. For the pair-wise statistical analysis (i.e. 
Welch T-test and Wilcoxon-Mann Whitney) a p-value is obtained for each FEATURE, 
comparing each individual group compared against each group except for itself with the same 
null hypothesis. 
 
Figure 26 - A table showing how pair-wise tests are conducted when four groups are 
being compared (An X represents a test being conducted). 
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For the ANOVA tests a post-hoc Tukey analysis is conducted to identify which groups 
display statistically significant differences. The post-hoc analysis for the Kruskal-Wallis test 
is actually the non pair-wise analysis of the Wilcoxon Mann-Whitney tests, so no further 
post-hoc testing is necessary. 
The univariate techniques also cover both parametric and non-parametric analysis methods. 
Non-parametric methods are usually less powerful as they use less information in their 
calculations. They do not consider the observed values. Instead these tests use the ranked 
order of these values for calculation. Parametric tests use information about the means and 
deviations from the mean, unlike the non-parametric options which only use the ordinal 
position of pairs of scores. Although parametric techniques lead to more conclusions, the 
non-parametric tests offer simplicity as the analysis is not affected by outliers. This is 
because the non parametric tests are concerned with the ranks of values rather than the actual 
values.
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2.2.2.2 Multivariate Analysis 
The use of classical statistical analysis hypothesis tests such as T-tests, Wilcoxon tests and 
Analysis of Variance tests (ANOVA) treat each individual variable to be treated 
independently. These tests therefore ignore any correlations or relationships that may exist 
between variables. This may prevent the identification of biomarkers that are combinations of 
individual variables. 
Univariate and multivariate statistical methods have both been used for the analysis of data 
from proteomic experiments. The advantage of incorporating a multivariate approach is the 
additional benefit of information about the relationships between samples and variables. The 
multivariate statistical methods enable the identification of the relevant proteins or peptides 
by focusing on the covariance structure between proteins rather than concentrating just on 
individual protein or peptides.  
The software therefore provides the user with the option of conducting a range of multivariate 
statistical tests. These methods are the focus of Chapter 6 which describes the available 
methods along with their advantages and limitations. These tests are: 
 Principal Component Analysis (PCA) 
 Hierarchical Cluster Analysis (HCA) 
o These techniques involve the use of distance and correlation measures. All the 
available distance and linkage algorithms can be used in Biomarker Hunter 
based on user choice. 
 Partial Least Squares – Discriminant Analysis (PLS-DA) 
There are other multivariate techniques that can be utilised to analyse data of this nature. 
These were not used in Biomarker Hunter as there was not enough time to apply these 
methods within the EngD study period. These methods include Support Vector Machines 
(SVM) and Neural Networks. SVM is a supervised machine learning model with associated 
learning algorithms that analyse data and recognise patterns, used for classification and 
regression analysis. A basic SVM uses a set of input data and predicts which of the two 
possible classes form the output (Hua & Sun, 2001). Neural networks are part of the field of 
artificial intelligence which, in contrast to being programmed, are trained. This means that 
examples are presented to the network and the network adjusts itself by some learning rule 
usually based on how correct the response is to the desired response (Livingstone et al, 1991). 
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2.2.2.3 Additional Analysis 
As well as the univariate and multivariate analysis conducted there are other pieces of 
information extracted from the dataset that help with the determination of a potential 
biomarker. These are returned in the output files. The additional analysis includes: 
2.2.2.3.1 Feature Presence  
This is the number of values present for each feature within each sample group. This is 
represented as a number rather than a percentage. The feature presence is useful, as certain 
potential biomarkers may have a low feature presence. These features are harder to detect 
making them relatively poor choices for biomarkers. If it is hard to detect using advanced 
proteomic techniques then this reduces the potential for practical application of the 
biomarker. There is also the issue that there is limited information used to conduct the 
statistical tests. The number of present values for each feature within all the samples will also 
be presented as the total feature presence. 
2.2.2.3.2 Mean Values 
The average of all the intensities within each sample group will be calculated to present the 
user with more information about the actual data within each group. This takes into account 
the presence of missing values (i.e. divides the sum of abundance by the number of present 
values rather than number of samples in question). 
2.2.2.3.3 Fold Change (Ratio) 
This is a number which explains how much a quantity varies between groups. This is 
calculated by dividing the mean of the primary group by the mean of the secondary group 
(i.e. Group 1 Vs Group 2 -> Mean(Grp1)/Mean(Grp2)). A negative value suggests that there 
is a decrease in means from the primary group to the secondary group.  A fold change will be 
calculated between all the sample groups involved. The fold change, or ratio, is usually 
considered a relevant criterion for stating difference and similarity between measurements 
(Tchitchek et al, 2012). As a rule of thumb, MS-based proteomics should aim to be accurate 
within a 1.3- to 2-fold change, which is a cut-off often chosen for biological significance 
(Mann & Kelleher, 2008). This fold-change level though depends on the experiment. There 
are open questions with regards to the reliability of the degree of fold change from proteomic 
quantitative data sets (Mahoney et al, 2011).  
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Selecting differentially expressed proteins only by fold change is thought to lead to more 
false conclusions than acceptable. It is however a useful piece of information which can be 
combined with other statistical information in order to lead to more reliable conclusions. For 
example higher abundance proteins have more quantifiable peptides, and the precision of 
quantitation is higher than for low-abundance proteins with few peptides. This means that the 
significance of an observed fold change should be considered in the context of absolute 
protein abundance. Some researchers have even developed improved versions of fold change, 
which incorporate other information for identifying differentially expressed proteins in 
shotgun proteomics (Carvalho et al, 2012). 
 
2.2.3 Data post-Processing (Multiple Testing Corrections) 
The user has the option to perform multiple testing corrections to allow for the error produced 
when performing a large number of statistical significance tests. This is presented as an 
option, as a user may not want to implement multiple testing because they want to retain all 
the potential biomarkers. There are also a number of multiple testing correction options 
available to the user. 
Once the p-values have been obtained the user is asked whether they would like to conduct 
any multiple hypothesis testing corrections. The user can choose from five different 
correction methods which are described in detail in section 4.3.2. Following all the above 
analysis the output is presented to the user in the form of comma separated value (.csv) files. 
If multiple testing corrections are applied then two output files are created (1: Uncorrected 
data, 2: Corrected data).  
2.2.4 Results Presentation 
This section describes the various outputs from the Biomarker Hunter Pipeline that can be 
used to help analyse the results from all the statistical tests. 
2.2.4.1 Univariate Output Files 
This .csv file will present all the p-values from the univariate analysis as well as the 
additional analysis conducted as described in section 2.2.2.3 (ProjectName_FullOutput.csv). 
Each row represents a feature (peptide or protein), while the columns are appropriately 
labelled as to the information they contain. The contents of this file are outlined in Table 8. If 
multiple testing corrections are applied then a version of this .csv will also be created with the 
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corrected p-values. As well as containing the relevant p-values for all the hypothesis tests the 
output files also contain group means, feature presence, and fold-changes between each 
group.  
 
Table 8 - An outline describing the contents of each column of the FullOutput.csv files 
(Shaded sections suggest multiple columns are included) 
Column Heading Contents 
Feature Identifier An identifier representing a feature (peptide) (PCI or MCI). 
Mean A mean abundance value is calculated for each sample group. 
Feature Presence 
Group  / Total 
Shows the number of samples within the group in which the feature 
has been detected. The total feature presence is the number of 
samples in which the feature is detected in all the groups. 
Fold Change A number explaining how the means vary between groups. 
Welch T Test (Pair-
wise comparisons) 
 The T-test p-value is returned comparing each group against the 
others.  
ANOVA p.value A single p-value comparing all the groups.  
ANOVA Tukey 
(Pair-wise 
comparisons) 
The ANOVA Tukey p-value is returned comparing each group 
against the others. 
Kruskal-Wallis    A single p-value comparing all the groups.  
Wilcoxon (Pair-wise 
comparisons) 
 The Wilcoxon p-value is returned comparing each group against the 
others.  
An additional .csv file is created containing lists of all the features that have been identified 
as a potential biomarker (ProjectName_BiomarkerList.csv). A potential biomarker is a 
feature which gives a p-value less than 0.05 for any of the univariate statistical tests. A list 
will be presented for each univariate test conducted showing the feature identifiers and their 
respective p-values as shown in Table 9. 
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Table 9 - An example of a potential biomarker list produced by Biomarker Hunter 
showing the feature identifiers and respective p-values for the biomarker candidates. 
This shows the results of a group comparison of hypothetical Groups A and B. 
Potential markers identified by            
T-Test ( A  / B ) 
P-Value Potential markers identified by 
Wilcoxon ( A  /  B ) 
P-Value 
63689 0.0172 63689 0.0198 
7323 0.0180 4091 0.0305 
 
Users may conduct multiple analyses using the same datasets but using the different options 
presented in Biomarker Hunter. In these cases it is of utmost importance to keep track of the 
different options used for the analysis. Therefore an options file is created for each analysis 
stating the various options used (Table 10). This provides traceability of the data pre- and 
post-processing options used for the analysis. 
Table 10 - An example of an options file. This identifies the user choices with regards to 
the various options available in Biomarker Hunter. 
Biomarker Hunter Options Filename: 
Is the data natural logs? n 
ClusterFix used? y 
Is Multiple Testing implemented? y 
Multiple Testing Method? BH 
Missing data imputed? y 
User defined Minimal Value Imputation used? N/A 
 
2.2.4.2 Clustering Output Files 
If the clustering option described in Chapter 2.2.1.3 is selected then there are a number of 
additional files created in the results folder. A copy of the dataset following clustering is 
presented as a .csv file (Table 11). Additionally a file which shows the result of the clustering 
on each feature is created in a .csv format (ProjectName_ ClusteredData.csv). This shows 
which features have been clustered together. 
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Table 11 - An outline describing the contents of each column of the ClusteredData.csv 
files (Shaded sections suggest multiple columns are included). 
Column  Notes 
Feature 
Identifier 
The following columns are present for each feature. The clustering loop iterates 
through each feature as the primary feature: the feature against which all other 
features (secondary features) will be checked for potential matches. 
 Status This column will state any clustering changes that are relevant to each 
feature. 
Number of 
potential 
matches 
The number of secondary features which have been found within the 
Primary features mass-retention time window.  
Clustered (as 2º) 
with Feature 
For any feature which has been classed as “Matched” this column will 
identify the feature they have been matched with (Primary feature). 
2º Matches The secondary features which are potential matches for the Primary 
feature. 
In order for users to observe the effectiveness of the clustering option a comparison table is 
created to be acquainted with the effects of clustering on the number of missing values as 
shown in Table 12. 
Table 12 - An example of a Cluster Comparison table which outlines the effectiveness of 
clustering on the dataset. 
 
2.2.4.2 Multivariate Results 
If the multivariate option is chosen the user will also be presented with multivariate results. 
This includes principal component analysis (PCA), hierarchical cluster analysis (HCA) and 
partial least squares discriminate analysis (PLS-DA). PCA results are presented as a plot of 
the two most important principal components (i.e. components that represent most of the 
variance between the groups). HCA results are presented as dendrograms showing the 
distance relationships between groups. The PLS-DA test returns a list of potential 
biomarkers. 
Initial Post-Clustering
Number of PCI 10,000 9,500
Total Possible Values 200,000 190,000
None Missing Values 170,000 170,000
Percentage of None missing Values 85.00 89.47
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2.2.4.3 Boxplots 
Biomarker Hunter gives the user the option to create boxplots for features of interest 
following the statistical analysis. Boxplots are a good method for displaying sample 
differences across groups of data for visual comparison. An illustration of the principle of 
boxplots is shown in Figure 27.   
2.2.4.3.1 Methodology of Boxplots 
These are also called box and whisker plots. They summarise the following measures: 
 The median of the group 
 The upper and lower quartiles of the group 
 The minimum and maximum data values from the data group 
The box in a boxplot contains the middle 50% of the data. The upper edge of the box 
indicates the 75th percentile (third quartile) of the data set, and the lower part indicates the 
25th percentile (first quartile). The range of the box is also known as the inter-quartile range 
(IQR). The line within the box represents the median value of the data in the group. If this 
line is not exactly in the middle of the box, this suggests the data is skewed. 
The "whiskers" or extremes of the vertical lines represent the minimum and maximum data 
values in the group. If there is a presence of outliers the whiskers extend to a maximum of 1.5 
times the inter-quartile range. The points outside the ends of the whiskers are outliers or 
suspected outliers. 
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Figure 27 - An example of a boxplot illustrating what various points of the boxplot 
represent. Outliers that do not fit the model will be represented by lone data points 
 
Boxplots present many advantages. They are a very convenient way to graphically display a 
variable's means and spread at a glimpse. They allow the indication of the data's symmetry 
and the presence of any data skewing, while taking the outliers into consideration. Creating a 
boxplot for a feature, one quickly can compare data between groups of samples side-by-side 
on the same graph. However, due to the large number of features in typical datasets, it is not 
practical to view boxplots for each feature. They can however be a good way to visualise data 
for features of interest (i.e. markers or non-markers) after the conclusions from the univariate 
or multivariate have been reviewed. 
A weakness of boxplots is that they have a propensity to give emphasis to the tails of a 
distribution, which are the least certain points in the data set. They also tend to conceal many 
of the particulars of the distribution (Tukey, 1977).  
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2.2.4.3.2 Implementation of Boxplots in Biomarker Hunter 
Following the statistical analysis of datasets and the creation of all the output files, the user 
has the option to create boxplots for features of interest or those that warrant further 
investigation. The user can input the feature identifier and a boxplot will be created using the 
bplot function in R, which is part of the “fields” package. 
2.2.4.3.3 Results of Boxplots in Biomarker Hunter 
Examples of boxplots created using Biomarker Hunter are presented throughout this thesis. 
 
2.2.5 The Use of Biomarker Hunter 
All algorithms used in the software pipeline have been individually validated using existing 
techniques. Results obtained for all calculations were compared against results from various 
validated tools such as Microsoft Excel, GeneSpring (Agilent, 2011) and manual calculations. 
Chapter 3 presents results from univariate analysis conducted using Biomarker Hunter for 
Dataset 3 described in section 2.1.3. This analysis does not apply any data pre- and post-
processing options discussed in this chapter. The effect of these options will be presented in 
Chapter 4. The options for dealing with missing values will be evaluated in Chapter 5. The 
uses of the multivariate options in Biomarker Hunter are presented in Chapter 6.  
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3 Univariate analysis 
Four univariate tests were chosen for this pipeline. The choice of these four tests was based 
on a review of appropriate analysis methods for this purpose (Bantscheff & Kuster, 2007). 
They were also chosen because this range of tests cover both a parametric and non-parametric 
univariate alternatives for both pair-wise analysis (i.e. 1 vs. 2), and group-wise analysis (i.e. 1 
vs. 2 vs. 3 vs. 4) as shown previously in Figure 25. Scores which indicates the number of tests 
that identify each individual peptide as differentially expressed (i.e. a potential biomarker) are 
also presented. 
The theory behind these tests is that for those features with a low p-value (i.e. p-value < 0.05) 
there is a 95% chance of the two groups being different, hence the treatment or differences 
between the groups have an effect on the peptide or protein. The features (MCI, PCI, protein 
or peptide) with the low p-values can then be investigated further as potential biomarkers. Of 
course just one low p-value doesn’t necessarily suggest a change between samples. So the 
result output from the software contains a column which counts the number of low p-values 
for each peptide or protein. This allows the determination of peptides or proteins (features) 
that warrant further investigation (i.e. as the number of statistical tests returning a low p-value 
increase, so does the confidence in the result not occurring simply by chance).  
This chapter concentrates on the four univariate techniques used for statistical analysis. Each 
technique will be reviewed by discussing the methodologies as well as the uses and 
limitations of each technique. Results of the univariate analysis conducted on Dataset 3 are 
also presented and finally the results from all four techniques will be compared and 
evaluated. Since these techniques do not allow for missing values to be involved in the 
analysis, the missing values in Dataset 3 will be replaced by zeroes for the purpose of 
statistical analysis in this chapter. This method of imputation is not ideal for this purpose. The 
reason this crude imputation was used for this section is that one of the project aims is to 
highlight the effects of imputation. This statistical analysis also does not involve the use of 
any of the data pre- and post-processing methods described in section 2.2 of the Materials and 
Methods chapter. These will be investigated later in the statistical analysis conducted for 
Chapter 4. 
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3.1 The T-test 
One of the major questions asked in the majority of biomarker studies is whether a particular 
treatment or intervention has caused a significant change in a biological parameter. The 
Student’s t-distribution (Appendix D) is a probability distribution, which allows the means of 
normally distributed datasets of relatively small number of samples to be compared against 
each other. This is done by comparing the means relative to the sample variation or 
dispersion (standard deviation of the difference between sample means) of the sample groups.  
For smaller datasets the calculated means and standard deviations are not representative of 
the actual mean and standard deviation (those which would be derived in the presence of 
larger datasets). In most real-life statistical studies the standard deviation of the population is 
unknown, so estimations need to be determined from the datasets themselves.  Using the 
Students’ version of the t-test allows for the existence of outliers in the data unlike normally 
distributed data. 
The paired t-test is a statistical hypothesis test which can be used when the comparison of two 
small sets of quantitative data is needed, where each of the samples are related in a certain 
way. The test is used to determine if two groups of samples are statistically different from 
each other (Figure 28). The statistical power of the paired t-test lies in studies where 
differences between groups are relatively small compared to that of the variation within 
groups. 
 
Figure 28 - Comparison of means of a control and a treatment group (Trochim et al, 
2006). 
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The paired t-test also allows determinations of whether differences between sample sets are 
significantly different. It is based on whether the differences between datasets are relative to 
the spread or variability of the data. When comparing sets of data, the differences between 
the mean values may be identical, however the variation between datasets may be different. 
Groups within datasets displaying low variability will appear as more different, as there is 
less overlap between the curves (Figure 29). When there is high variance the difference 
between groups will appear as less important.  
The most common design of a paired t-test would be where one attribute variable represents 
different individuals and the other may be before and after some form of treatment. 
Sometimes pairs can be spatial rather than temporal (i.e. left vs. right etc). An example may 
be a patients resting and active heart rates following heart surgery. 
 
Figure 29 - Different variability between datasets (Trochim et al, 2006). Samples with 
lower variability appear as more differentiated due to less overlap, compared to those 
displaying a low variability. 
 
The null hypothesis of a paired t-test would be that the mean variation between paired 
observations is zero. A prerequisite for the test is that the differences between pairs are 
normally distributed. Where this is not the case, the Wilcoxon signed rank test can be used 
instead (Rosner et al, 2006). Alternatively the Welch version of the T-tests can be applied to 
allow for non-normality of data distribution. 
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3.1.1 Methodology of the T-test 
There are various forms of the t-tests and it is important to use the appropriate method for the 
intended purpose. This section describes the process of both the Students t-test as well the 
paired t-test. 
3.1.1.1 Methodology of the Students T-test 
The null hypothesis of the Student’s t-test assumes that the test data displays a student’s t 
distribution (Equation 1). The probability density function for the Student’s t-distribution has 
the similar bell shape of the normal distribution curve with a zero mean and a variance of 
one. The bell is however usually shorter and wider as actual statistical data is not usually 
evenly distributed but approaches the taller and narrower shape as the number of degrees of 
freedom increases. The reason for the shape is because real life data would usually have more 
occurrences in the tails.  
      
  
   
  
     
 
  
     
  
 
 
  
   
  
 
Equation 1 - Probability density function for the Student t-distribution (v = Degrees of 
freedom, Γ = Gamma function, t = t-statistic). 
The student form of the t-test also assumes that the variances of the involved data sets are 
equal (i.e. display homoscedasticity). The original form of the student t-test cannot be 
conducted unless this is the case. The homogeneity of variances between groups can be 
checked, usually by utilisation of Levene’s test (Livingston, 2004). The test involves 
calculation of a t value which is checked against the relevant threshold p-value at the required 
statistical significance level from the students t-distribution table, which is usually 0.05 (95% 
significance level) for most biological research. As the calculated t-value increases so does 
the probability that there is a statistically significant difference between the groups of data. If 
the value is higher than the threshold value then the null hypothesis can be rejected and the 
conclusion can be made that the variations between the samples are not simply due to chance. 
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A T-test can be conducted on groups of data using the following steps: 
1. The null hypothesis (H0) assumes there is no difference between the sample means. 
The alternative hypothesis (HA) is that there is a difference caused by the treatment. 
2. n1, n2 = Number of replicates of each respective sample 
3. 1, 2 = Mean of respective sample sets 
4. ,  = Standard deviation of respective sample sets  
5.   = Variance of the difference between the means 
                 
   
  
  
   
  
 
 
6. A t-value can then calculated 
   
       
    
  
       
  
 
7. Obtain p-value from t-table (Appendix D) 
a. Degrees of freedom:- total number of samples – 2 
b. Significance level:- Usually 0.05 (i.e. 95% significance level)  
8. The null hypothesis is rejected if the calculated t-value is above that of the p-value 
and a conclusion can be made that there is a significant difference in the two samples.  
The t-value increase as differences between the means become more significant. The t-
value is positively correlated with the number of samples so lower sample sizes cause 
lower t-values. The t-value will also increase as the standard deviation of the samples 
decreases, because when samples are less scattered the groups are more likely to be 
significantly different if the means of the groups are different. Care needs to be taken 
when conducting multiple t-tests as this can result in incorrect conclusions (false 
positives), because this results in multiplication of the probabilities. As the number of 
successive t-tests goes up, the probability of significance decreases.  
 
3.1.1.2 Methodology of the Paired T-test 
Firstly the differences between the observations from the two samples are calculated for each 
pair of samples. Subsequently the mean and the standard error of these differences are 
determined. The mean is divided by the standard error of the mean to generate a t-statistic 
(Ts). The Ts is t-distributed with degrees of freedom equal to one less than the number of 
pairs. 
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The t-test is performed using a formula which involves a ratio. The methodology is similar to 
that of the signal-to-noise ratio (Trochim et al, 2006). The difference between the two means 
is divided by a measure of the dispersion or variability of the scores, which is the standard 
error of the difference (1). The difference between the means is simply the difference 
between the obtained means for the two groups. The symbol  refers to the mean of the 
treatment sample and  being the mean of the control sample. The standard error of differences 
(variability) needs to actually be calculated. It is obtained by calculating the variance for each 
group, which is done by squaring the standard deviation. The variance is then divided by the 
population of the sample. These values are then added together and their square root is taken 
(3). If the treatment mean is larger than that for the control sample the t-value will be positive 
and vice versa.  
Once the t-value has been obtained it is compared against the t distribution table to determine 
whether the ratio is big enough to be significantly different. The table has columns which 
represent the different significance levels (0.05 (95% confidence) is usually the accepted 
significance level. A 95% significance level suggests that there is a 5% chance that the 
difference may be classed as statistically significant but actually are not different, and are just 
differentiated through chance. The rows of the table represent the degrees of freedom for the 
analysis. For the t-test the degrees of freedom would be the total population of samples in 
each group minus the number of groups (two for the paired t-test). The relevant t-statistic can 
be found from the significance level and degrees of freedom and subsequently compared to 
the t-value obtained from the calculations. If the calculated t-value is higher than that of t-
statistic obtained from the table, the null hypothesis can be rejected and we can conclude that 
the two sets of data are statistically different. 
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3.1.2 Constraints to the T-test 
3.1.2.1 Constraints to the Students T-test 
T-tests are very sensitive to the interdependence of data. If individual samples within the data 
sets have intrinsic relationships with each other the tests may conclude that differences are 
present between the groups, even when there are not any. These may occur due to: 
  Unknown relationships existing within the datasets. E.g. A particular group of 
patients who may be intolerant to the treatment existing in one group. 
 Time-series effects where the time of sample collection has an effect on the biological 
data. E.g. Circadian rhythm may have an effect on the proteins expressed in a 
biological system. 
 Effects caused by the origin of the data. E.g. One group of data being heavily 
represented by a minority not representative of the actual population. 
Like all other statistical studies the analysis of the data can only be as good as the quality of 
the data collected. If the experimental design used to collect the information is flawed then no 
amount of statistical manipulation can surmount the inability to interpret the results 
(Livingston, 2004). Therefore it is essential the data is of the correct nature and correctly pre-
treated, if necessary, before conducting the student t-test (or any statistical analysis for that 
matter), to avoid misuse of the test(s) (Table 13). As with any statistical test the limitation of 
the test is that nothing can be proved or disproved, however statements with a degree of 
accuracy can be made. 
The size of a sample is positively correlated with the probability that the sample of the mean 
is the same as the mean of the entire population. The central limit theorem suggests that when 
smaller numbers of values are used to represent larger populations there is a lower probability 
that the calculated mean is the same as the actual population mean (Livingston, 2004).  
The t-test is not suited to studies where the comparison of more than two groups is required 
because the test compares one group directly against another. One reason for this is that the 
number of tests increases as a function of the number of groups leading to increased 
complexity. Also due to the increased number of analyses there will be an increase in the 
possibility of Type I (false positive) errors.  
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Table 13 - Conditions that must be considered when applying T-tests (Livingston, 2004). 
Factor Explanation Test for factor Solution 
Implicit 
factor 
Data are not 
randomly 
distributed; the value 
of a data point is 
dependent on some 
factor relating to 
how it was collected.  
Determine correlation 
between the data and 
the order in which it 
was collected either 
statistically or by 
plotting as a graph. 
Evaluate experimental design; 
randomise when possible. 
Consider regression analysis 
with statistical control for 
implicit factors. 
Sample 
independence 
Samples in the two 
groups depended on 
one another. 
Determine correlation 
between the two 
samples. Evaluate 
experimental design. 
Paired t-test. 
Outliers Outliers will affect 
both mean values 
and variances. 
Evaluate probability 
graphs to determine 
the effect of outliers. 
Use nonparametric statistics. 
Normal 
distribution 
If the population 
from which the 
sample is derived is 
skewed, t-testing 
may be invalid. 
View probability or 
box plot; quantitate 
skewness. 
If the skew in the two 
populations is the same, then t-
tests are generally accurate as 
long as the sample sizes are 
approximately equal. Skew has 
little effect if sample sizes are 
greater than 10 in each group. 
Perform log, square root, or 
inverse transform on original 
data. Check normalisation 
following transformation with 
repeat probability or box plot. 
Unequal 
variance 
Conventional t-tests 
require that the two 
populations being 
compared have 
equal variance. 
Examine the sample 
distributions 
graphically or perform 
f-test for equal 
variance on the 
samples. 
Nonparametric tests or t-tests for 
unequal variances. If the two 
samples have the same number 
of samples, then the t-test is 
likely to not be affected by 
unequal variance. Variance can 
be equalised by log 
transformation. 
Unequal 
sample size 
Small sample sizes 
tend to have large 
variances. If one 
sample is large and 
the other small, it is 
likely that there are 
unequal variances. 
Determine power of 
the t-test. 
Increase sample size. 
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3.1.2.2 Constraints to the Paired T-test 
Biomarker discovery studies search for the causes of changes in biological state. As well as 
the various biological states, there are sometime other factors that are associated with the 
exposures that the study is investigating which independently affects the biological states. If 
the occurrence of these factors varies between groups being compared, they distort the 
observed association between the disease and exposure under study.  These are called 
confounding factors or variables (CDPH, 2009). Additionally, although the paired t-test is 
ideal for the evaluation of differences between two sets of values, however problems may 
occur when trying to analyse other types of differences (Linnet, 1999).  
3.1.3 Alternatives to the T-test 
Non-parametric statistical tests can be used as alternatives to the student’s t-test where t-
testing is inappropriate. The ability of non-parametric tests to detect differences is not as 
powerful as the parametric counterparts so they should usually not be used as a first choice 
(Dallal, 2000).  
3.1.4 T-test Implementation in Biomarker Hunter 
The Welch version of the T-test was used in Biomarker Hunter because the alternative, 
student’s T-test requires the samples to display equal variances. Since the Welch T-test does 
not make any assumptions about the variance between sample groups, it is more preferable. 
This test however does assume that both populations have the same standard deviation. Since 
different biological samples are used for each run, the unpaired version of the T-test is used, 
as the paired algorithm assumes the samples being compared are from the same biological 
sample. 
The T-test is applied by comparing each of the treatment sample groups against an untreated 
control sample group. The T-test returns a p-value, which is the probability of the two groups 
being compared being significantly different. This test compares peptide intensities for each 
group against each of the other groups. For the purposes of analysis there is a numerator 
(primary sample group) and a denominator (secondary sample group) as described in the 
previous section. This test is implemented in R using a loop, which conducts a test conducted 
individually on each feature being analysed, comparing every group of samples against each 
other. The test is applied using the t.test function in R. 
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3.1.5 T-test Results 
The Welch T-test was conducted on Dataset 3 (Xenograft Pre-Clinical Project - label-free 
analysis) which aims to compare four groups of samples. This resulted in a total of 1171 
features (peptides) being identified as potential biomarkers (i.e. showing a statistically 
significant difference in expression) between the different sample groups (Table 14). Some of 
these potential markers were identified as significantly differentially expressed in more than 
one group comparison, and subsequently 806 unique features were classed as features of 
interest (i.e. returning a p-value lower than 0.05 for the T-test). 
Table 14- The number of biomarkers (statistically different features) found using the 
initial Welch T-tests on Dataset 3, for each group comparison. The first column states 
the groups being compared. 
Groups 1 2 3 4 
1 1171 
 
2 160       
3 264 265     
4 124 142 216   
 
Researchers may want to identify how many features are identified as significantly 
differentiated in more than one pair-wise univariate test as shown in Table 15. This shows 
that eight features were identified as significantly differentially expressed in four of the six 
group comparisons. These features are identified in Table 16, and are likely to be strong 
candidates for further validation. However this fact can only be determined once these results 
are compared with a list of validated biomarkers identified from this study. This information 
was not available so it was not possible to determine whether those potential markers 
identified in more than one pair-wise test is more likely to be a stronger marker. 
Table 15 - The count of features found as significant in the Welch T-test for Dataset 3 
and the number of tests in which they were identified as such. 
 
 
 
+ve Hypothesis Tests Number of 
Features 
1 530 
2 195 
3 73 
4 8 
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Table 16 - The feature identifiers and p-values for the eight features that were identified 
as significantly different in four of the group comparisons, using the Welch T-tests on 
Dataset 3.  
 
 
 
 
 
 
 
 
 
Table 17 shows a list of features with the ten lowest p-values for each group comparison. 
From this list of 60 features, ten of them were identified as potential biomarkers in more than 
one comparison (Table 17), suggesting they may be stronger candidates for further validation. 
It was noticed that feature 1722 was identified as a biomarker in four group comparisons 
(Table 16) as well as having the lowest p-value for two group comparisons (Table 17), 
suggesting that this feature may be of interest and warrants further study. A boxplot was 
created using Biomarker Hunter to visually inspect the data for feature 1722 (Figure 30), in 
order to determine whether the results from the T-tests correlate with the raw data. 
 
 
 
 
 
 
 
 
 
Potential Biomarkers in 
Four T-tests 
p-values 
1722 0.000361 0.040343 0.000368 0.03478 
18970 0.02488 0.022415 0.012784 0.011264 
2364 0.04088 0.036751 0.038101 0.041704 
2658 0.007867 0.017965 0.016167 0.037666 
4427 0.006579 0.024673 0.005383 0.030516 
6856 0.005809 0.001557 0.006438 0.00175 
7603 0.028199 0.047512 0.026475 0.044272 
9166 0.016999 0.028767 0.023953 0.041033 
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Table 17 - The list of features with the lowest p-values for each of the group 
comparison, using the Welch T-tests on Dataset 3. 
Welch T 
Test (2/1) 
p-
values 
Welch T 
Test (3/1) 
 p-
values 
Welch T 
Test (4/1) 
 p-
values 
9066 0.000428 12800  0.000131 
1020 
 0.000819 
6427 0.000944 1250  0.000141 
9660 
 0.00174 
1599 0.002371 2159  0.000197 
20767 
 0.002691 
6144 0.002671 4485  0.00021 
3260 
 0.004108 
7010 0.003387 10036  0.000214 
10383 
 0.005261 
1775 0.003643 5839  0.000231 
2122 
 0.006272 
8051 0.0038 5384  0.00028 
4240 
 0.00888 
8408 0.003922 8215  0.000303 
20722 
 0.009928 
5135 0.004778 1722  0.000361 
6113 
 0.010344 
2692 0.005423 1231  0.000369 
2929 
 0.0105 
Welch T 
Test (3/2) 
p-
values 
Welch T 
Test (4/2) 
 p-
values 
Welch T 
Test (4/3) 
 p-
values 
8973 0.000162 10383  0.000481 6635  0.000197 
11067 0.000232 22835  0.001195 2159  0.000209 
12800 0.000238 749  0.001331 1803  0.000247 
10034 0.000316 6427  0.002542 10547  0.000448 
10202 0.000355 21970  0.003182 5839  0.000457 
1722 0.000368 531  0.003554 8151  0.000481 
4262 0.000411 11899  0.003818 4824  0.000738 
9303 0.000543 8051  0.004224 7767  0.000744 
8032 0.000571 404  0.004862 9077  0.000847 
8215 0.000624 4427  0.005383 8973  0.000917 
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Table 18 - A list of features which returned the lowest p-values in more than one group 
comparison using the Welch T-test, with the number of tests in which they were 
identified as such. 
Welch 
Lowest P-
Values 
Number of 
Occurrences 
8051 3 
1722 2 
2159 2 
5839 2 
6427 2 
8215 2 
8408 2 
8973 2 
10383 2 
12800 2 
Looking at the boxplot for feature 1722 (Figure 30) it can clearly be determined that the 
intensity values from group 3 are significantly lower than the other three groups. The plot 
shows that 50% of its values are almost out of the total range of values for the other groups 
(i.e. the box for Group 3 is almost outside the range of the whiskers for the other groups). 
This boxplot supports the Biomarker Hunter conclusion that this feature is a strong candidate 
as a potential biomarker.  
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Figure 30 - A boxplot comparing the four groups of intensity data presented for feature 
1722, which was identified as a biomarker in four group comparisons as well as having 
the lowest p-value for two group comparisons 
For comparison a boxplot was also created for feature 12004 which was only identified in 
one group comparison and had a relatively higher p-value (i.e. 0.049985), than the other 
biomarker candidates. This was done to determine whether the data correlates with the 
Biomarker Hunter conclusions. It is expected that the groups of data will show a difference; 
however the variance between the groups in these cases is less likely to be as obvious, 
compared to those displayed by feature 1722. These expectations were confirmed in the 
boxplot for feature 12004 shown in Figure 31. Looking at this there is no clear distinction in 
the abundance of this protein between the groups. 
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Figure 31 - A boxplot comparing the four groups of intensity data presented for feature 
12004, which had a relatively higher p-value, than the other biomarker candidates. The 
dots represent outliers which were outside the accepted values for the whiskers. 
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3.2 The Wilcoxon Mann-Whitney Test 
Also known as the Wilcoxon rank-sum test, this is a non parametric alternative to the two-
sample t-test, and allows researchers to signify if two samples appear as if they are from the 
same distribution. It uses the Hodges-Lehman estimate of variance in central tendencies 
between populations. As with all of these statistical models, the null hypothesis is that the 
samples belong to the same population and they subsequently have the same probability 
distribution (Variances in central tendencies between populations is zero).  
The Wilcoxon Mann-Whitney test assumes that the two samples being compared are 
independent of each other, and allows for different sample sizes. The test is very similar to 
Student’s t-test. It can only be conducted on numeric or ordinal data. Although the 
distribution doesn’t need to display normality and may have arbitrary values; however they 
must have the same shape. 
 
3.2.1 Methodology of Wilcoxon Mann-Whitney Test 
The model requires computation of a U value (often referred to as a U statistic). When using 
large samples, which is typical of biological data, computation is required; however when 
using smaller samples a simpler direct method is preferred. The Wilcoxon Mann-Whitney 
can be conducted to compare data using the following steps: 
1.  The data from all experiments used for the test should be arranged in a single list 
ordered by their value. Each value is then ranked. 
2. The ranks for each observation in Sample X are added up.  
R = Sum of all the ranks 
N = Number of observations  
                      
3. nx = Sample size for sample X 
Rx = Sum of ranks for Sample X 
         
          
 
 
The greatest value for U is the product of the number of observations in both groups 
(i.e. If Ux is at the maximum value, then the U value for Sample Y would be zero).  
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4. If the U value for Sample X is more than that the U value for most of the U values if 
the data was rearranged in random orders, the null hypothesis can be rejected. 
Therefore a conclusion can be derived that Sample X is significantly different to Y. 
 
When using biological samples the above method would become complex very quickly, so 
the normal approximation method can be used. 
 
1.    = Standard deviation of U 
     
                
  
 
2. μU = Mean of U 
μ
    
  
      
 
 
3. z-value = Standard normal deviate 
 
   
       
  
 
4. The significance of the z-value is checked against the normal distribution table 
(Appendix D). 
3.2.2 Constraints to the Wilcoxon Mann-Whitney Test 
When applied to smaller datasets, the generality of the test can make the test less powerful 
than the t-test. This also applies when there are small numbers of samples or replicates in 
each group. For example if there are only two replicates in each group, such as used in 
iTRAQ analysis the use of the Wilcoxon test is not useful. This is because the technique deals 
with ranks rather than the values so when the number of replicates is reduced, so is the power 
of the Wilcoxon analysis. Additionally the test doesn’t allow for the conclusion of two 
sample groups being the same even if no significant differences are found. 
3.2.3 Alternatives to Wilcoxon Mann-Whitney Test 
The Wilcoxon Mann-Whitney test can be used in all the situations where an independent 
samples Student’s t-test is appropriate. The Wilcoxon test is more robust with regards to the 
distribution of the samples, as it is not based on any assumptions of distribution, so is used 
more widely. However, the cost of this generality is that the t- test is more powerful because 
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it is based on actual values rather than ranks. When larger biological samples are used this 
loss of power is not significant.  
3.2.4 Wilcoxon Mann-Whitney Implementation in Biomarker Hunter 
The Wilcoxon test is the non parametric alternative to the two-sample T-test, and allows 
researchers to discover if two samples appear as if they are from the same distribution. It is 
also applied by the comparison of each of the treatment sample groups against an untreated 
control sample group. As with the T-test, the Wilcoxon test also returns a p-value indicating 
the probability of the null hypothesis being incorrect (i.e. the two groups being significantly 
different). This test also compares peptide intensities for each group against each of the other 
groups, as with the T-test. This is conducted in R using the wilcox.test function. 
3.2.5 Wilcoxon Mann-Whitney Results 
The Wilcoxon Mann-Whitney test was conducted on Dataset 3 (Xenograft Pre-Clinical 
Project) comparing four groups of samples. This resulted in a total of 1151 features being 
identified as potential biomarkers (i.e. showing a statistically significant difference in 
expression) between the different sample groups (Table 19). Some of these biomarkers were 
identified as significantly differentially expressed in more than one group comparison, and 
subsequently 805 unique features were classed as features of interest (i.e. returning a p-value 
lower than 0.05 for the Wilcoxon Mann-Whitney test). 
Table 19 - The number of biomarkers (statistically different features) found using the 
initial Wilcoxon Mann-Whitney tests on Dataset 3, for each group comparison. The first 
column states the groups being compared. 
Groups 1 2 3 4 
1 1151 
  
  2 137       
3 281 297     
4 106 108 222   
 
To identify how many features were identified in more than one test the number of 
occurrences for each feature were evaluated as shown in Table 20. This shows that two 
features were identified as significantly differentially expressed in five of the group 
comparisons, while four were identified in four group comparisons. These features are 
identified in Table 21, and are likely to be features that are of interest to researchers. Without 
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comparing these results with a list of actual, validated biomarkers it is not possible to assess 
whether the number of significant group comparisons affects the likeliness of that feature 
being an actual biomarker. This information was not available for the purpose of this study.    
Table 20 - The count of features found as significant in the Wilcoxon tests for Dataset 3 
and the number of tests they were identified as such. 
+ve Hypothesis Tests Number of 
Features 
1 534 
2 201 
3 63 
4 4 
5 2 
Table 21 - The feature identifiers for the features that were identified as significantly 
different in four or five of the group comparisons, using the Wilcoxon tests on Dataset 3. 
Feature 
Identifier 
Number of 
Positive Wilcoxon 
Tests 
4607 5 
6856 5 
18970 4 
2658 4 
4427 4 
540 4 
Table 22 shows a list of features with the ten lowest p-values for each group comparison. 
From this list of 60 features, nine of them were identified as potential biomarkers in more 
than one comparison (Table 22), suggesting they are likely to be of interest to researchers as 
potential biomarkers. It was noticed that features 4607, 540 and feature 4427 were identified 
as potential biomarker candidates in multiple group comparisons (Table 22) as well as having 
the lowest p-value for multiple group comparisons (Table 23), suggesting that these features 
are  likely to be of interest and warrant further study. A boxplot was created using Biomarker 
Hunter to visually inspect the data for feature 4607 (Figure 32), in order to determine whether 
the results from the Wilcoxon tests correlate with the raw data. 
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Table 22 - The list of features with the lowest p-values for each of the group 
comparison, using the Wilcoxon tests on Dataset 3. 
WilcoxTest 
(2/1) 
p-values WilcoxTest 
(3/1) 
p-values WilcoxTest 
(4/1) 
p-values 
1020 0.000487 540 0.000149 1020 0.000725 
9066 0.00105 4607 0.000206 20767 0.00414 
6427 0.001572 1231 0.000325 9660 0.00493 
7757 0.002455 9954 0.000418 7675 0.006253 
8408 0.002786 3333 0.000487 10383 0.007932 
7010 0.004571 8215 0.000487 3260 0.008218 
1599 0.005434 1250 0.000487 10553 0.008665 
4427 0.006815 12800 0.000566 916 0.008931 
3309 0.006841 4675 0.001293 3290 0.009004 
3921 0.007707 10036 0.001505 2071 0.009004 
WilcoxTest 
(3/2) 
p-values 
WilcoxTest 
(4/2) 
p-values 
WilcoxTest 
(4/3) 
p-values 
11067 0.000111 749 0.000325 540 0.000149 
540 0.000203 22835 0.001329 1058 0.000206 
1231 0.000206 7918 0.003363 1803 0.000206 
10034 0.000325 6427 0.00356 8151 0.000325 
8602 0.00038 10383 0.003775 10547 0.000431 
10202 0.000487 21970 0.004069 4824 0.000529 
8973 0.000725 11899 0.005328 4607 0.000572 
4262 0.000784 4427 0.006815 16924 0.000756 
12800 0.000784 4607 0.007913 4262 0.000784 
7268 0.00105 8051 0.008594 10375 0.000861 
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Table 23 - A list of features which returned the lowest p-values in the Wilcoxon analysis 
in more than one group comparison, with the number of tests in which they were 
identified as such. 
Wilcox 
Lowest P-
Values 
Number of 
Occurrences 
540 3 
4607 3 
1020 2 
1231 2 
4262 2 
4427 2 
6427 2 
10383 2 
12800 2 
Looking at the boxplot for feature 4607 (Figure 32) it can be seen that there are differences in 
the intensity values between the groups. The values from Groups 1 and 4 are significantly 
lower than the other two groups, while there is evidence to suggest that the abundance of this 
feature in Group 4 is significantly different to those in Group 3. The plot shows that 50% of 
the values from Group 4 are above the total range of values for the other groups (i.e. the box 
for Group 3 is outside the range of the whiskers for the other groups). This boxplot supports 
the Biomarker Hunter conclusion that this feature may be a strong candidate as a potential 
biomarker.  
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Figure 32 - A boxplot comparing the four groups of intensity data presented for feature 
4607, which was identified as a potential biomarker in multiple group comparisons. 
 
A boxplot was also created for feature 14340 which was only identified in one group 
comparison and had a relatively higher p-value (i.e. 0.048892), than the other biomarker 
candidates (Figure 33). This was done to determine whether the data displays the expected 
features. Again it was expected that the groups of data will show a difference; however it will 
show fewer differences between the groups. This boxplot showed that the differences 
between the values in Group1 are significantly different to Group 3 however there is 
insufficient data to compare with the other two groups. 
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Figure 33 - A boxplot comparing the four groups of intensity data presented for feature 
14340, had a relatively higher p-value than other features. 
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3.3 Analysis Of Variance (ANOVA) 
ANOVA represents a group of statistical models which help explain the variances within 
datasets by partitioning them into components by their different explanatory variables. It is a 
versatile model allowing data from a number of experiments to be analysed collectively and 
accounts for missing data, which is a typical trait of most proteomic data. The t-test is used to 
determine whether data contained in two groups is significantly different; however it is not 
able to deal with a larger number of groups in one computation. ANOVA compresses data 
into a single F-value to be able to evaluate the null hypothesis (that there is no difference 
between the different groups, i.e. a non-marker or that treatment has no effect on this feature). 
The technique allows distinguishing between the differences in the samples that occur due to 
group membership to those that occur simply due to chance or sampling errors. 
An example of how ANOVA is used in biological research can be explained using the 
Dataset 3. One-way ANOVA could be used for this study. There are four different groups of 
samples; where A, B, and C represent mice that have been administered with different doses 
of a treatment and the vehicle (control) group are mice which have not received treatment. 
The categorical variable to evaluate whether the treatment has had an impact would be the 
dose administered. The response variables would be the protein expression of the groups. 
One of the requirements of the ANOVA test is that the datasets are independent of each 
other. It assumes that all the data is normally distributed and displays homoscedasticity (i.e. 
display equal variances). The Kolmogorov-Smirnov and Shapiro-Wilk tests can be used to 
test the normality of the data, and Levene’s test is usually used to test that the datasets display 
homoscedasticity. ANOVA also assumes that samples have been randomly analysed. An 
ANOVA analysis should yield very similar result to t-tests, but ANOVA is preferred by 
researchers due to its increased power to deal with more complex experimental design.  
There are three main variations of ANOVA: 
 One-way ANOVA: This version is ideally suited to studies where there is one 
control group and several treatment groups. One-way ANOVA can be applied to two 
or more independent datasets but usually used when more than two datasets are 
involved (otherwise the t-test can be used). The one-way ANOVA can also be used on 
repeated measures, where a particular sample is used to measure the effect of different 
treatments (i.e. protein expression before and after a treatment on a sample). 
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 Factorial ANOVA: This is the ANOVA application used when the aim of the study 
is to evaluate the effects of two or more treatments. The most common form of the 
test is the two-by-two version (two independent variables, each with two levels). 
 MANOVA (Multivariate ANOVA): Can be applied when more than one dependent 
variable is present. 
One-way ANOVA tests are useful in evaluating the effects of different doses of treatment by 
identifying differences between various groups of data. ANOVA can also be used to analyse 
iTRAQ data from complex biological samples across several MS experiments (Oberg et al, 
2008). This is the form of ANOVA used in Biomarker Hunter and remains the focus of this 
topic. 
 
3.3.1 Methodology of ANOVA 
The aim of the technique is to obtain two independent estimates of population variance. One 
estimate is sensitive to the effects of any particular treatments and any errors between the 
groups, and the other is sensitive to errors within the group. If the null hypothesis is true, and 
there is no difference between treatment groups, then both these estimates should be equal 
resulting in an F-value of one. A ratio of larger than one suggests that the difference between 
the groups is larger than the error within the sample so the groups are significantly different.  
The general models usually used in ANOVA are: 
 Fixed effects model: Assumes all data is normally distributed and varies only in their 
means. In this model multiple treatments are applied to the datasets to observe if there 
are any changes in the response variable values. This allows estimation of the ranges 
of values that a particular treatment would generate in the population.  
 Random effects model: Assume the data describes a hierarchy of different datasets 
where the differences are constrained by the hierarchy. It is used in instances where 
treatments are not fixed, such as when various treatments (random variables) are 
sampled from larger populations.  
 Mixed effects model: A combination of fixed and random effects are observed in the 
datasets 
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ANOVA is conducted on data using the following technique: 
1. The null hypothesis for ANOVA assumes that there is no difference between groups 
(i.e. the treatments have no effect on the proteins expressed) 
2. Degrees of freedom (numerator) = number of groups – 1 
3. Degrees of freedom (denominator) = Total number of samples - number of groups 
This is also known as the expected variation of the group 
4. The formula for variance is: 
               
  
  
 
SS = Sum of squared deviation about the mean 
df = Degrees of freedom 
5. An F-ratio is calculated from the  
         
                                            
                                          
 
6. An f-value of around one is expected if the null hypothesis is correct, allowing for the 
conclusion that there is no difference between the datasets. If there is a significant 
difference between datasets (e.g. a particular treatment has an effect on protein 
expression) a significantly larger value is observed and the null hypothesis can be 
rejected.  When there are only two means being compared the F-test is equivalent to 
the t-test. The relationship between the two tests are: 
      
7. If the null hypothesis is rejected then the levels which differ should be investigated 
further. 
8. Tukey analysis on the ANOVA results can be conducted in order to identify the 
groups between which there are statistically significant differences. These results are 
also presented as p-values and are usually similar to results from the T-tests. 
 
3.3.2 Constraints to ANOVA 
ANOVA has limited strength in detecting linear relationships, due to the higher p-values 
(Lazic, 2008). This may result in more Type II errors (False negatives), and significant 
differences may not be noticed.  
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3.3.3 Alternatives to ANOVA 
If the data does not display normality the non-parametric Kruskal-Wallis test can be used as 
an alternative. The Kruskal-Wallis test allows for non-normality of data within the samples. 
A possible alternative to one-way ANOVA for the Dataset 3 may be to consider the doses as 
a continuous numeric variable and using a regression analysis method (Lazic, 2008). In some 
cases this may be more appropriate. When four samples (three treatments and one control) 
are used ANOVA will treat them as four parameters where regression only considers two 
parameters (the slope and the intercept). Due to the loss of a degree of freedom for every 
estimated parameter the ANOVA analysis has fewer degrees of freedom than the regression 
method. As a general rule, as the number of samples increase so does the power of regression 
analysis compared to ANOVA. There is the argument that using the regression method may 
increase the occurrence of Type I errors (false positives); however the inclusion of Type II 
errors is more of an issue.  
The results obtained from regression analysis are also less complex and in turn more 
informative. Care needs to be taken when using the regression method to avoid misuse. For 
example the predictor variable must be continuous and the relationship between the response 
and predictor variables must be linear.  
Another alternative is the two stage technique ANOVA-PCA which aims to compare the 
variance between datasets with the variance of the residual error (Sarembaud et al, 2007). The 
technique of principal component analysis is discussed in section 6.2. The variance is 
separated into factors.  
1. The data matrix is decomposed into data matrices based on different 
experimental factors (Principal Components). 
2. Principal Component Analysis (PCA) is conducted for each factor matrix with 
the residual error matrix taken into account. 
3.3.4 ANOVA (Analysis of Variance) Implementation in Biomarker Hunter 
One-way Welch ANOVA compresses data into a single F-value to be able to evaluate the 
null hypothesis that there is no difference between the different groups (e.g. that treatment 
has no effect). The technique allows distinguishing between the differences in the samples 
that occur due to group membership to those that occur simply due to chance or sampling 
errors. This test works in a group-wise manner and returns only one p-value for each peptide, 
which specifies the probability that there are statistically significant differences between all 
the groups. This is achieved in R using the aov function. 
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3.3.5 One-Way Welch ANOVA (Analysis of Variance) Results 
ANOVA analysis, and subsequent Tukey analysis, was conducted on Dataset 3 (Xenograft 
Pre-Clinical Project) which was provided by OBT comparing four groups of samples. This 
resulted in a total of 221 features being identified as potential biomarkers (i.e. showing a 
statistically significant difference in expression with a confidence level of 95%) between all 
the different sample groups (Table 24). Some of these features were identified as significantly 
differentially expressed in more than one group comparison.  
Table 24 - The number of potential biomarkers (statistically different features) found 
using the initial ANOVA analysis as well as the subsequent Tukey analysis on Dataset 3, 
for each group comparison. The first column states the groups being compared. 
Groups 1 2 3 4 
1 221 
2 25       
3 88 61     
4 23 22 83   
To identify how many features were identified as potential markers in more than one test the 
number of occurrences for each feature was evaluated as shown in Table 25. This shows that 
21 features were identified as significantly differentially expressed in three of the group 
comparisons. These features are identified in Table 26, and are likely to be strong candidates 
for further validation; however this can only be determined by comparing these results with a 
list of actual, validated biomarkers. As this information is not available it is not possible to 
identify whether this is true. 
Table 25 - The count of features found as significant in the ANOVA Tukey tests for 
Dataset 3 and the number of tests in which they were identified as such. 
+ve Hypothesis Tests 
Number of 
Features 
1 115 
2 62 
3 21 
 
Table 27 shows a list of features with the ten lowest p-values for each group comparison as 
well as the overall ANOVA analysis. From this list of 70 features, three of them were 
identified as potential biomarkers in three group comparisons (Table 28), suggesting they are 
strong candidates for further validation. Feature 8791 was the feature with the lowest p-value 
when all the groups were compared together so this feature requires further study. This 
feature was also identified in two post-hoc Tukey tests as a feature of interest.  
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Table 26 - The feature identifiers for the features that were identified as significantly 
different in three of the ANOVA Tukey tests on Dataset 3. 
Potential Biomarkers in Three 
ANOVA Tukey Tests 
12568 4427 
14297 4485 
1775 4515 
20955 4824 
23223 540 
2760 5839 
2929 6144 
31924 8791 
3226 8936 
4262 97 
9954   
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Table 27 - The list of features with the lowest p-values for each of the group 
comparison, using the overall ANOVA and subsequent Tukey tests on Dataset 3. 
Overall 
ANOVA   
P-Value 
p-
values 
ANOVA 
Tukey  
Group2-
Group1 
p-
values 
ANOVA 
Tukey  
Group3-
Group1 
p-
values 
ANOVA 
Tukey  
Group4-
Group1 
p-
values 
8791 0.000127 6144 0.001311 540 0.000272 10383 0.006943 
10375 0.00013 6427 0.00576 5839 0.000273 20767 0.008426 
2159 0.000139 7010 0.007135 1250 0.000483 9660 0.010865 
1231 0.000291 1775 0.008338 6985 0.000668 3260 0.013874 
5384 0.000312 31924 0.009498 9954 0.000751 3063 0.014104 
1020 0.00039 7415 0.013863 4485 0.000958 11164 0.015279 
941 0.000464 4427 0.014599 7010 0.001019 5052 0.018804 
5839 0.000673 1599 0.015373 4824 0.001559 2929 0.019387 
8237 0.000736 11164 0.015939 6641 0.003086 20955 0.024916 
9954 0.00077 2692 0.023826 3333 0.004006 4515 0.025333 
 
ANOVA 
Tukey  
Group3-
Group2 
p-
values 
ANOVA 
Tukey  
Group4-
Group2 
p-
values 
ANOVA 
Tukey  
Group4-
Group3 
p-
values 
2159 0.000102 22835 0.005237 10547 0.000137 
8215 0.000458 31924 0.007616 4824 0.00016 
4824 0.000766 9902 0.010395 10375 0.000369 
8791 0.000798 18970 0.012488 540 0.00064 
6144 0.00154 749 0.013451 97 0.000786 
7001 0.002145 6427 0.017372 4607 0.000867 
9723 0.002146 1775 0.017634 6076 0.001179 
1722 0.003091 2929 0.01945 6985 0.001195 
97 0.003728 6144 0.022393 916 0.001693 
5839 0.003906 10383 0.022831 4262 0.001767 
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Table 28 - A list of features which returned the lowest p-values in more than one group 
comparison, with the number of tests in which they were identified as such. 
ANOVA 
Lowest P-
Values 
Number of 
Occurrences 
4824 3 
5839 3 
6144 3 
97 2 
540 2 
1775 2 
2159 2 
2929 2 
6427 2 
6985 2 
7010 2 
8791 2 
9954 2 
10375 2 
10383 2 
11164 2 
31924 2 
 
It was also noticed that features 4824, 5839 and feature 6144 were identified as a potential 
biomarker in three group comparisons (Table 26) as well as having the lowest p-value for 
three post-hoc ANOVA Tukey tests (Table 26), suggesting that these features are also likely 
to be of interest and warrant further study. 
A boxplot was created using Biomarker Hunter to visually inspect the data for feature 8791 
(Figure 34), in order to determine whether the results from the ANOVA analysis correlate 
with the raw data. Looking at this boxplot, there is some evidence to suggest that there are 
differences between the groups. The values from Groups 3 are significantly lower than the 
Groups 2 and 4, as well as a slight difference in median values compared to Group 1. The 
plot shows that 50% of the values from Group 3 are almost below the total range of values for 
Groups 2 and 4 (i.e. the box for Group 3 is outside the range of the whiskers for Groups 2 and 
4). This boxplot supports the Biomarker Hunter suggestion that this feature may be a 
potential candidate as a biomarker.  
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Figure 34 - A boxplot comparing the four groups of intensity data presented for feature 
8791, which was the feature with the lowest p-value when all the groups were compared. 
A boxplot was also created for feature 8653 which was only identified as a potential 
biomarker in one group and returned a relatively higher p-value (i.e. 0.049230) for overall 
ANOVA analysis, than the other potential biomarker candidates (Figure 35). This was done 
to determine whether the data displays the expected features. Again it was expected that the 
groups of data will show a difference; however it will show fewer differences between the 
groups. This boxplot shows that the differences between the values between the groups are 
not as clear as compared to feature 8791 (Figure 34). This may suggest that feature 8653 may 
not be as strong a candidate as a potential biomarker as feature 8791; however it is not 
possible to make a definitive conclusion regarding this until the results are compared to a list 
of actual, validated biomarkers. 
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Figure 35 - A boxplot comparing the four groups of intensity data presented for feature 
8653, which returned a relatively higher p-value. 
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3.4 Kruskal-Wallis Test 
The Kruskal-Wallis is a non-parametric alternative to the ANOVA statistical hypothesis test. 
It is an extension of the Mann Whitney U test. Like the other methods used the Kruskal-
Wallis is a test for equality of population means between three or more groups. The test is 
identical to the Welch ANOVA but rather than testing the data, the data is replaced by their 
ranks (similarly to the Wilcoxon test). The Kruskal-Wallis compares the medians of the 
different sample groups (different treatments) to determine whether the null hypothesis can 
be rejected. Similarly to the other tests used the null hypothesis is that the sample groups 
come from the same population. The alterative hypothesis would be that there is a difference 
between the means of the groups being tested (i.e. the samples come from different 
populations). When using samples where the distributions of the sample groups have been 
proved to be non-normal and the variances have been found to be different, the Kruskal-
Wallis test is more ideally suited to the data than the Welch ANOVA.  
 
3.4.1 Methodology of the Kruskal-Wallis tests 
The Kruskal-Wallis test is conducted by: 
1. Ordering the data of all the samples in a single sequence in ascending order. 
2. A rank is given to all the values (the smallest value being ranked 1). If there are any 
equivalent values, the rank position is averaged. 
3. The ranks of the samples are split into their groups and are summed up in each group. 
4. The following formula is used to create a K (Kruskal-Wallis) statistic: 
  
  
      
 
  
 
  
 
   
         
n = total number of observations, i=sample, Ri = Rank of the sample 
5. If the calculated k value is less than the chi-squared table value then the null 
hypothesis is accepted (i.e. there is no difference between the populations of the group 
being tested). If it is greater than this value then we accept the alternative hypothesis, 
that there is a difference between the groups’ populations. A p-value is extracted, 
which is the probability of the null hypothesis being false. A p-value of 0.05 (5%) 
suggests that there is a 95% probability that the samples belong to different groups. 
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The parametric methods being used are the Welch T-test and its group-wise equivalent the 
Welch ANOVA. The Welch ANOVA analysis also returns what is referred to as the ANOVA 
Tukey p-values, which are the results of the Tukey HSD (Honestly Significant Difference) 
tests. The HSD tests are post-hoc tests used in conjunction with ANOVA, in which the p-
values from these tests show the probability of the individual group means being different 
from each other, allowing identification of groups whose means come from different 
populations. Since the ANOVA method is similar to the Welch T-test, the ANOVA Tukey 
conclusions are usually similar to the pair-wise Welch T-test results.  
 As described earlier the Kruskal-Wallis test is the non-parametric alternative to the group-
wise ANOVA. The non-parametric alternative to the T-test is the Wilcoxon-Mann Whitney 
test. As the Kruskal-Wallis test ignores the values, instead using the ranks, its post-hoc Tukey 
analysis is exactly the same as the pair-wise Wilcoxon-Mann Whitney p-values.  
3.4.2 Constraints to the Kruskal-Wallis Test 
Being a non-parametric analysis method, no assumptions are made about the populations’ 
normality and variance unlike ANOVA. It however does assume that the data distribution is 
identically shaped and scaled. When there is evidence of normality the Kruskal-Wallis is not 
as powerful as the ANOVA due to the fact that it is a non-parametric method. It works best 
when there are at least five samples present in each group (Gaten, 2000). Ideally both sample 
groups should have an equal feature presence but some differences are allowed.  
3.4.3 Alternatives to the Kruskal-Wallis Test 
An alternative to Kruskal-Wallis is to perform a one way ANOVA on the ranks of the 
observations. ANOVA when carried out on the actual data rather than the values is also a 
parametric alternative to the Kruskal-Wallis test. 
3.4.4 Kruskal-Wallis Implementation in Biomarker Hunter 
The Kruskal-Wallis was also implemented to offer a full range of statistical tests in 
Biomarker Hunter as well as to provide a group-wise alternative to the Wilcoxon Mann-
Whitney tests. It also provides the non-parametric alternative to the One-way Welch 
ANOVA. As with the ANOVA this test works in a group-wise manner and returns one p-
value for each peptide, specifying the probability that there are statistically significant 
differences between all the groups. This test is conducted in R using the kruskal.test function. 
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3.4.5 Kruskal-Wallis Test Results 
The Kruskal-Wallis group-wise analysis was conducted on Dataset 3 comparing four groups 
of samples in one test for each feature. This resulted in a total of 203 features identified as 
potential biomarkers (i.e. showing a statistically significant difference in expression) between 
all the different sample groups (Table 29). As stated earlier the post-hoc analysis for the 
Kruskal-Wallis is the same as the Wilcoxon pair-wise analysis.  
Table 29 - The number of potential biomarkers (statistically different features) found 
using the initial Kruskal-Wallis analysis on Dataset 3. 
Kruskal-Wallis TEST 
Number Of 
Biomarkers 
Overall KW 203 
Table 30 shows a list of features with the ten lowest p-values for the Kruskal-Wallis analysis, 
suggesting they are of further interest. Feature 4607 was the feature with the lowest p-value 
when all the groups were compared together. Both this feature and 4262 were identified as 
being in the list of ten features with the lowest p-values, as well as being identified in the list 
of ten lowest Wilcoxon p-values for multiple group analyses (shown earlier in Table 23). 
This suggests that both these features may be of potential interest as a biomarker. 
Table 30 - The list of features with the lowest p-values for each of the group 
comparison, using the overall Kruskal-Wallis tests on Dataset 3. 
Kruskal 
Wallis Lowest 
P-Values 
p-values 
4607 0.000125 
8215 0.000321 
10547 0.000407 
9723 0.000906 
4824 0.000998 
6856 0.001235 
4262 0.001421 
8791 0.001503 
8615 0.001531 
9954 0.001738 
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3.5 Analysis of Univariate Results 
3.5.1 Strongest Biomarker Candidates 
As stated earlier the validation stages have great time and cost constraints. Because of this it 
may be necessary to identify the features which have been identified as potential biomarkers 
in more than one test, as there may be more confidence that this feature is significantly 
responsible for the physiological differences between the groups. Without knowing the actual 
answers (i.e. a list of actual validated biomarkers), it is not possible to determine which tests 
are more appropriate, or in fact if all the tests are necessary or appropriate. It is also not 
possible to determine whether important biomarkers are found in specific tests that are not 
found in others. If this is the case, all the tests should be conducted in order to identify these 
novel markers that would not be found if only one or two methods of univariate analysis are 
conducted.  Additionally the tests need to be conducted on a much larger number of datasets 
from various studies, with validated biomarkers, in order to identify the best statistical 
approach. 
Features identified in all four tests may be stronger because they are identified as having 
statistically significant differences in abundance despite the limitations of each technique. 
Each univariate test is applied with a 95% confidence level. The theory of the confidence 
level suggests that it is unlikely for a false positive occurrence in all the tests. The results 
from all the univariate analysis techniques were compared in an attempt to identify the 
potential biomarker candidates that were significant in multiple univariate tests. However, as 
stated previously, it is not yet clear whether those features that are significantly differentiated 
in multiple statistical tests are more likely to be actual biomarkers. This can only be 
determined following comparison with a list of actual, validated biomarkers.  
In the absence of such information, only predictions (based on the premise that all univariate 
tests should be conducted) can be made as to which features are the strongest biomarker 
candidates. Using all four univariate methods a total of 3,048 features were identified as 
potential biomarkers with 1,023 unique features identified as potential biomarkers across all 
four tests. In total there were 14 statistical tests for each feature. This includes six for each of 
the pair-wise tests and one for each group-wise test. Table 31 shows that 14 features were 
identified as potential biomarkers in more than ten univariate tests, which are identified in 
Table 32. 
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Table 31 - The count of features found as significant in the univariate tests for Dataset 3 
and the number of tests in which they were identified as such.  
+ve Hypothesis Tests Number of Features  
1 359  
2 279  
3 97  
4 87  
5 49  
6 31  
7 21  
8 40  
9 25  
10 21  
11 10 14 
12 3 
13 1 
 
Table 32 - A list of the features identified as potential biomarkers more than ten 
univariate tests. A full version of this table is given as an output when using Biomarker 
Hunter. 
Feature 
Identifier 
Positive 
Tests Count 
4427 13 
18970 12 
2658 12 
4607 12 
1775 11 
2760 11 
2929 11 
31924 11 
3226 11 
4485 11 
4824 11 
5839 11 
6856 11 
97 11 
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3.5.2 Comparison of Univariate Techniques 
Methods exist to validate these potential biomarkers from statistical analysis, such as multiple 
reaction monitoring (MRM) (Anderson & Hunter, 2006) and Immunohistochemistry (IHC) 
methods (Sullivan & Chung, 2008). These methods however are limited by the time and cost 
bottlenecks that exist between the biomarker discovery and validation stages (Glaser, 2007). 
Due to this the validation stages are often only conducted on those features that are more 
likely to be responsible for the differences between the groups. Therefore researchers may 
want to see how many features are identified in more than one test. 
This section compares the univariate techniques to identify any relationships or correlations 
between the results (i.e. the features that are identified as potential biomarker candidates). 
These comparisons are shown using Venn diagrams. This is achieved by showing the number 
of features identified as potential biomarker candidates using the various methods and the 
number of features identified by both techniques (i.e. shown in the overlapping region). In 
total, there were 1,023 unique features identified as potential markers by the univariate 
statistical tests. The four univariate statistical methods gave complementary results (Figure 
36). This shows that 134 features were identified as potential biomarker candidates by all 
four univariate methods prior to the application of multiple testing corrections. With the 
exception of the Kruskal-Wallis technique all the other techniques also identify unique 
features as potential biomarker candidates that the other techniques do not, especially the two 
pair-wise hypothesis tests (The Welch T-test and the Wilcoxon Tests). 
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Figure 36 - A Venn diagram comparing the number of biomarkers identified from all 
four univariate approaches. 
Figure 37 compares the results from both the pair-wise techniques, i.e. the Welch T-tests and 
the Wilcoxon Mann-Whitney univariate tests. The Venn diagram shows that 595 features 
were identified as potential biomarker candidates by both techniques. These features may be 
more likely to be of interest as potential biomarkers than the features identified in only one 
test. Once again, this can only be determined following comparison of these features with a 
list of actual, validated biomarkers. 
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Figure 37 - A Venn diagram comparing the number of features identified by both the 
pair-wise univariate techniques (i.e. the T-test and Wilcoxon test). 
 
The Welch T-tests analysis identified 211 features as potential biomarkers, which were not 
identified by the Wilcoxon. Similarly there were 210 features that were not identified by the 
Welch T-test analysis. These results suggest there is good correlation between the two 
methods; however there are differences in the techniques which allow the identification of 
additional potential biomarkers for both techniques. This information can be useful in two 
ways. It gives further confidence to the features that were identified in both techniques. 
Additionally the identification of features as potential biomarkers in just one of the tests can 
be useful when there are only a small number of total features identified as potential 
biomarker candidates. When this is the case, it may be necessary to retain as many potential 
biomarker candidates as possible. 
Figure 38 compares the results from both the group-wise univariate techniques, i.e. the Welch 
ANOVA and the Kruskal-Wallis univariate tests. This Venn diagram shows that 138 features 
were identified as potential biomarkers by both techniques. These features may be more 
likely to be of interest as potential biomarker candidates than the features identified in only 
one test. 
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Figure 38 - A Venn diagram comparing the number of features identified by both the 
group-wise univariate techniques (i.e. the ANOVA and Kruskal-Wallis tests). 
 
The Welch ANOVA analysis identified 83 features as potential biomarkers, which were not 
identified by the Kruskal-Wallis tests. Similarly there were 65 features that were not 
identified by the Kruskal-Wallis analysis. These results also display good correlation between 
the two methods; while the differences in the techniques allow the identification of additional 
features as potential biomarker candidates for both techniques.  
Figure 39 compares the results from both the parametric univariate methods, i.e. the Welch 
T-tests and the ANOVA univariate tests. The Venn diagram shows that 219 features were 
identified as potential biomarkers by both techniques. These features may be more likely to 
be of interest as potential biomarkers than the features identified in only one test. 
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Figure 39 - A Venn diagram comparing the number of features identified by both the 
parametric univariate techniques (i.e. the T-test and ANOVA tests). 
The comparison shows the individual pair-wise univariate analysis identifies a relatively 
large number of potential biomarkers which are not identified by Welch ANOVA analysis 
(i.e. 587). There are only two features that were identified by the group-wise ANOVA 
analysis which were not identified by the Welch T-test. It was expected that the pair-wise 
analysis would identify a higher number of potential biomarkers. This is simply because there 
was a large number of tests conducted (i.e. there are six pair-wise analyses for every group-
wise analysis). The majority of the features identified by the group-wise analysis should be 
identified by the pair-wise tests as the p-values for the pair-wise tests will usually be lower. 
This is because there is more confidence in these pair-wise comparisons in supporting the 
alternative hypothesis for the univariate tests (i.e. there is a statistically significant difference 
between the groups). In the pair-wise analysis only two groups are compared, so when 
differences are found there is higher confidence in the conclusion, as opposed to when four 
groups are compared. 
A boxplot was created for the features that were identified as potential biomarkers using the 
ANOVA group-wise analysis but not by the T-tests. However both of these features did not 
contain sufficient data points to create boxplots. One of these features was 12361 for which 
the boxplot is shown in Figure 40. This boxplot shows that data is sparse and the differences 
between the groups are not as obvious as those observed earlier for high confidence 
biomarkers. This boxplot suggests that those features identified as potential biomarkers by 
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ANOVA, but not the Welch T-test, may not be features that warrant further study. However 
these features cannot be dismissed as non-markers until these results are compared with the 
list of features that are actual, validated biomarkers. 
 
Figure 40 - A boxplot comparing the four groups of intensity data presented for feature 
12361, which was identified as potential biomarker using the ANOVA group-wise 
analysis but not by the T-tests. 
Figure 41 compares the results from both the non-parametric univariate methods, i.e. the 
univariate Wilcoxon and Kruskal-Wallis tests. The Venn diagram shows that 203 features 
were identified as potential biomarkers by both techniques. These features may be more 
likely to be of interest as potential biomarker candidates than the features identified in only 
one test. As the non-parametric test compares the ranks of values as opposed to the actual 
values there is no difference between the Kruskal-Wallis post-hoc analysis and the Wilcoxon 
Page | 112  © Cranfield University, 2011 
 
Mann-Whitney pair-wise tests. There were an additional 602 features that were identified by 
the pair-wise Wilcoxon analysis alone. As expected there were no features identified by the 
Kruskal-Wallis analysis that were missed by the Wilcoxon tests. When a feature is identified 
as a potential biomarker by the Kruskal-Wallis it is certain that at least one of the pair-wise 
Wilcoxon tests will identify that feature as a potential biomarker. 
 
 
Figure 41 - A Venn diagram comparing the number of features identified by both the 
non-parametric univariate techniques (i.e. the Wilcoxon and Kruskal-Wallis tests). 
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3.5.3 Conclusions from Initial Univariate Analysis 
The results from the univariate analysis techniques identify potential biomarker candidates 
with reasonably good correlation between the different types of analysis. This is shown by 
the fact that a number of features have been identified as potential biomarkers by multiple 
univariate tests. There is also a relatively good overlap of features identified by multiple 
techniques as shown by the Venn diagrams in the previous section. 
This initial univariate analysis however is limited by the fact that there is a large percentage 
of missing values in the dataset. Dataset 3 has 40 samples and 94,727 features identified in 
each sample meaning there are a total of 3,789,080 possible values. Of these 3,421,648 
values are actually missing (i.e. over 90% missing values). This is not atypical of data from 
these types of proteomic methods and the reasons for these missing values will be explained 
and dealt with later in this thesis in Chapter 5. 
Additionally the number of potential biomarkers is relatively high and the time and cost 
constraints mean it may not always be possible to validate all these biomarkers. It is therefore 
important to reduce the number of false positive identifications of features as potential 
biomarker candidates. This is because the current number of potential biomarkers is too large 
to justify validating them all, especially if a large number of them are thought to be false 
positive results. This selection needs to be more refined. This leads to the need for multiple 
testing corrections. 
Whenever these statistical tests are conducted there is a 5% confidence level used. This 
means there is a one in twenty chance (i.e. %5 chance) that the difference observed between 
the groups is due to chance. Datasets from proteomic biomarker experiments are generally 
large datasets and involve the analysis of a large number of peptides or proteins (features). 
When the statistical tests are carried out in such a large number times there is an increased 
probability of error. This theory suggests that out of the thousands of features identified as 
potential biomarkers, 5% of these features may have been observed simply by chance. 
Multiple testing correction methods exist to take this into consideration, and will be evaluated 
in the next chapter along with the other data pre- and post-processing options. 
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4 Improvements to the Statistical Analysis Workflow 
Although the statistical analysis conducted in Chapter 3 identified a list of potential 
biomarkers from Dataset 3, there remain unaddressed issues. There are existing methods of 
data pre- and post-processing that can be respectively applied to the datasets and the results 
of the statistical analysis. There may be technical variance due to the systematic errors 
involved with proteomic techniques. This technique analyses each sample in the experiment 
individually. Due to systematic error between LC-MS runs there may be technical variation 
between the data from each sample. Methods such as Total Abundance Normalisation can be 
used to account for this technical variation. Another option to average out technical variance 
is to average the values obtained from the technical replicates. This chapter discusses both the 
use of normalisation and the averaging of technical replicates to reduce technical variation. 
Another issue with the univariate results is the large number of potential biomarkers 
identified. Validation is a long and expensive process so it is not feasible to attempt to 
validate thousands of potential markers, so there is a need to address this. However, it is 
important that plausible markers are not ignored simply because of cost. It is of great 
importance that the validation of biomarkers is based on the plausibility of the potential 
marker as opposed to just consideration of the cost of validation. This chapter offers multiple 
testing corrections as a solution to reduce the amount of false positive identifications of 
features as potential biomarker candidates. This gives researchers more confidence in the 
potential biomarkers outlined by Biomarker Hunter.  
Biomarker Hunter offers both pre- and post-processing options. Prior to conducting statistical 
analysis, the software offers methods for scaling, technical replicate averaging and missing 
value imputation. Following the statistical hypothesis testing the software pipeline also offers 
multiple testing correction options to control the error rates of these tests. These methods 
have been researched and implemented in a pipeline in Biomarker Hunter. There are three 
stages of analysis that comprise the pipeline which are: 1) Data Pre-Processing, 2) Statistical 
Analysis and 3) Data Post-Processing. This chapter discusses the available methods of data 
pre- and post-processing that will be made available using the Biomarker Hunter pipeline. 
The effect that these processes have on the results from Biomarker Hunter will be evaluated 
in order to identify the recommended method of evaluating potential biomarkers from 
proteomic data. Although pre-processing also involves dealing with missing values; this will 
be focused on later in Chapter 5. 
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4.1 Data Pre-Processing 
The raw data which obtained from quantitative biomarker experiments are usually unsuited 
for the purpose of statistical analysis. This means that the raw data requires some pre-
preparation before it can be used for analysis. The issues with the raw data include: 
 Often biological data is not normally distributed, and a number of statistical tests 
assume the data is normally distributed. Raw data is also affected by the problem of 
variance which can distort the results obtained from any statistical tests. These issues 
can be addressed using log transformation. 
 Systematic variations may obscure real biological changes between groups.  
 Most biomarker experiments involve the inclusion of technical replicates. This causes 
the problem of technical bias if used at the expense of biological replicates (Dowsey 
et al, 2010). If technical replicates are used it is essential that normalisation is carried 
out, otherwise technical bias may eclipse the biological effects. 
 Due to the limitations of the proteomic tools, not all the features, present in these 
samples, are identified in each sample by these tools. This is especially true for 
features that are present in low abundance, and those with poor detectability. The 
result of this is that a number of missing values may exist for each sample in the 
dataset. Statistical techniques usually require, and work best with, complete datasets. 
This issue can be addressed by estimating the values that are missing. There are a 
number of techniques available to do this which will be discussed in detail in Chapter 
5. It should be noted that as the number of estimated values in a dataset increases, the 
statistical power of the tests is essentially decreased. 
 There are usually a number of outliers included in the data that require special 
attention. Outliers are values that are grossly dissimilar from other comparable 
observations (Bantscheff & Kuster, 2007). Outliers may be a true observation of a 
special case peptide species such as post translational modifications (PTMs), or they 
may be false readings. These can be visually inspected and excluded from any 
statistical analysis but this can result in a loss of data. 
 Data may contain noise, which may be mistaken for a low abundance protein or 
peptide; hence the inclusion of false positives in the data.  
The two optional data pre-processing steps offered in Biomarker Hunter, that are discussed in 
this section are: 1) Normalisation and 2) Averaging of technical replicates.  
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4.1.1 Normalisation  
Occasionally the data obtained has previously been normalised using log normalisation. If 
this is the case it is necessary to specify this as it may have an effect on how subsequent 
calculations are done. When logarithmic values are used, multiplication is achieved by adding 
the values rather than the standard approach of multiplication (Brown, 2011).  
This study involves the comparison of samples from different experiments, which may have 
limited reproducibility due to differences in sample preparation and sample loading. 
Additional issues in reproducibility are presented when using gel-based techniques due to 
staining or image acquisition. These systematic variations may obscure real biological 
changes between and within sample groups (i.e. Type I or Type II errors). Therefore Total 
Spot Normalisation (gels) or Total Intensity Normalisation (MS) may be used to reduce the 
systematic variance, which may otherwise distort the biological differences between samples.  
 
4.1.1.1 Available Methods for Normalisation of Technical Variance 
Data pre-treatment methods convert the raw data to a different scale such as a relative or 
logarithmic scale. Different data pre-treatment methods such as auto-scaling and range-
scaling greatly affect the outcome of the data analysis. This is because different pre-treatment 
methods emphasise different aspects of the data. As well as all the other methods of pre-
treating the data, both these methods have their own advantages and disadvantages.  
Auto-scaling is based on data dispersion. It uses the standard deviation as the scaling factor 
so the mean-centred values are divided by the standard deviation. Range scaling uses 
biological range as the scaling factor. The biological range can be described as the difference 
between the minimum and maximum values reached in the experimentation. This is usually a 
much higher value than the standard deviation. As a result of this the data is scaled down to a 
greater degree. It clusters the data into tighter packed groups. The advantage of using auto-
scaling over range-scaling is that the standard deviation, which is used as the scaling factor, 
accounts for all of the measurements rather than just two values as in range-scaling. 
Therefore range-scaling is more sensitive to the presence of any outliers. 
Total abundance normalisation has been employed as a normalisation technique specifically 
for the purpose of dealing with the occurrence of systematic variation in both gel-based and 
MS-based proteomic analysis (Berth et al, 2007). It is currently employed in the commercial 
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Progenesis software range developed by Nonlinear Dynamics. For 2D gel experiments, this 
involves dividing the volume of each spot by the total volume of all the spots in that sample. 
This usually results in very small values so it is then multiplied by a scaling factor. This can 
also be applied to MS experiments by dividing the intensity of each peak by the sum of all the 
intensities in that sample and then multiplying this by a scaling factor. This normalisation 
technique assumes that the changing values don’t account for a large proportion of the total 
sums of values, and that methods that do not display technical variance such as DIGE are not 
being used.  
For 2D Gel experiments: 
                    
                
                         
                 
 
For MS experiments: 
                       
                   
                            
                 
4.1.1.2 Implementation of Normalisation in Biomarker Hunter 
The pipeline’s normalisation offers the total abundance normalisation, created specifically for 
this purpose, to scale the data. Auto-scaling and range-scaling are particularly good methods 
but are generally more suited for multivariate techniques (Berg et al, 2006).Although auto-
scaling and range-scaling are potential options, following further literature searches, total 
abundance normalisation emerged as the appropriate scaling method (Albertin et al, 2007). It 
is currently the normalisation technique used in commercially available software used for 2D 
gel electrophoresis experiments (Nonlinear, 2010). This uses the same formula as Total Spot 
Normalisation. 
Total Abundance Normalisation: 
                       
                      
                               
                      
4.1.1.3 Univariate Results Following Normalisation of Technical Variance 
The use of total abundance normalisation on Dataset 3 was conducted using Biomarker 
Hunter to observe the effects it has on the identification of potential biomarker candidates. 
Following total abundance normalisation 3,127 features were identified as potential 
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biomarkers using all the tests. A number of these features were identified in multiple tests and 
it was found that using all the techniques 1,040 unique features are identified as potential 
biomarker candidates. This is slightly more than the 1,024 unique potential biomarker 
candidates identified when normalisation was not applied. Table 33 shows the number of 
times a feature is identified as a potential biomarker alongside the number of features in each 
category. It shows that 39 features were identified in ten or more univariate group 
comparisons, and one feature was identified in fourteen univariate group comparisons. Prior 
to normalisation 35 features were identified in ten or more statistical tests.  A list of the 
strong candidates for potential biomarkers (i.e. features identified in eleven or more statistical 
tests) is shown in Table 34. This needs to be compared with a list of actual, validated 
biomarkers to identify if normalisation has a positive impact on the quality of potential 
biomarker candidates. 
Table 33 - The comparison of positive hypothesis tests with and without normalisation 
for Dataset 3. 
 
With Normalisation No Normalisation 
 +ve 
Hypothesis 
Tests 
Number of 
Features 
+ve 
Hypothesis 
Tests 
Number of 
Features 
 1 357 1 359 
 2 289 2 279 
 3 110 3 97 
 4 77 4 87 
 5 54 5 49 
 6 24 6 31 
 7 31 7 21 
 8 26 8 40 
 9 33 9 25 
39 
10 19 10 21 
11 15 11 10 
12 3 12 3 
13 1 13 1 
14 1   
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Table 34 - A list of the features identified as potential biomarkers in eleven or more 
univariate tests following normalisation for Dataset 3. A full version of this table is 
given as an output when using Biomarker Hunter. 
Feature 
Identifier 
Positive 
Tests 
Count 
4427 14 
6856 13 
18970 12 
4607 12 
6641 12 
10547 11 
1722 11 
1775 11 
19450 11 
2658 11 
2760 11 
2929 11 
31924 11 
3226 11 
4485 11 
4615 11 
5839 11 
6427 11 
794 11 
9954 11 
 
This list is similar to the results presented prior to normalisation. To see the overlap of 
features identified with and without normalisation a Venn diagram is presented in Figure 42. 
This shows that 889 features were identified in both sets of statistical analysis. There were 
also 151 features which were identified as a potential biomarker following normalisation, 
which were not previously identified. It also shows that 134 of the original potential 
biomarker list were not identified in this statistical analysis run. It was expected that the 
normalisation would have an effect on the resultant biomarker candidates as the 
normalisation adjusts the raw data to deal with the systematic error. The choice of whether to 
use this normalisation option is mainly dependent on the nature of the data. If there is any 
chance that the data may be subject to systematic error, then normalisation should defientely 
be used. However if the technique accounts for this systematic error, such as DIGE, then this 
option may be ignored. 
Page | 120  © Cranfield University, 2011 
 
 
Figure 42 - A Venn diagram comparing the number of features identified in Dataset 3 
prior to normalisation and after normalisation. 
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4.1.2 Dealing with Technical Replicates 
Technical replicates are produced by multiple labelling of the same sample as opposed to 
biological replicates, which are actually different samples. These are explained in detail in 
section 1.3.2. 
4.1.2.1 Available Methods for Dealing with Technical Replicates 
There are two options with regards to the management of technical replicates. These can 
either be treated as individual samples or can be averaged prior to analysis. For comparative 
purposes it is useful to see results from an averaged dataset as well as a non-averaged dataset, 
so the user is presented with the option to average the technical replicates or leave them as 
they are.  
4.1.2.2 Implementation of Dealing with Technical Replicates in Biomarker Hunter 
Ideally the technical replicates should not be averaged prior to analysis. This is because 
averaging these samples results in the subsequent analysis losing substantial power. 
Additionally, following manual inspection of the data there are many peptides detected in one 
replicate and not the other. If the averaging option is used then the data, for each feature 
(peptide or protein) is averaged using the following conditions: 
 If each technical replicate of the sample has a value, the average (mean) is used as the 
value representing both replicates 
 If only one run of the sample has a value, the present value is used to represent both 
replicates (i.e. no averaging) 
 If both runs have missing values, a single missing (NA) value is used to represent 
both replicates 
4.1.2.3 Univariate Results Following Averaging of Technical Replicates 
The effect of averaging technical replicates was observed on Dataset 3 using Biomarker 
Hunter to observe the effects it has on the identification of potential biomarkers. Following 
the averaging of technical replicates 2,481 features were identified as biomarkers using all the 
tests. A number of these features were identified in multiple tests and it was found that using 
all the techniques 959 unique features are identified as potential biomarkers. This is slightly 
lower than the 1,024 unique potential biomarker candidates identified when the replicates 
were not averaged.  
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Table 35 shows the number of times a feature was identified as a potential biomarker 
alongside the number of features in each category. It shows that 19 features were identified in 
eight or more univariate group comparisons, out of which two features were identified in 
eleven univariate group comparisons. A list of the strong candidates as potential biomarkers 
(i.e. features identified in eight or more statistical tests) is shown in Table 36. 
Table 35 - The comparison of positive hypothesis tests with and without averaging of 
technical replicates for Dataset 3. 
 
Averaging No Averaging 
 +ve 
Hypothesis 
Tests 
Number of 
Features 
+ve 
Hypothesis 
Tests 
Number of 
Features 
 1 273 1 359 
 2 337 2 279 
 3 151 3 97 
 4 71 4 87 
 5 43 5 49 
 6 36 6 31 
 7 29 7 21 
19 
8 12 8 40 
9 5 9 25 
10 0 10 21 
11 2 11 10 
 
  
12 3 
 
  
13 1 
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Table 36 - A list of the features identified as potential biomarkers in eleven or more 
univariate tests following the averaging of technical replicates for Dataset 3. The full 
table is given as an output when using Biomarker Hunter. 
Feature 
Identifier 
Positive 
Tests 
Count 
7514 11 
9843 11 
196 9 
2649 9 
2931 9 
334 9 
8858 9 
10240 8 
1050 8 
1417 8 
256 8 
373 8 
6404 8 
6840 8 
8280 8 
8317 8 
8611 8 
8885 8 
8994 8 
 
To see the overlap of features identified with and without the averaging of technical 
replicates, a Venn diagram is presented in Figure 43. This shows that only 132 of the features 
were identified in both sets of statistical analysis. There were over 1,600 features which were 
only identified as a potential biomarker in only one set of statistical analysis. This shows poor 
correlation between these results and those prior to averaging of the replicates.  
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Figure 43 - A Venn diagram comparing the number of features identified in Dataset 3 
prior to the averaging of technical replicates and after the averaging of technical 
replicates. 
 
Looking at these results it shows that the averaging of replicates drastically changes the 
identification of the potential biomarkers. As stated earlier, the averaging of technical 
replicates causes a substantial loss in power of the statistical analysis. This is because the 
inclusion of technical replicates allows the “averaging out” of technical variation (Ekefjard, 
2010). Additionally when technical replicates are not averaged, the analysis includes 
information of the technical variation in the experiement. This means that any protein 
expression changes which are due to subtle differences in the experimental technique would 
not be seen after averaging of these replicates (Krawetz, 2009). This averaging option is still 
provided in the Biomarker Hunter pipeline, but it will not be used for the suggested strategy 
for the identification of biomarkers suggested by this thesis. Unlike the other options there is 
not good correlation between the two analysis runs. It would be of great interest to compare 
results from these different techniques against a list of actual, validated markers to identify 
whether averaging of technical replicates is actually a good option. 
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4.2 Data Post-Processing 
Once statistical analysis has been conducted on the data there is often a need to conduct post-
processing of the analysis results. When there are a large number of potential biomarker 
candidates identified, it is important to ensure that these significant differences which have 
been observed simply due to chance are removed from the list. This is especially the case for 
datasets such as Dataset 3 (which was analysed in Chapter 3). For this data, thousands of 
features were identified as significant potential biomarkers. Although there are a large 
number of tests, allowing for more consideration being given to those features identified 
multiple times, it may be possible that important biomarkers are lost in the large clutter of 
features. This chapter investigates multiple testing corrections as a solution to reduce the 
number of false negative occurrences and reduce the list of potential biomarkers by 
attempting to reduce the number of false positive identifications of potential biomarkers. 
4.2.1 Multiple Testing Correction 
Statistical analysis of biological data rarely involves testing just a single hypothesis. 
Biomarker studies typically rely on techniques that allow large numbers of proteins, peptides, 
genes etc to be monitored in one experiment. The statistical hypothesis tests such as Welch’s 
T-test, ANOVA or the Kruskal-Wallis return a p-value, which signifies the probability of the 
null hypothesis being correct. The null hypotheses in all the statistical tests used in the 
Biomarker Hunter pipeline assume that there is no difference between the means of the 
groups being compared.  
For any individual statistical test there is a pre-set probability of the inclusion of a Type I 
error. These tests are vulnerable to Boole’s Inequality (Seneta, 2004), meaning that the 
probability of at least one of the peptides in the experiment list being differentially expressed 
is less than or equal to the sum of the probabilities of all the individual events. Using a 
confidence interval of 0.05 (5%), about one out of twenty tests will typically produce a false 
positive. 
If a multiple number of tests (n) are conducted, each with a significance probability (β), then 
the probability that one of the tests is significant is: 
       
When the number of tests is greatly increased, to thousands for example, as in the 
experiments conducted for biomarker discovery there is an implied occurrence of false 
Page | 126  © Cranfield University, 2011 
 
positives (i.e. a rejection of the null hypothesis, in a case where it is actually true) or a “Type 
I error”. Multiple testing corrections amend all the p-values from these statistical hypothesis 
tests to allow for the occurrence of these false positives. The p-values for each peptide, or 
protein, is corrected to account for the family-wise error rate and to maintain the overall error 
rate equal to, or below the p-value cut-off used for the tests. A widespread problem, 
encountered with computational statistical hypothesis testing, is how to approach multiple 
testing corrections.  
When applying Univariate hypothesis tests repeatedly there are additional issues presented. 
When any statistically significant change in the protein volume is concluded, it is based on 
the probability of observing that change. The chance always remains that any statistically 
significant protein or peptide is only reported as significant due to natural variation. These are 
examples of type I errors or “false positives”. The generally accepted significance level is 
95% which means that results with less than 5% chance of being different due to natural 
variation will be reported as significant. Because of the sheer number of variables analysed 
the chance of false positives is greatly increased. This problem can be addressed through 
algorithms which have been devised to adjust p-values based on the number of variables 
involved in the analysis. These methods are referred to as multiple testing correction 
methods. 
The datasets from OBT biomarker experiments measure the presence of several thousand 
peptides or proteins (i.e. 8,000 to around 90,000 PCIs (Peptide Cluster Indexes) or MCIs 
(Molecular Cluster Indexes)) simultaneously across varying groups, which may indicate 
disease, or varying treatments. So the statistical tests (e.g. T-test) are carried out on each 
feature separately. So for example if the significance level is 0.05 signifying a 5% probability 
that the null hypothesis has been falsely rejected, so when 100,000 tests are conducted 5,000 
of these could potentially be false positives. When conducting 100 tests, there is a 99.4% 
chance that at least one of the results is a false positive (Stark, 2011). Table 37 illustrates the 
importance of implementing multiple testing corrections when carrying out multiple 
comparisons, because we would like to minimise the inclusion of false positives not just for 
individual tests but also for the collection of features being tested. It shows how the 
probability of a false positive incidence is affected by an increase in the number of features. 
 
 
Page | 127  © Cranfield University, 2011 
 
Table 37 - Rate of Occurrence of false positives with increasing number of statistical 
tests. Adapted from Silicon-Genetics, 2003 
Number of 
features 
tested (N) 
False positive 
incidence 
Probability of calling 1 or more 
false positives by chance (100(1-
0.95
N
)) 
1 1/20 5% 
2 1/10 10% 
20 1 64% 
100 5 99.40% 
 
4.2.1.1 Available Methods for Multiple Testing Correction (MTC) 
All available methods of MTC available in the R stats package were investigated and 
implemented in the pipeline. The Biomarker Hunter pipeline software offers five methods for 
multiple testing corrections which will all be described in this chapter, outlining the benefits 
and drawbacks of each method. This section will also compare the techniques to identify the 
difference between the techniques. These methods are:  
1. Bonferroni (Bland & Altman, 1995) 
2. Holm (Holm, 1979) 
3. Hochberg (Hochberg, 1988) 
4. Hommel (Hommel, 1988) 
5. Benjamini Hochberg (Benjamini et al, 1995) 
4.2.1.1.1 Bonferroni Correction Method 
This method is based on the first-order Bonferroni inequality, which is a modification of the 
Boole’s inequality (Bland & Altman, 1995). The Bonferroni inequality concludes that in any 
given set of outcomes (p(1), p(2), p(3)....p(n)), the probability of their union (i.e. of the event 
p(1) or p(2) or p(3) or p(n)) cannot be greater than the sum of their probabilities (Shaffer, 
1995). It is a simpler, but more stringent method than the Holm approach (Dunnett & 
Tamhane, 1991). The Bonferroni approach simply rejects any null hypotheses if the corrected 
p-value, in this case obtained by multiplying the actual p-value by the total number of tests 
conducted, is below the critical (cut-off) p-value. 
P-value(Corrected)   P-value * Total Number of statistical tests(n) 
P-value(Corrected)   0.0    SIGNIFICANT 
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4.2.1.1.2 Holm Correction Method 
The Holm method is a modified, slightly less rigorous, version of the Bonferroni correction 
and is also known as the Bonferroni Step-down correction method. It is a sequentially 
rejective technique. The Holm method rejects the null hypothesis in cases only where the p-
value, and subsequently its corrected (lower) p-value is below the p-value cut off. The Holm 
corrected p-values are obtained by: 
A. Ranking the p-values for each individual PCI (or MCI) in ascending (small to large) 
order. 
B. Multiplying the smallest p-value (p(A)) by the total number of tests. P-values less 
than the 0.05 (5%) cut-off point suggest the null hypothesis should be rejected. 
P-value(A)(Corrected)   P-value(A) * Total Number of statistical tests(n)   
P-value(A)(Corrected)   0.0    SIGNIFICANT 
C. The next p-value (p(B)) is then multiplied by the total number of statistical tests 
minus one. 
P-value(B)(Corrected)   P-value * (n – 1)   
P-value(B)(Corrected)   0.0    SIGNIFICANT 
D. The third p-value (p(C)) in the ranked set is then multiplied by the total number of 
statistical tests minus two. 
P-value(C)(Corrected)   P-value * (n – 2)  
P-value(C)(Corrected)   0.0    SIGNIFICANT 
E. This routine is continued, decreasing the multiplying factor by one in each step, until 
a FEATURE(x) is classified as not significant 
P-value(x)(Corrected)   0.0    NOT SIGNIFICANT 
The strength of the Holm method is that it is a statistically very powerful despite the values of 
the unobservable parameters. This method does not assume independence of data, which is 
useful especially when dealing with biomarker data. Often in biomarker experiments there is 
a relation between the data. For example when dealing with peptides there is a relationship 
between the intensities of the peptides which belong to the same protein. There may also be 
relationships between proteins with regards to their function or up-down regulation. 
This method returns a family-wise error rate comparable to that of the Bonferroni method. 
The Holm method; however does not guarantee confidence levels less than those provided 
using the original Bonferroni correction. As the p-value increases, the test gets progressively 
less corrective; therefore the test becomes less conservative.  
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4.2.1.1.3 Hochberg Correction Method 
This method is also known as the Simes-Hochberg correction method as it is based on the 
Simes Inequality (Simes, 1986). The Hochberg method is a simpler but sharper correction 
technique than the Holm correction method (Hochberg, 1988). Like the Holm method the 
Hochberg approach is based on ordered p-values. Unlike the Holm method the Hochberg 
method rejects all hypotheses with p-values less than or equal to the p-value cut-off point. 
The Holm correction method stops checking through the ranked p-values as soon as the null 
hypothesis has been rejected. The Hochberg correction works in reverse, starting first with 
the larger p-values in the ranked list. The Hochberg corrected p-values are obtained by: 
A. Ranking the p-values for each individual PCI (or MCI) in descending order. 
B. Unless the highest p-value (p(1)) is less than the critical (cut-off) p-value, in which 
case all the null hypotheses must be rejected, the correction starts with the second 
highest value. The correction starts by multiplying this p-value by two. If this value is 
less than the 0.05 (5%) cut-off point then the feature would be classed as significant. 
P-value(2)(Corrected)   P-value(2) * 2   
P-value(Corrected)(2)   0.0    NOT SIGNIFICANT 
C. The next p-value (p(3)) is then multiplied by 3. 
P-value(3)(Corrected)   P-value * 3  
P-value(3)(Corrected)   0.0    NOT SIGNIFICANT 
D. This routine is continued, increasing the multiplying factor by one in each step, until a 
feature is classified as significant 
P-value(Corrected)   0.0    SIGNIFICANT 
 
The corrected p-values are uniformly lower than those produced by the Holm method. This 
suggests the Hochberg step-up approach has more power than the Holm step-down approach.  
The high power of the Hochberg method; however comes at the expense of having to assume 
the p-values are all independent of each other (Walsh, 2004). This could be a cause for 
concern for the biomarker data, especially if dealing with peptides. When using peptides 
some features will not be independent of others as many will belong to the same protein, so 
this must be taken in to consideration when choosing this correction method. When some of 
the data is not independent it is better to use the Holm approach as it does not assume 
independence of data. 
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4.2.1.1.4 Hommel Correction Method 
As with the Hochberg approach the Hommel correction method is based on Simes Inequality. 
It is more powerful and slightly more complicated than the Hochberg method (Shaffer, 1995). 
This technique is also based on the ordered p- value procedure and like the Hochberg 
approach starts with the largest p-value first. The Hommel method rejects all hypotheses in 
which the corrected p-value is less than or equal to the critical value divided by k (π/k). The 
value k can be calculated by: 
      
 
           
 
 
             
Where: π   Critical p-value, n = total number of statistical tests 
A. Ranking the p-values for each individual PCI (or MCI) in descending (large to small) 
order. 
B. For the highest p-value (p(1)) : i = 1, j = 1.  
So if p(1)  0.0 (π) then all the null hypotheses must be rejected suggesting that all the 
features are significant biomarkers. If this is not the case then the next iteration of the 
test is conducted. 
C. For the next highest value (p(2)) : i = 2, j = 1,2. 
If P(2) > 0.05*(1/2) then the next iteration of the test is conducted. 
D. For the next p-value in the ranked list p(3): 
If p(3) > 0.05*(1/3) 
Then p(2) is retested to check whether p(2) > 0.05*(2/3)  
E. These iterations are continued until a p-value is equal to or less than the critical value 
multiplied by the multiplying factor (   ). When this occurs the i + j values are used: 
Corrected critical p-value cut-off   0.0 (π)/(i+j) 
F. All null hypotheses are rejected if their p-value is less than or equal to (π)/(i+j). 
 
4.2.1.1.5 Benjamini-Hochberg Correction Method 
The correction methods described thus far have been based on ordered p-values. These 
techniques provide a strong control over the family-wise error (FWE) rate. The less stringent 
Benjamini-Hochberg approach aims instead to control the false discovery rate (FDR) 
(Benjamini et al, 1995). The false discovery rate can be described as the fraction of false 
positives throughout all the tests which are classed as significant (Walsh, 2004). Like the 
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Simes-Hochberg correction, the Benjamini-Hochberg is a step-up procedure. This correction 
technique is a relatively less conservative technique so is relatively more tolerant towards 
false positives; however it also reduces the occurrence of false negatives (Type II) errors (i.e. 
not rejecting the null hypothesis when there is a significant difference between groups). 
Benjamini-Hochberg corrected p-values can be obtained using the following approach: 
A. Ranking the p-values for each individual feature in descending (large to small) order. 
B. As with the Simes-Hochberg approach the largest p-value (p(1)) is left as it is 
and the correction starts with the second largest p-value (p(2)). The second 
largest p-value is multiplied by a multiplying factor, obtained by dividing the 
total number of statistical tests conducted (n) by its rank in the list. If this 
corrected p-value is less than the critical (cut-off) p-value (π   0.0 ) then the 
null hypothesis can be rejected. 
P-value(Corrected)   P-value * 
Total Number of statistical tests(n)
Total Number of statistical tests(n) – 1 
 
P-value(Corrected)   0.0    SIGNIFICANT 
C. This sequence is continued for all the ranked p-values for example for the next 
p-value in the ranked list (p(3)). 
P-value(Corrected)   P-value * 
Total Number of statistical tests(n)
Total Number of statistical tests(n) – 2 
 
P-value(Corrected)   0.0    SIGNIFICANT 
As the rank increases, and the p-value decreases, the corrections become more stringent 
similarly to the Bonferroni step-down approach. As the false discovery rate (FDR) approach 
gives an error rate that is proportionate to the number of features it provides a good 
alternative to family-wise error rates (FWR). 
Compared to the first four methods, the Benjamini-Hochberg approach is relatively more 
ideally suited to data from biomarker experiments where we are dealing with an extremely 
large number of significance tests, due to the fact that it is a less conservative method. The 
statistical hypothesis tests (i.e. ANOVA, Kruskal) reduce a large dataset to a significantly 
smaller one. For some researchers analysing biomarker data, it may be a concern to ensure 
that no true positives are removed from the significance list, even if this comes with the slight 
inclusion of false positives (Shaffer, 1995). Usually however due to extreme validation costs 
it is of utmost importance for researchers to reduce the occurrence of false positive 
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identification of biomarkers. This suggests that MTC should be used but the Benjamini –
Hochberg is most ideal as it is less stringent. 
 
4.2.1.2 Implementation of Multiple Testing Correction in Biomarker Hunter 
The pipeline software allows the user to use any of the methods described in the previous 
section to conduct multiple testing corrections. These were implemented using the p.adjust 
function in the R stats package. As stated previously the Benjamini-Hochberg correction 
approach is most ideally suited to data from biomarker experiments. These methods along 
with the other correction approaches were conducted on Dataset 2 to compare the effects the 
corrections have on the results. Table 38 shows the difference between the correction 
approaches. The p-values for the Welch T-test comparing Group one against Group two were 
corrected using the five different methods.  
Table 38 - The effect of Multiple Testing Corrections on Dataset 2 
 
The Benjamini-Hochberg correction method retained more significant features than the other 
approaches. This may have been due to the fact that the Benjamini-Hochberg is a less 
stringent method and aims to protect the true-positive values. As the number of statistical 
tests is significantly large it can be seen that to maintain a family-wise error rate the number 
of significant markers is substantially reduced to a single digit. Upon examination of the 
corrected datasets the two significant features (feature 3810 and feature 243) were common 
through all five correction approaches. Four other features were also classed as significant 
using the Benjamini-Hochberg approach (features: 1234, 3936, 4005, and 3324). As the 
experiment involved study at the peptide level it is very possible that these identified features 
may belong to the same protein. 
This shows good correlation between the techniques as well as suggesting that for the types 
of datasets being analysed the Benjamini-Hochberg may be the most ideal as it retains a 
higher number of true positive statistical hypothesis tests.  
 
Page | 133  © Cranfield University, 2011 
 
4.2.1.3 Univariate Results Following Multiple Testing Corrections 
When the multiple testing correction methods were applied to Dataset 3 there were no 
differences between the different correction methods. Unlike when multiple testing 
corrections were applied to Dataset 2, all five methods of p-value correction returned the 
same biomarkers. Following multiple testing correction a total of 281 features were identified 
as biomarkers, of which 180 were unique. Compared to the uncorrected analysis, this list of 
180 features is far more manageable than the list of over a thousand unique features. This 
suggests that when there is time and cost constraints the multiple testing methods should be 
implemented when there are a large number of potential biomarkers.  
Table 39 shows the number of times a feature is identified as a biomarker alongside the 
number of features in each category. It shows that one feature was identified in five 
univariate group comparisons. As the multiple testing is only conducted on the p-values from 
the original statistical analysis, all of the features identified after correction were identified in 
the original analysis. 
Table 39 - The comparison of positive hypothesis tests with and without multiple testing 
corrections for Dataset 3. 
MTC No MTC 
+ve 
Hypothesis 
Tests 
Number of 
Features 
+ve 
Hypothesis 
Tests 
Number of 
Features 
1 102 1 359 
2 57 2 279 
3 20 3 97 
4 0 4 87 
5 1 5 49 
  
6 31 
  
7 21 
  
8 40 
  
9 25 
  
10 21 
  
11 10 
  
12 3 
  
13 1 
A list of features identified in three or more statistical tests is shown in Table 40. The analysis 
from this dataset suggests the method of correction used is not important. However the results 
from Dataset 2 as discussed in the implementation of MTC, as well as the available literature 
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suggest that the Benjamini-Hochberg algorithm is the most appropriate for this use (Shaffer, 
1995).  
Table 40 - A list of the features identified as potential biomarkers in three or more 
univariate tests following Multiple Testing Correction for Dataset 3. A full version of 
this table is given as an output when using Biomarker Hunter. 
Feature 
Identifier 
Positive 
Tests 
Count 
540 5 
12568 3 
14297 3 
1775 3 
20955 3 
23223 3 
2760 3 
2929 3 
31924 3 
3226 3 
4262 3 
4427 3 
4485 3 
4515 3 
4824 3 
5839 3 
6144 3 
8791 3 
8936 3 
97 3 
9954 3 
4.3 Conclusions for the Use of Data Processing 
If there is the possibility of technical variance between samples then total abundance 
normalisation should be applied prior to statistical analysis. Ideally technical replicates 
should be treated as individual samples (i.e. not averaged). Following statistical analysis 
MTC is strongly suggested as it is not justifiable to validate thousands of features, so false 
positives should be avoided. Although there was no difference when these methods were 
applied to Dataset 3, the results from Dataset 2 agree with the theory from the literature that 
Benjamini-Hochberg approach may be more appropriate (Pascual et al, 2010). However; it is 
impossible to determine whether the Benjamini-Hochberg is actually more appropriate 
without comparing this list of markers with a list of actual, validated biomarkers. 
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5 Evaluation of Solutions for Missing Values 
One of the first main concerns when the datasets, provided by OBT were analysed were the 
high number of missing values that were contained in the data. Dataset 2 had 64% of the 
values missing and Dataset 3 had more than 90%. This is not atypical of proteomic datasets 
and remains a big issue in proteomics (Albrecht et al, 2010). For the analysis of these datasets 
it was important to first understand the reasons for the presence of missing values. From there 
the next challenge was to create provisions in the created pipeline software to deal with these 
missing values in an effective and appropriate manner, in order to provide accurate 
conclusions without causing the data to be skewed. 
After consulting various journal articles it was obvious that missing values is a widespread 
issue encountered by many studies in the field (Vlahou, 2008) (F Li et al, 2011). It also 
became clear that systematic approaches to dealing with these missing values are still lacking 
(Sariyar et al, 2011). This chapter describes why missing values are so common in biomarker 
experimental data. It then describes two of the main provisions that have been included in 
Biomarker Hunter to help tackle these issues. The first solution offered is the commonly 
applied technique of imputation of missing values, which is not restricted to biomarker 
studies, but is also used in various other fields for statistical analysis. The second solution is 
more problem-specific to the issue of missing values in label-free biomarker experiment data. 
This clustering solution identifies those peptides that have not been matched correctly and 
correlates their intensity values. Following the evaluation of the recommended strategy for 
missing values combined with conclusions made in Chapters 3 and 4 a suggested strategy is 
identified. This strategy and the results of analysis using this process are presented in section 
5.3 of this chapter. 
Firstly we must consider the causes of these missing values. As the number of features (i.e. 
peptides, proteins or genes) is increased there is an associated higher problem of missing 
values in the proteomic datasets.  These missing values occur through the experimental 
techniques used to obtain biomarker data. For example, when using 2D gel techniques, less 
intense spots are more susceptible to missing values. These missing values may still be very 
important with regards to regulation and signalling of the peptide or protein in question. 
Sensitive MS techniques allow the identification of this low abundant class of proteins, but 
are still prone to missing values for various reasons. 
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Figure 44 - A graph showing the occurrence of features in Dataset 3 in each feature presence group 
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Figure 44 shows the frequency of features with the possible feature presence levels for 
Dataset 3. It can be seen over 33,000 of the features have a feature presence of one, meaning 
that there are thirty nine missing values in each of these features. The graph also shows that 
only a small percentage of features contain full or high feature presence. 
All proteomic data contains missing values which may either be due to: 
 The peptide or protein being present, but at a level below the limit of detection of the 
mass spectrometers or other analytical methods. For these cases, there is an increased 
error if the user imputes the missing values with a zero. A zero value would suggest 
that the sample is not present at all, which is not the case.  
 The occurrence of mismatching caused due to feature distortion. This happens when 
values which belong to the same marker (e.g. peptide) are classed into two or more 
different features. This may occur when values from the same marker fall outside the 
stringent mass and retention time windows used by the clustering algorithms provided 
by the mass-spectrometry providers. Mismatching may occur in both mass 
spectroscopy and gel-based methods. 
 Truly missing data. This refers to true zero values. This suggests that the feature 
(protein or peptide) is not present in the sample being tested. 
Additionally when gel-based techniques are used: 
 Spots may be missing because of poor transfer from the first to second dimension.  
 Another biological reason may be the shift of the protein to a different point in the 
pI/molecular weight gel co-ordinate due to post translational modifications (PTMs).  
It is of great importance to replace as many of these missing values with plausible values, a 
process known as imputation, to avoid leading to false conclusions (Azuaje, 2005). Any 
amount of missing data can cause significant effects on the conclusions made based on the 
data. It is also necessary to distinguish those values that are truly missing as imputing these 
values will cause a great bias in the dataset. There are two categories of missing values 
(Little, 1987). Values may be missing at random (MAR), meaning the likelihood of a missing 
feature may be determined by the observed data. The second category is those values that are 
Missing Completely at Random (MCAR) which means the values are missing, independent 
both of observable variables and of unobservable parameters of interest. 
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5.1 Selective Missing Value Imputation 
Imputation involves the substitution of certain, plausible, values to replace missing data 
points. It is a preferred method of pre-processing a dataset with missing data prior to 
statistical analysis. In most biomarker discovery experiments the problem of missing values 
cannot simply be dealt with (Aittokallio, 2010), and are sometimes simply ignored. 
If the discarded cases form a representative and relatively small portion of the entire dataset, 
then feature deletion may indeed be a reasonable approach. However, case deletion leads to 
valid inferences in general only when missing data are missing completely at random in the 
sense that the probabilities of response do not depend on any data values observed or missing. 
In other words, case deletion implicitly assumes that the discarded cases are like a random 
subsample. When the discarded cases differ systematically from the rest, estimates may be 
seriously biased. Moreover, in multivariate problems, case deletion often results in a large 
portion of the data being discarded and an unacceptable loss of power. 
There have been methods published to deal with these missing values such as: 
o Row-average method 
o K-nearest neighbour (KNN) 
o Singular Value Decomposition (SVD) 
o Bayesian Principal Component Analysis (BPCA) missing value estimation 
o Maximum Likelihood Algorithm 
Whichever approach is used there needs to be consideration of the structure of the datasets 
and the nature of the experiment.  
With regards to univariate tests (such as ANOVA) there is an argument suggesting that 
missing values can be ignored. However the reduced number of replicate values within 
features leads to lower power in the statistical tests.  
When conducting multivariate statistics, it is very important to deal with these missing values 
correctly to be able to draw accurate and realistic conclusions as the missing values can skew 
the dataset and lead to wrong conclusions. This is due to the increase in score error estimation 
when too many missing values are present. 
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5.1.1 Available Methods of Imputation 
5.1.1.1 No Imputation 
This simple but very crude approach to missing value treatment is to ignore the cases which 
have a percentage of missing values above a desired threshold. This approach is appropriate 
when the percentage of missing values is very low but analysis of the OBT datasets and 
reference from previous experiments show that this is not usually the case in proteomic 
biomarker experiments. If the percentage of missing values is high, there is a vast loss of 
information and may introduce a bias. 
5.1.1.2 Minimal Value Imputation (MIN) 
This approach is also a simple and crude method which involves replacing the missing values 
with zeroes. This is the method currently employed by all the commercially available image 
analysis software (Albrecht et al, 2010). This approach works under the assumption that all 
the missing values are due to the protein either being actually absent in the sample groups or 
the proteins being below the detection level of the analysis tools. This method ignores the 
prospect of missing values due to technical reasons.  
This approach can be modified by replacing the missing values with a non-zero minimal 
intensity value. One option for this includes using the global minimum intensity value of all 
the present values (Almeida et al, 2005), however other variations of this imputation do exist. 
This choice of imputation does not make a difference to the detection of statistically 
significantly different peptides and proteins. 
5.1.1.3 Average Imputation 
This simple approach involves imputing the missing values with the average value of all the 
present values for that peptide or protein. This can be either the row mean or the row median. 
The assumption behind this method is that the abundances of proteins do not vary much 
between different sample groups. This can be a problem as the assumption is not always true 
and the method becomes more complicated as the percentage of missing values for the 
protein or peptide is increased. This method deals with the missing values caused by both 
biological and technical reasons. This method is more often used to compare the other 
imputation methods rather than being used as an actual imputation technique (Jung et al, 
2006). 
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A variation of this method is to impute missing values with a median of the present values 
within the sample group. This method is referred to as REPMED. This ignores the 
assumption of the low variance in abundance between groups and is better suited to 
proteomic biomarker studies. The limitation to this approach is that there needs to be a 
minimum of three present values within the sample group for the relevant protein or peptide 
in order to be able to calculate a median. This approach has not yet been applied to proteomic 
data as this is not always the case with these datasets (Albrecht et al, 2010). 
5.1.1.4 Multiple Imputation 
Multiple Imputation (MI) is a Monte Carlo procedure in which the missing values are 
replaced by m>1 simulated versions, where m is typically small (i.e. < 10). Each simulated 
dataset is analysed and the results are combined to calculate estimates and confidence 
intervals which incorporate the missing data uncertainty (Schafer, 1997). Due to advances in 
computational methods and software, the MI procedure has become useful in the eye of 
researchers in biomarker research, whose studies are often hindered due to the presence of 
missing data. Unless the rate of missing information is extremely high, there is little 
advantage to producing and analyzing more than a few imputed datasets. The imputed model 
at best is an approximation; fortunately MI tends to be quite forgiving of departures from the 
imputation model. If working with binary or ordered categorical variables, it is satisfactory to 
impute under a normality assumption and then round off the continuous imputed values to the 
nearest category. If the distribution of the variables are heavily skewed, these may be 
normalised (e.g. by taking logarithms) then returned to their original scale after imputation. 
5.1.1.5 K Nearest Neighbour (KNN) 
This approach is often used for both proteomic and transcriptomic data. The assumption 
behind this approach is the relationship between expression profiles of the values of certain 
peptides or proteins (Albrecht et al, 2010). The missing values are imputed with a weighted 
mean of the available values of the k most related values in this particular sample. The 
relation is estimated using Euclidean distance. An optimal value of k is calculated empirically 
for each dataset (Troyanskaya et al, 2001). The method is robust and sensitive, especially in 
cases where the percentage of missing values is less than 20% for the particular peptide or 
protein. It performs better than the average imputation techniques with regards to 
deterioration of power when the missing value percentage is increased. This method however 
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does not account for truly absent proteins. In these cases KNN imputation will cause artificial 
values which may not represent the true biological nature of the data. 
5.1.1.6 Bayesian Principal Component Analysis (BPCA) 
This method assumes that missing values occur randomly and independent of other features. 
This assumption is not often true for proteomic data therefore BPCA is not the most ideal 
technique for proteomics. 
5.1.1.7 Weighted Estimation Procedures 
In some situations, good estimates can be obtained through weighted estimation methods. In 
fully parametric models, maximum-likelihood estimates can be obtained from the incomplete 
data by specialised numerical methods, such as the Estimation Maximisation (EM) algorithm. 
Those procedures are more efficient than MI because they do not involve simulation. In most 
cases one could perhaps derive a better statistical procedure than MI for any statistical 
problem. However in most situations where the missing data is considered an annoyance 
rather than the primary focal point, a simpler, approximate solution with good properties can 
be preferable to one that is more efficient but problem-specific or difficult to implement. 
 
5.1.2 Constraints to Missing Value Imputation 
It should be taken into account that there is a greater degree of uncertainty, following 
imputation, than if the imputed values had actually been observed. It is important that the 
appropriate technique for imputation is used for the study as applying a non-suitable method 
can be more harmful than if the missing values were left as they were. Incorrect imputation 
leads to problems such as distorted estimates, standard errors and hypothesis tests (Little, 
1987).  
Real-life data very rarely conforms to such convenient models and even the very best case 
scenario for imputed data is that the model is approximately true. This is especially the case 
for the drug biomarker datasets provided by the sponsor company. As described earlier, these 
datasets have more than half of the values missing. Imputing all of these values will seriously 
skew the data as there are more imputed values than actual values in the model. 
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5.1.3 Implementation of Imputation Methods in Biomarker Hunter 
5.1.3.1 Choice of Imputation Method for Biomarker Hunter 
The chosen imputation model needs to be compatible with the analyses to be performed on 
the subsequent datasets. The imputation model should preserve the associations or 
relationships among variables that will be the focus of later investigation.  
For Biomarker Hunter the choice of imputation method was based on the results of a 
comparative study of these techniques (Albrecht et al, 2010). This study compared results 
using different imputation techniques to identify the most appropriate method to use for 
proteomic biomarker data. This study involved evaluating the imputed datasets against the 
original data with respect to: 
 Root Mean Squared Error (RMSE) 
 Sensitivity 
 Specificity 
 Precision 
 Jaccard Index 
 F-measure 
This study found that Minimal Value Imputation (MIN) produces the largest amount of errors 
whereas the average imputation method, REPMED, was the best single method for the 
imputation of partial datasets. This conclusion suggests that the majority of the missing 
values are the result of technical reasons as opposed to the protein or peptide being actually 
absent. Both Bayesian Principal Component Analysis (BPCA) and K-Nearest Neighbours 
(KNN) approaches work well in cases of proteins or peptides with higher feature presence 
(i.e. a lower number of missing spots). When these techniques are conducted on the entire 
dataset there is a more error involved. 
None of these methods individually give perfect results; however the best results are obtained 
when a combination of these techniques are used dependent on the situation. The 
combination of MIN and KNN gave the best results in this study (Albrecht et al, 2010).  
For those proteins or peptides which have a low feature presence (i.e. below 26%) the best 
imputation method is MIN. For those proteins and peptides with a high feature presence (i.e. 
above 74%) KNN (with k=15) was seen to be the best approach. This study concluded that 
there is no most effective method for those features with a feature presence between 26% and 
74%, however the REPMED imputation technique resulted in the fewest errors for this group. 
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5.1.3.2 Implementation of Imputation Method in R 
In order to ensure the optimum method of imputation is applied to the dataset the Biomarker 
Hunter software has the option for selective imputation. The method of imputation is 
dependent on the percentage of missing values for each peptide (i.e. the feature presence for 
each peptide).  
If the user chooses the imputation option then no further actions are necessary, and 
imputation will be applied to the dataset. If the clustering option, described in the following 
section, is also used then clustering will take place prior to imputation. This is because 
clustering aims to reduce the number of missing values rather than replace them with new 
values, and therefore increase the feature presence of the peptides. 
The feature presence (i.e. Percentage of non missing values) for each peptide is calculated 
prior to imputation so these values are called upon for the imputation section of Biomarker 
Hunter. The dataset is split into three smaller sections of peptide lists based on the feature 
presence. This is illustrated in Figure 45 which shows that the peptides with a low feature 
presence will undergo minimal value imputation (MIN). Those with a high feature presence 
will undergo K-nearest neighbours’ imputation (KNN), and the remaining data will have 
values imputed by the average imputation method (REPMED). The following three sections 
describe how the datasets are affected depending on their feature presence. 
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Figure 45 - An illustration of how a dataset may be split prior to imputation. Features 
with a i) low feature presence undergo MIN imputation ii) high feature presence 
undergo KNN and the rest use the REPMED technique. 
5.1.3.2.1 Data Section with Low Feature Presence 
The section of the dataset that has a low feature presence (i.e. less than 25%) undergoes 
Minimal Value Imputation (MIN). This is done in R by replacing all of these features with 
zero. 
5.1.3.2.2 Data Section with High Feature Presence 
The section of the dataset that has a high feature presence (i.e. larger than 75%) undergoes K-
nearest neighbours’ imputation (KNN). This is done in R using the impute.knn function. The 
K Nearest Neighbour (KNN) imputation method is implemented using the R package 
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“impute”.  This package provides the function to impute missing values in incomplete 
datasets using the nearest neighbour averaging algorithm (impute.knn).  
5.1.3.2.3 Data Section with a Feature Presence between 26% and 74% 
The section of the dataset that has a feature presence between 26% and 74% undergoes the 
repeated median method (REPMED). The data is first split into its sample groups. Following 
this a median value is calculated for each row (peptide) in each sample group. The missing 
values for each peptide are then replaced with the median of values from its group. This is 
illustrated in Figure 46. 
 
Figure 46 - A section of data before and after REPMED imputation 
 
5.1.4 Univariate Results Following Missing Value Imputation 
Selective imputation based of the feature presence was conducted to observe the effects it has 
on the identification of potential biomarker candidates. Using all four univariate methods a 
total of 1,394 features were identified as potential biomarkers following use of the clustering 
algorithm. Many of these features occurred in multiple tests. A total of 403 unique features 
were identified as potential biomarkers. This is significantly lower than the 1,024 unique 
potential biomarker candidates identified when the missing value imputation was not applied.  
Table 41 shows the number of times a feature is identified as a potential biomarker candidate. 
It shows that 16 features were identified in ten or more univariate group comparisons. Prior to 
missing value imputation 35 features were identified in ten or more statistical tests.  Once 
again this was expected as there are more features with a higher feature presence. When there 
are too many missing values it may not be possible to conduct a statistical test. Because the 
imputation techniques account for these missing values the tests would be conducted for 
those features with an originally low feature presence. 
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Table 41 - The comparison of positive hypothesis tests with and without missing value 
imputation for Dataset 3. 
Missing Values Imputed No Imputation 
+ve 
Hypothesis 
Tests 
Number of 
Features 
+ve 
Hypothesis 
Tests 
Number of 
Features 
1 115 1 359 
2 92 2 279 
3 52 3 97 
4 28 4 87 
5 31 5 49 
6 21 6 31 
7 22 7 21 
8 11 8 40 
9 15 9 25 
10 8 10 21 
11 7 11 10 
12 1 12 3 
  
13 1 
A list of the strong candidates for potential biomarkers (i.e. features identified in ten or more 
statistical tests) following clustering is shown in Table 42. 
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Table 42 - A list of the features identified as potential biomarkers in ten or more 
univariate tests following the use of missing value imputation. A full version of this table 
is given as an output when using Biomarker Hunter. 
Feature 
Identifier 
Positive Tests 
Count 
3062 12 
1231 11 
2325 11 
2956 11 
4607 11 
5384 11 
5688 11 
10547 11 
38 10 
2485 10 
3519 10 
4902 10 
5262 10 
5752 10 
8209 10 
8936 10 
 
To see the overlap of features identified with and without missing value imputation a Venn 
diagram is presented in Figure 47. This shows that 218 features were identified in both sets of 
statistical analysis. There were also 185 features which were identified as a potential 
biomarker following missing value imputation, which were not previously identified. It also 
shows that 985 of the original potential biomarker candidate list were not identified following 
missing value imputation.  
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Figure 47 - A Venn diagram comparing the number of features identified in Dataset 3 
prior to missing value imputation and after imputation. 
 
Looking at these results it shows that missing value imputation significantly changes the 
number of potential biomarker candidates identified. As stated before the original dataset had 
a high number (over 90%) of missing values. This means a large number of the values in the 
dataset which has the missing data imputed are modelled values rather than real values. This 
was expected to have a significant affect on the statistical analysis.  
Feature 9838 was recognised as a feature which was not identified as a potential biomarker 
prior to missing value imputation but was identified following missing value imputation. A 
boxplot for this feature is presented in Figure 48.  
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Figure 48 - A boxplot comparing the four groups of intensity data presented for feature 
9838, which was not identified as a potential biomarker prior to missing value 
imputation but was identified following missing value imputation. 
 
This feature originally had 23 missing values out of 40. This means it falls into the category 
of features which are imputed using the REPMED technique. The missing values are replaced 
by a median value of the actual data in the group. The original boxplot does show slight 
variation between samples and imputing the missing data may bring out this variation.  
A reason for the lower number of features identified as potential biomarkers may have been 
due to the fact that the original dataset had a large number of features (i.e. 84,487 feature) 
that had a low feature presence (Table 43). The missing values in this group are replaced by 
zero. This causes a restriction in the statistical analysis. Because a lot of these features 
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contain a large number of zeroes the data becomes essentially constant between groups. This 
means a t-test can not be conducted using this data, due to the limitations of the t.test function 
in R. This function returns an error when the two groups of data being compared are constant. 
Looking at Table 43 it can be seen that it will not be possible to conduct the univariate 
statistical tests on a large number of features. This is responsible for the large number of 
features that were not identified as potential biomarkers following missing value imputation. 
Table 43 - A breakdown of features from Dataset 3 based on the feature presence. The 
second column states the number of features in each group. 
Imputation 
Method 
Number of 
Features 
Feature 
Presence 
MIN 
Imputation 84,487 Low (<25%) 
REPMED 9,070 
Middle (25%-
75%) 
KNN 1,170 High (>75%) 
 
The choice whether imputation should be used or not is not obvious, especially since there is 
no list of actual, validated biomarkers to compare these results with. It is a useful tool for 
identifying features which have a reasonable amount of actual values (i.e. above 50%). It 
makes the variations in the data more apparent. However when there is a large number of 
missing values the technique actually hinders the analysis of these features. Ideally data with 
a low feature presence (i.e. below 25%) should be excluded from the analysis (Albrecht et al, 
2010). This is a preferred solution as it is not really possible to make strong conclusions using 
such little amounts of data. If statistical analysis is conducted on these features then ideally 
missing value imputation should not be used on this portion of the data.  
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5.2 Creation of a Clustering Algorithm to Effectively Reduce the 
Amount of Missing Data 
5.2.1  Why Imputation Isn’t Enough - The Problem  
Although missing value imputation is commonly used and a useful tool in biomarker 
discovery, there are limitations to what can be achieved with imputation alone. Although 
Biomarker Hunter distinguishes between the qualities of the data and uses the appropriate 
imputation method; the number of missing values to begin with is so great that imputation 
alone would create a large degree of uncertainty that the imputed values represent the actual 
values. Due to the high number of missing values that are typical of the datasets from 
biomarker experiments, there is a need for a more intuitive, problem-specific solution to deal 
with this issue. 
For the scope of this project, there was not much need to deal with truly missing values 
(biological missing values). Although these may also be important it is possible to conduct 
statistical analysis by ignoring or removing these values prior to data analysis. However there 
is a pressing issue to deal with the technical reasons for missing values. This is because 
simply ignoring these values can lead to false conclusions. 
As determined in Chapter 5.0.1 a major issue with these experiments is the features that may 
be incorrectly matched during the mass spectrum or gel spotting stage of the experiment. This 
occurs when a feature representing a peptide or protein is incorrectly identified. This can 
occur due to a number of reasons which can be illustrated using Figure 49 as an example. If 
the mass and retention time windows set in the peak selection or spot detection software are 
less (i.e. more accurate) than the accuracy of the mass spectrometry instruments used for the 
experiment. This results in cases where a feature (i.e. peak representing a peptide) found in a 
particular sample is labelled as a different peptide (feature) in other samples. This may be 
because it lies outside the mass/retention time window set by the feature detection software.  
As illustrated in Figure 49, feature one (F1) lies outside the mass and retention time window 
of feature two (F2), whereas feature three (F3) lies within the window.  In some cases it may 
be possible that features such as F1 are incorrectly classed as different features even though 
they actually represent the same peptide. This occurs when the mass and retention time 
window (circle in Figure 49) is less than the accuracy of the mass spectrometer used. It is this 
problem that will be dealt with, in this section, using a clustering algorithm. 
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Figure 49 - A chart plotting mass vs. retention time for a collection of features from 
Dataset 3. The circle represents a mass and retention time window around Feature F2. 
F3 lies within the mass and retention time window whereas F1 lies slightly outside this 
window. 
5.2.2 Method: Reducing the Missing Values by Identifying Mismatched 
Features - The Solution  
Re-clustering of features provides an alternative approach to imputation which is specific to 
the biomarker experiments conducted by OBT. The aim was to create software based in R to 
reduce the number of missing values, and subsequently implement this option in the R based 
pipeline Biomarker Hunter.  
This was achieved by searching for features which are likely to have been mismatched and 
then combining the values of these features. The option goes through each feature (Primary 
Feature) and firstly finds any features that are potential matches. The hypothesis underlying 
this clustering approach is that some features appear as missing because the mass and 
retention time windows are too stringent in relation to the accuracy of the analytical tools 
used (Mass Spectrometers). This causes certain peptides or proteins to appear as two or more 
features rather than one. This clustering option identifies features to cluster together based on: 
 Mass and retention time windows 
 Missing value Patterns 
 Dealing with more than one potential match 
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5.2.2.1 Mass and Retention Time Window 
The potential matches must lie within the user defined mass and retention time window of the 
primary feature. For each feature, the first task carried out by the algorithm is to identify all 
other features that lie within the mass and retention time window. The accuracy of the 
clustering (i.e. the size of the mass and retention time windows) can be set by the user. 
Ideally this level should be set depending on the accuracy, or just slightly outside, the 
accuracy of the mass spectrometer. This will allow any features that may actually relate to the 
same peptide, as the primary feature, to be identified. Table 44 illustrates an example of a 
potential match list, created following this step. It may be possible that a number of these 
potential matches may not represent the primary feature so it is necessary to identify which of 
the potential matches, truly represent the primary feature. This issue is dealt with using the 
missing value pattern of the potential matches. 
Table 44 - An example of a potential match list, including intensity values, for a primary 
feature. This shows that features 265, 345 and 400 lie within the mass and RT window 
of feature 1. NA represents missing values. 
Feature # Sample 1-1 Sample 1-2 Sample 2-1 Sample 2-2 Sample 3-1 Sample 3-2 
1 (Primary 
Feature) 12.52 13.26 25.22 NA NA NA 
265 15.57 15.26 26.54 25.63 34.55 35.93 
345 15.29 NA NA 26.99 33.45 33.98 
400 NA NA NA 24.91 34.11 34.25 
 
 
5.2.2.2 Missing Value Pattern 
Once a list of potential matches has been created, the features that cannot possibly be a match 
are eliminated from the list. This section of the algorithm ensures that features that definitely 
do not relate to the same peptide are not clustered together. Using the example match list in 
Table 44, it can clearly be seen that feature 265 does not represent the primary feature 1 
because it does not have any missing values. Feature 345 also does not represent feature 1 as 
the missing value pattern does not match (i.e. there is a present value for sample 1-1 in both 
the primary feature and feature 345). From the list only feature 400 is a match there are no 
conflicting values between this feature and the primary feature. In this case the values from 
both from both features will be merged to create one full feature as shown in Table 45. 
 
Page | 154  © Cranfield University, 2011 
 
Table 45 - Primary Feature 1 data following clustering 
Feature # Sample 1-1 Sample 1-2 Sample 2-1 Sample 2-2 Sample 3-1 Sample 3-2 
1 (Primary 
Feature) 12.52 13.26 25.22 24.91 34.11 34.25 
 
 
5.2.2.3 Conflicting Matches 
It may be possible that there are two or more potential matches for the primary feature as 
illustrated in Table 46. In this example feature 1 is the primary feature for which a match is 
being searched for. A conflicting match occurs when two or more features lie within the mass 
and time retention window and also have a matching missing value pattern. In these cases the 
feature which lies closest to the primary feature in the mass and retention time window is 
used as the matching secondary feature. The methodology used is described in more detail in 
the following section. 
Table 46 - An example of a potential match list, including intensity values, for a primary 
feature with two possible matches 
Feature # Sample 1-1 Sample 1-2 Sample 2-1 Sample 2-2 Sample 3-1 Sample 3-2 
1 (Primary 
Feature) 12.52 13.26 25.22 NA NA NA 
400 NA NA NA 24.91 34.11 34.25 
426 NA NA NA 25.99 33.99 36.66 
5.2.3 Constraints of the Clustering Algorithm  
Although this technique will reduce the number of missing values it is important that it is 
used properly. It is imperative that the correct mass and retention time windows are 
employed. If this is not done the use of the clustering algorithm could result in serious 
misrepresentation of the biomarkers identified.  
An alternative to this clustering algorithm is available in the Progenesis SameSpots software 
(Non-Linear, 2010). This is a commercially available package that deals solely with 2D gel 
data. This presents a novel alignment approach which allows for gel distortions in the 
analysis of 2D gels without incurring any missing values. This is done by positioning all the 
spots in exactly the same location so all the gels contain the same number of spots. This 
software however is used earlier in the biomarker discovery workflow described earlier in 
section 1.3.1. This software needs to be implemented at the gel image analysis stage. This is 
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seen as the superior tool to use for the purpose of reducing missing values compared to other 
available methods (Fong et al, 2009). The Progenesis LC-MS software also applies a similar 
algorithm to eliminate missing values in LC-MS data. Unfortunately using the Progenesis 
tools was not an option for this project as the gel images and MS peaks had already been 
identified. 
5.2.4 Implementation of the Clustering Algorithm in Biomarker Hunter 
This section describes in detail how the clustering algorithm works and conducts the solution 
as described in section 5.2.1. 
5.2.4.1 Data Importing and Extraction of Feature 
The script imports a .csv file of data from either mass spectrometry or 2D-gel experiments. It 
allows the user to remove any unnecessary rows which may be contained in the file. For the 
clustering script the first column should contain the identifier of the index, which is referred 
to as PCIs or MCIs. The following columns should contain the intensity values from the 
experiments. The final two columns should contain the relating mass and retention times. The 
program extracts the information separates this information into its relevant components.  
1. Feature List: A list (Vector) of all the identifiers (“PCIList” in R). 
2. Intensity Data: A matrix of all the intensities with each row representing an index 
(identified by the Feature List), and each column representing a different sample 
(“IntensityData” in R). 
3. Mass Data: A vector containing the mass data (“MassData” in R). 
4. RT Data: A vector containing the retention time data (“RTData” in R) 
 
5.2.4.2 Calculating Feature Matrix 
To allow both quick calculations of the feature presence and for subsequent pattern matching, 
a binary version of the intensity data is created. This is referred to as the feature presence 
matrix (“FeaturePresenceMatrix” in R). An example of a feature presence matrix is shown in 
Figure 51, which shows the resultant matrix from the example dataset shown in Figure 50. 
This is achieved by making a copy of the intensity data and changing all the missing values to 
a zero and giving all other (present) cells a value of one. The feature presence for each feature 
can then easily be calculated by using the R function rowSums on the feature presence 
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matrix. This creates a vector of the feature presence results (FeaturePresenceResult), for 
which the Feature List can be used as a reference index.  
 
Figure 50 - An example of proteomic data 
 
 
 
Figure 51 - An example of a Feature Presence matrix for Figure 50 
Figure 52 Illustrates the preparation steps required prior to the clustering steps which are 
described above.  
 
Figure 52 - The preparation of a dataset prior to clustering. 
 
5.2.4.3 Create Clustering Results File 
A blank output data frame (“ClusterInfo” in R) is created which will subsequently be used to 
display the information of which features have been clustered together. Table 47 is a column 
by column brief of the output data frame. 
 
 
 
 
 
 
 
 
PCI Grp1 Grp1 Grp2 Grp2
1 8.51 0.00 1.59 2.02
2 0.00 8.14 0.00 0.00
PCI Grp1 Grp1 Grp2 Grp2
1 1 0 1 1
2 0 1 0 0
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Table 47 - Explanation of the Output File (ClusterInfo) 
Column 
Heading 
Notes 
1 Feature 
Identifier 
The following columns are present for each feature (Data may include NA’s). 
The clustering loop described later in this section will iterate through each 
feature as the primary feature: the feature against which all other features 
(secondary features) will be checked for potential matches. 
2 Status 
 
This column will state the outcome, for each feature, of the clustering 
loop. This information will be either: 
 “100% Actual Feature Presence” – These features already have 
100% feature presence so do not need any clustering. 
 “No Potential Secondary Matches” – These features cannot be 
clustered with any other features. This suggests there are no 
features which fall within the mass-retention time windows and 
also have no conflicts in the Feature Presence matrix. These 
potential secondary matches will be identified in column five and 
onwards. 
 “Clustered as Primary” – These features have one or more potential 
matches which fall within the mass-retention time windows and 
also have no conflicts in the Feature Presence matrix. 
 “Matched” – These features, as a secondary feature, have been 
found as a clustering match for another feature (Primary feature) 
 “Conflicting Matches” – These are features for which more than 
one feature has been found to be a potential match, but there is a 
conflict in the Feature Presence matrix between the secondary 
features. 
3 Number of 
potential 
matches 
For any feature which has been “Clustered as Primary”, or “Conflicting 
Matches”, this column will contain the number of secondary features 
which have been found within the Primary features mass-retention time 
window. There should also be no intensity values in the secondary Feature 
Presence matrix for samples that contain values in the Primary feature. 
4 Clustered (as 
secondary) with 
features 
For any feature which has been classed as “Matched” this column will 
identify the feature they have been matched with (Primary feature). 
5 – 20 
Secondary 
Matches 
These columns identify the secondary features which are potential matches 
for the Primary feature. 
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5.2.4.4 The Clustering Loop 
This section describes the process which finds features which can be clustered together. This 
loop is conducted for each feature in the list of data. Figure 53 illustrates the loop that goes 
through each feature.  
i. Firstly the feature presence is checked. If the feature presence is already 100%, 
this means that all the samples have an intensity value for this feature which 
means clustering is not needed. Unless this is the case the algorithm continues to 
step ii. 
ii. A mass and retention time window is created using the primary features Mass and 
retention time values along with the user defined mass and retention time 
tolerance levels.  
 
Figure 53 - The Primary Loop 
iii. A secondary loop searches through all the other (secondary) features to see if they 
are potential matches for the candidate (primary) feature. It immediately rejects 
those features which: 
a) have already been matched 
b) display 100% feature presence 
c)             have a feature presence more than the number of missing    
values in the primary feature 
iv. The remaining rows are checked to find those that fit within the created mass-
retention time window. For those features which fall into this category the binary 
Feature Presence matrix is checked for any conflicts between the primary and 
secondary features. This is done by adding together the binary rows of the primary 
feature and the secondary feature and ensuring there is no values above 1 in the 
results list. Figure 54 and 37 show examples of conflicting and non-conflicting 
matches. In Figure 55, the feature 2 would be rejected as a possible match as the 
second sample has intensity values in both features. 
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Figure 54 - An example of two non-conflicting feature presence matches 
 
 
Figure 55 - An example of two conflicting feature presence matches 
 
Figure 56 illustrates the process of searching for potential matches for each Primary feature. 
If there is at least one other (secondary) feature whose mass and retention times fall into this 
category, the algorithm for this feature continues to step v. Those features with no matches 
are classed as “No Potential Secondary Matches” in the status column of the ClusterInfo 
output data frame. 
 
 
Figure 56 - The secondary loop which searches for potential matches 
v. A subset of the Feature Presence matrix (PatternMatchMatrix” in R) is created 
using the primary features and secondary features which may be potential matches 
(Figure 57). Column sums are created using the R function colSums to ensure 
there is no pattern matching conflicts like those illustrated in Figure 58. If any of 
the column sums contain a value greater than one, the primary feature is classed as 
“Conflicting Matches” in the status column of the ClusterInfo output data frame. 
 
Figure 57 - An example of a non-conflicting feature presence matrix 
 
PCI Grp1 Grp1 Grp2 Grp2
1 1 0 1 1
2 0 1 0 0
PCI Grp1 Grp1 Grp2 Grp2
1 1 1 0 1
2 0 1 1 0
PCI Grp1 Grp1 Grp2 Grp2
1 1 0 0 1
2 0 1 0 0
3 0 0 1 0
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Figure 58 - An example of a conflicting feature presence matrix 
vi. Assuming there are no pattern match conflicts in the previous steps (Figure 57), 
the remaining features are “Clustered” together. A loop iterates through each 
sample in the primary feature. If there is a value present then this is ignored. If a 
value is missing, the secondary features are searched for a value within that 
sample to replace any missing values that it can. 
 
5.2.4.5 Clustering output Files 
Once the above steps have been conducted on each feature a clustered version of the original 
dataset is created. This is done by removing the rows of data which have been clustered as 
secondary features. Three csv files are created: 
1. Clustered data (Projectname_ClusteredData.csv) – A copy of the clustered dataset.  
2. Clustering information (Projectname_ClusteredInfo.csv) – The results of how the 
clustering algorithm has performed for each feature as described in Table 47. 
3. Clustered comparison information (Projectname_ClusterComparison.csv) – This 
table contains the statistics comparing both the original and clustered dataset. It 
contains the number of features, total possible values and the number and percentage 
of present values as shown in the hypothesised example in Figure 59. 
 
Figure 59 - An example of a Cluster Comparison table which outlines the effectiveness 
of clustering on the dataset. 
 
 
 
PCI Grp1 Grp1 Grp2 Grp2
1 1 0 0 1
2 0 1 0 0
3 0 1 1 0
Initial Post-Clustering
Number of PCI 10,000 9,500
Total Possible Values 200,000 190,000
None Missing Values 170,000 170,000
Percentage of None missing Values 85.00 89.47
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5.2.5 Results of using the Clustering Algorithm 
The Clustering algorithm was used on Dataset 3 to identify its effects on the univariate 
analysis conducted. This section describes the use of this algorithm as well as its impact on 
the results obtained. 
5.2.5.1 The Mass and Retention Time Window Used  
It was necessary to identify the number of features which fall within the mass and retention 
time windows of each other feature. This was tested using different mass and retention time 
windows to give an idea of which tolerance levels should be used. The ideal tolerance level is 
variable depending on factors such as, the accuracy of the analysis tools (LC-MS), the 
tolerance levels used on the original clustering software or the companies’ requirements. 
Figure 60 shows a graph of the number of features which fall within the mass and retention 
time tolerance levels for each other feature (Mass tolerance: ±0.1  RT tolerance: ±0.5s). This 
is the mass and RT tolerance levels that were used on Dataset 2. This shows that over 54,000 
features have no close neighbours within the tolerance levels. The various mass and retention 
time windows were also tested. These graphs are also presented in Figure 60. 
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Figure 60 - Number of potential matches within the mass and tolerance windows for 
each feature 
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Following discussions with the laboratory the ideal mass and retention time windows for this 
dataset were: Mass tolerance: ±0.1 & RT tolerance: ±0.5seconds. This was because these 
values matched the sensitivity of the mass spectrometer. 
Looking at the graphs in Figure 60 it can be seen that the other mass and retention time 
windows were not ideal. Increasing the mass tolerance has an effect on the number of 
features within the windows. This is because the mass accuracy is much higher than accuracy 
of the retention time. The graphs show that increasing the mass window creates a larger 
number of features within the windows. This would cause clustering of features that don’t 
belong to the same peptide, which would lead to huge errors in the dataset. This was also the 
case when the retention time window was increased to ±1second. When the retention time is 
decreased the increased stringency decreases the number of mismatched peptides that can be 
clustered. 
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5.2.5.2 Evaluation of the Clustering algorithm in Use  
Once the Clustering algorithm was applied to Dataset 3, the nature of the dataset was 
compared prior to clustering and following clustering. The comparison is shown in Table 48. 
This shows that the number of features was reduced which in turn resulted in a decrease in 
the percentage of missing values in comparison to the original dataset. This shows the 
clustering algorithm software does have a significant impact on the number of missing values 
in the dataset. It is important that the ideal tolerance levels are adjusted depending on the data 
source (i.e. the accuracy of the LC-MS technology). Although the results shown only display 
a slight increase, this is because the initial percentage of missing values was large.  
Table 48 - Comparison of the dataset before and after ClusterFix was applied 
  Initial 
Post-
Clustering 
Number of Features 94727 75863 
Total Possible Values 3789080 3034520 
Present Values 367432 367193 
Percentage of Present 
Values 9.69713 12.1005299 
5.2.5.3 The Effect of Clustering on Statistical Analysis Results 
The use of the clustering algorithm on Dataset 3 was analysed to observe the effects it has on 
the identification of potential biomarkers. Using all four univariate methods a total of 3,510 
features were identified as potential biomarkers following use of the clustering algorithm. 
Many of these features occurred in multiple tests. A total of 1,163 unique features were 
identified as potential biomarkers. This is slightly more than the 1,024 unique potential 
biomarker candidates identified when the algorithm was not applied. This was expected as 
the use of the clustering algorithm, although reducing the number of features, increases the 
feature presence of the remaining features. This gives more confidence to the individual 
univariate tests for these features. 
Table 49 shows the number of times a feature is identified as a potential biomarker alongside 
the number of features in each category. It shows that 43 features were identified in ten or 
more univariate group comparisons, and one feature was identified in thirteen univariate 
group comparisons. Prior to clustering 35 features were identified in ten or more statistical 
tests.  Once again this was expected as there are more features with a higher feature presence.  
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Table 49 - The comparison of positive hypothesis tests with and without using the novel 
clustering algorithm for Dataset 3. 
Clustering Algorithm 
Used No Clustering 
+ve 
Hypothesis 
Tests 
Number of 
Features 
+ve 
Hypothesis 
Tests 
Number of 
Features 
1 383 1 359 
2 344 2 279 
3 97 3 97 
4 97 4 87 
5 65 5 49 
6 41 6 31 
7 29 7 21 
8 39 8 40 
9 25 9 25 
10 27 10 21 
11 14 11 10 
12 1 12 3 
13 1 13 1 
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A list of the strong candidates for potential biomarkers (i.e. features identified in eleven or 
more statistical tests) following clustering is shown in Table 50. 
Table 50 - A list of the features identified as potential biomarkers in ten or more 
univariate tests following use of the clustering algorithm. A full version of this table is 
given as an output when using Biomarker Hunter. 
Feature 
Identifier 
Positive 
Tests Count 
31189 13 
4607 12 
16780 11 
17500 11 
1775 11 
2760 11 
2929 11 
3226 11 
4485 11 
4824 11 
5103 11 
53826 11 
5839 11 
6856 11 
9077 11 
97 11 
 
To see the overlap of features identified with and without clustering a Venn diagram is 
presented in Figure 61. This shows that 875 features were identified in both sets of statistical 
analysis. There were also 288 features which were identified as a potential biomarker 
following clustering, which were not previously identified. It also shows that 148 of the 
original biomarker list were not following clustering. It was expected that the clustering 
would have an effect on the resultant biomarker candidates as the clustering changes the 
nature of the dataset by combining values of certain features.  
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Figure 61 - A Venn diagram comparing the number of features identified in Dataset 3 
prior to clustering (Chapter 3) and after clustering. 
 
Looking at these results it shows that clustering does not drastically change the number of 
potential biomarkers identified. The results also show that there are a number of features 
identified following clustering that were previosly ignored. One of these features was Feature 
31189. Looking at the clustering information this feature was clustered with Features 38386 
and 2658. Feature 2658 was previously identified as a strong candidate as a potential 
biomarker which would explain why Feature 31189 is now identified as a potential biomarker 
following clustering. 
Feature 840 was identified as a potential biomarker following clustering but not prior to it. 
Looking at the clustering information this feature was clustered with Features 64515, 48867, 
17489, and feature 20271, which are all features that were also not identified as a potential 
biomarker candidate following clustering. Before clustering occurred all these features had a 
low feature presence (i.e. Feature 840 had 36 missing values). Following clustering with four 
other features only five of the values for this feature were missing. Figure 62 shows a boxplot 
of the data following clustering. This boxplot suggests there may be significant differences in 
the data between the groups, specifically between group 3 and the other groups.  
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Figure 62 - A boxplot comparing the four groups of intensity data presented for feature 
840, which was identified as a potential biomarker following clustering but not before. 
 
It would be interesting if it was possible to identify the features that have been clustered 
together for Feature 840, in order to identify whether this clustering was appropriate. This 
would help validate the clustering algorithm, but unfortunately this information is not 
available due to the confidentiality of the experiment. 
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5.3 The Suggested Analysis Strategy for Biomarker Identification 
Following the conclusions from this chapter and Chapters 3 and 4 a suggested statistical 
analysis strategy was decided. The suggested analysis steps are outlined in the options file 
obtained from Biomarker Hunter (Table 51). Statistical analysis was conducted on Dataset 3 
using this strategy. Technical replicates were not averaged. Total abundance normalisation 
was implemented to reduce technical variation. The clustering algorithm was used to reduce 
the presence of missing values prior to missing value imputation. Following statistical 
analysis the Benjamini Hochberg algorithm was used as the multiple testing correction 
method. It is important to remember that this suggested strategy relies more on the theories 
suggested by the literature as opposed to results compared with actual, validated biomarkers. 
An actual ideal statistical analysis strategy can only be suggested following this comparison. 
Table 51 - The options file for the statistical analysis using the suggested strategy.  
Biomarker Hunter Options Used? 
Total abundance normalisation ? Y 
Averaging of technical replicates? N 
ClusterFix used? Y 
Missing data imputed? Y 
User defined Minimal Value Imputation used? N 
Is Multiple Testing implemented? Y 
Multiple Testing Method? Benjamini-Hochberg 
 
Using this suggested analysis strategy a total of 302 features were identified as potential 
biomarkers of which 201 were unique. Table 52 shows the number of times a feature is 
identified as a potential biomarker alongside the number of features in each category. It 
shows that twenty six features were identified in three univariate group comparisons. This 
suggests that these are the features of greatest potential interest and are identified in Table 53. 
Proteins are usually made up of a number of peptides. As this experiment involved on the 
study of peptides it is expected that a number of these features will relate to the same 
proteins. This is because all the features relating to protein biomarkers will be differentially 
expressed between the groups. This will reduce the number of potential biomarker 
candidates. 
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Table 52 - The comparison of positive hypothesis tests using the suggested analysis 
strategy and the original analysis (Chapter 3) without any data processing for Dataset 3. 
Suggested Strategy Used 
Chapter 3 (No 
Processing) 
+ve 
Hypothesis 
Tests 
Number of 
Features 
+ve 
Hypothesis 
Tests 
Number of 
Features 
1 126 1 359 
2 49 2 279 
3 26 3 97 
  
4 87 
  
5 49 
  
6 31 
  
7 21 
  
8 40 
  
9 25 
  
10 21 
  
11 10 
  
12 3 
  
13 1 
 
Table 53 - A list of the features identified as potential biomarkers in three univariate 
tests following the suggested statistical analysis strategy for Dataset 3. A full version of 
this table is given as an output when using Biomarker Hunter. 
Feature 
Identifier 
Positive Tests 
Count 
Feature 
Identifier 
Positive Tests 
Count 
1250 3 49809 3 
12568 3 5103 3 
14297 3 53826 3 
16294 3 540 3 
16780 3 5839 3 
1722 3 6144 3 
17500 3 6427 3 
1775 3 794 3 
23223 3 83143 3 
2760 3 8936 3 
2929 3 91342 3 
3226 3 9954 3 
3570 3 4485 3 
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6 Multivariate analysis 
This chapter now focuses on the multivariate analysis options available for the use of 
biomarker identification from proteomic experimental data. The principal advantage of 
proteomic analysis is the quantification of a large number of variables simultaneously, 
allowing the generation of very large multivariate datasets. Due to the large dimensionality of 
proteomic biomarker datasets, and intrinsic difficulty in identifying small differences 
between groups, they can be effectively analysed through statistical multivariate tools. The 
main benefit of multivariate techniques is that they allow combinations of features to be 
identified, as opposed to the univariate methods which just provide information about each 
individual variable independently.  
These tools are effective in representing the multivariate structure of the proteomic data. 
Although these techniques are usually used to identify any relationships between sample 
groups, post-hoc analysis can be conducted to identify the features (peptides or proteins) that 
are responsible for the variations between the sample groups (if any). 
The use of multivariate statistical methods or pattern recognition techniques which analyse a 
group of peptides rather than only concentrating on a single peptide at a time can help with 
this loss of correlation information. These techniques are generally better, than univariate 
methods, at dealing with “long-lean datasets”, in which the number of proteins or peptides 
being analysed greatly outnumber the number of samples. This is usually the case with 
proteomic biomarker experiment data. Any models that are constructed through these 
multivariate techniques must be robustly tested using cross validation through a “train and 
test” procedure.  
As mentioned earlier in section 2.2, the Biomarker Hunter pipeline offers three multivariate 
methods. These are Principal Component Analysis (PCA), Hierarchical Cluster Analysis 
(HCA) and Partial Least Squares – Discriminant Analysis (PLS-DA). Both PCA and HCA 
are methods which have been designed to identify the relationships between the samples and 
proteins rather than identifying differences in protein abundance like the univariate tests. 
Although PLS-DA is a classification technique, it can be used to identify features (peptides or 
proteins) that are responsible for the classification of these sample groups. 
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In this chapter, these multivariate methods are evaluated on proteomic experimental data. The 
chapters will explain the methodologies of the techniques along with their uses and 
limitations. The results offered by these methods will also be presented. The multivariate 
techniques HCA and PCA were conducted on Dataset 1 (Circadian Variation). These 
techniques were implemented to determine whether time of sample collection significantly 
affects the proteomic composition of Zebrafish Embryos (ZFEs). These results will be in the 
form of PCA scores plots and HCA dendrograms. The PCA analysis will be used to 
investigate the features that are responsible for the variance between datasets. The 
multivariate technique PLS-DA was used on Dataset 3, the same data that the univariate 
analysis was conducted on, allowing direct comparison. These results will be compared with 
the univariate results obtained for this dataset in Chapter 3. To allow a fair comparison the 
PLSDA will be conducted without any data pre- or post-processing options. The missing 
values were replaced by zeroes. 
 
6.1 Hierarchical Cluster Analysis (HCA) 
Cluster analysis is a set of techniques usually conducted on datasets in order to form 
homogenous groups of samples, based on their observed characteristics. Cluster analysis can 
be used in tests where classification of a sample is needed as well as when data needs to be 
simplified or relationships within datasets need to be identified. It allows a large number of 
variables to be represented by a lower number of factors. Cluster analysis allows the 
extraction of information from datasets with large amounts of inter-related data to assist in 
making conclusions about the data. Identification of groupings among variables based on 
relationships which emerge from the correlation matrix allows conclusions to be made 
regarding the nature of an unknown or unclassified sample.  
Hierarchical cluster analysis uses nested tree-like dendrograms which reflect the relationship 
between samples based on their distance from each other. Each sample starts off as its own 
cluster and they are appropriately merged until each sample belongs to a larger cluster. There 
are a variety of distance measures and clustering methods that can be utilised for HCA. The 
three general types of similarity measure are: 
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1. Distance measures: These are most commonly used in biological studies. The most 
common distance measure used is the Euclidean distance (Bagnall & Janacek, 2005) 
                
dxy is the distance between samples x and y related to the variable in question. X is the 
variable in question. 
2. Correlation measures 
3. Agreement or matching-type measures 
There are also various methods used to cluster the samples. The most common used is the 
average linkage algorithm. The results may differ dependent on which of these are used. All 
these methods have their own uses and advantages.  
6.1.1 Methodology of HCA 
The basic theory behind cluster analysis is the minimisation of the ratio: 
                            
                              
 
First the problem or question being evaluated needs to be defined. For example is sample X 
from a diseased or normal state individual, or are there any relationships between groups of 
samples. Then a representative set of attributes are identified (i.e. in this case the abundance 
of peptides or proteins in each sample are obtained from proteomic techniques). These 
variables are converted into comparable, compatible units to allow direct comparison 
between samples. A correlation matrix is then created using the required distance measure to 
use (e.g. Euclidean or Mahanolobis distance measures). The entities are then grouped using a 
linkage algorithm (e.g. Single or complete linkage). These methods determine the number of 
clusters presented. A HCA dendrogram is then created which can be visually analysed by 
researchers. 
6.1.2 Constraints of HCA 
Issues arise with cluster analysis due to the fact that it is a highly subjective process and no 
tests are implemented to test the significance of the results (Child, 2006). Most cluster 
analysis use relatively simple methods which are not usually supported by an extensive body 
of statistical reasoning. Compared to other statistical methods it largely relies on the user to 
make correct conclusions based on the dendrogram. Additionally the different linkage 
methods usually generate different solutions for the same dataset, so it is often difficult to 
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evaluate the quality of the clustering and therefore difficult to make confident statements with 
regards to HCA results. Some problems may also arise when comparing variables using 
different units as well as when variables are correlated with others 
6.1.3 HCA Implementation in Biomarker Hunter 
If multivariate analysis is selected then the user is asked for the required distance measure 
and agglomeration methods. Once these have been selected a distance matrix is created in R 
using the dist function by calculation of the distances between the rows of a data matrix. 
Using this distance matrix a dendrogram is created using the hclust function in R which is 
then saved as a plot (Figure 63) in the results folder. The pipeline offers all the available: 
 Distance measures (Gordon, 1999) 
o Euclidean 
o Maximum 
o Manhattan 
o Canberra 
o Binary 
o Minkowski 
 Linkage algorithms (Gordon, 1999) 
o Ward 
o Single 
o Complete 
o Average 
o Mccquitty 
o Median 
o Centroid 
6.1.4 HCA Results 
Hierarchical Cluster Analysis (HCA) was conducted on Dataset 1. Examples of dendrograms 
produced can be seen in Figure 63 and Figure 64, using different distance measure methods. 
As described in section 2.1.1 there were a total of ten samples analysed for this study. The 
study aims to determine whether there are significant differences in protein expression 
between samples collected at 0900 and those collected at 1200. There are five samples (A-E) 
in each time group (9 or 12). If the circadian rhythm (i.e. time of sample collection) has a 
significant effect on protein expression then this will be displayed by tight clustering of 
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samples A:E9 and tight clustering of samples A:E12. The dendrogram should also display 
clear differences between the two clusters of samples from group 9 and group 12. 
There was evidence of grouping between the different time points, but there was also some 
evidence of close grouping between samples from different time points. This is shown in 
Figure 63 with the close relationship between samples A-9 and D-12, as well as between B-9 
and E-12. This suggests that the time may have an effect between the groups however there 
are also variations between the sample groups that are not due to time 
 
Figure 63 - HCA cluster dendrogram for the circadian rhythm study, using Euclidean 
distance measure and complete linkage algorithm. 
Similar traits were shown when the Manhattan distance measure is implemented rather than 
the Euclidean measure (Figure 64). Although there is some separation between samples from 
different time groups, this dendrogram shows very close relationships between E-9 and E-12. 
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Figure 64 - HCA cluster dendrogram for the circadian rhythm study, using Manhattan 
distance measure and complete linkage algorithm 
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6.2 Principal Component Analysis (PCA) 
PCA is a non-parametric, multivariate technique used to analyse large datasets which is 
ideally suited to a study where the structure of relationships among samples is being 
examined within interdependent datasets. It can be useful for extracting relevant information 
from confusing datasets. PCA involves the elimination of data redundancy hence reducing 
the number of variables. It is usually used for the investigation of the relationships within 
datasets with a large number of variables, and can help explain these variables in terms of 
their common underlying structure. PCA involves aggregation of the information obtained 
from a set of variables into a simpler, more manageable set of variables, referred to as 
components and factors, while still retaining as much of the data contained in the original 
dataset. PCA reduces the dimensionality of the data by retaining the characteristics of the 
data which contribute the most to its variance.  
A factor or component can be referred to as a linear combination of the original variables. 
They represent the underlying dimensions which summarise the information obtained from 
the original set of variables. Mathematically PCA can be described as an orthogonal linear 
transformation that converts the larger dataset into a simpler co-ordinate system in a way that 
the greatest variance by any projection of the data comes to lie on the first principal 
component (PC) and the second greatest on the second and so on. 
6.2.1 Methodology of PCA 
PCA involves decomposition of the matrix X into a smaller dataset Y which has a dimension 
of L. Matrix Y is the Karhunen-Loeve transform (KLT) of matrix X (Gerbarands, 1981). 
            
If matrix X has a dimension (Number of variables) of L. PCA must reduce the data in a 
manner that the entire dataset can be described with a lower number of components M. The 
data is arranged into N number of vector each representing a single grouped observation of 
the M variables. A matrix is then formed with dimensions of M x N.  
PCA is done by considering the total variance of the variables. The Eigenvalue (or latent 
root) is the amount of variance accounted for by a factor. A factor matrix shows factor 
loadings. Factor loadings show the correlation of each variable to each factor.  
First the problem or question being evaluated needs to be defined. For example, is sample X 
from a diseased or normal state individual, or are there any relationships between groups of 
Page | 179  © Cranfield University, 2011 
 
samples. This is followed by selection of samples for the purpose of analysis. The relevant 
factors (i.e. the variables and the respondents) are then extracted (Shlens, 2005). The data is 
then organised in a m x n matrix, where m = number of variables and n = number of samples. 
From this the co-variance of the variables is calculated using either the SVD or eigenvector 
decomposition methods (Jolicoeur & Mosimann, 1960). This leads to a reduced list of 
variables (factors) which are then labelled based on the amount of variance each factor 
captures. The criteria for the Eigenvalue suggest that the factors included in the analysis 
should account for the variance of more than a single variable (i.e. Eigenvalue > 1). 
 
6.2.2 Constraints of PCA 
PCA does have some limitations however the majority of these lie within its actual strengths. 
PCA is a non-parametric test and no prior knowledge is incorporated therefore the 
compression of the data matrix may incur loss of information. The technique relies on second 
order statistics and can be statistically dependent, in which case PCA may fail to find the 
most compact description of the data (Kambhatia & Leen, 1997). As with most analysis 
techniques the amount of noise in the dataset must be low so this should be removed prior to 
PCA analysis (Shlens, 2005). 
PCA is a linear method and may cause problems where relations between the X and Y values 
are not linear: This has lead to non-linear PCA algorithms such as kernel PCA. If the data 
contains sufficiently large anomalies this may misconstrue the PCA’s definition of normal 
variance, PCA assumes that the mean and the variance in a dataset entirely describe the 
probability distribution of it (Ringberg et al, 2007). Additionally In cases where PCA is used 
for clustering it doesn’t account for class separation. 
 
6.2.3 PCA in Biomarker Hunter 
If multivariate analysis is required then a PCA graph comparing the two most significant 
principal components against each other as shown in Figure 65 is saved in the results folder. 
The principal component analysis is conducted using the prcomp function in R. Following 
that a plot is created using the scores matrix and the plot function in R. 
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6.2.4 PCA Results 
Principal Component Analysis (PCA) was conducted on Dataset 1 to provide a visualisation 
that would allow conclusions to be made regarding the sensitivity of circadian rhythm 
between samples collected at 09:00 and samples collected at 12:00. The PCA analysis was 
conducted twice on Dataset 1. The first analysis was done by removing the missing values 
from the dataset (Figure 65), while the second analysis was done with the missing values 
being replaced by zero (Figure 66). 
 
Figure 65 – A PCA plot to identify any possible relationships between samples collected 
at 09:00am compared to samples collected at 1200noon from Dataset 1 (Ignoring 
missing values).  
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Table 54 - Variance attributable to each Principal Component (PC) for the analysis of 
Dataset 1 (Ignoring missing values).  
Principal Component Variance Variance (%) Cumulative variance (%) 
PC1 0.792294548 79.23% 79.23% 
PC2 0.178102698 17.81% 97.04% 
PC3 0.006567569 0.66% 97.70% 
PC4 0.002632282 0.26% 97.96% 
The results of the first analysis show that the first two principal components (PCs) capture 
97% of the variance (Table 54), with PC1 representing more than 79% of the variance. If the 
samples are significantly differentiated into the two time bands with respect to PC1 (i.e. 
differentiated horizontally) then it can be concluded that circadian rhythm severely affects the 
expression of proteins. 
 
Figure 66 - A PCA plot to identify any possible relationships between samples collected 
at 09:00 am compared to samples collected at 1200 noon from Dataset 1 (Missing values 
replaced by zero). 
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Table 55 - Variance attributable to each Principal Component (PC) for the analysis of 
Dataset 1 (Replacing missing values with zero). 
Principal Component Variance Variance (%) Cumulative variance (%) 
PC1 0.703707109 70.37% 70.37% 
PC2 0.164424594 16.44% 86.81% 
PC3 0.026567569 2.66% 89.47% 
PC4 0.026322827 2.63% 92.10% 
PC5 0.020633945 2.06% 94.17% 
The results of the second PCA show that the first two principal components (PCs) capture 
86% of the variance (Table 55), with PC1 representing more than 70% of the variance. So 
again if the samples are significantly differentiated with regards to PC1 (i.e. differentiated 
horizontally) then it can be concluded that circadian rhythm severely affects the expression of 
proteins. 
In both the PCA analyses there is some evidence of differences between samples taken at 
0900 hours and those from 1200 hours, in that those taken at 0900 hours appear higher in the 
plot. However, the vertical axis only represents 16% of the variance within the samples, so 
the influence of sampling on the overall variance is low. The horizontal axis however 
(representing 70% of the variance) does not show correlation with the time of collection. The 
PCA results suggest that there are small differences between samples collected at 0900 and 
those at 1200 but there is more variation within the samples which is due to factors other than 
time. Through Biomarker Hunter a list of features (gel spots) which contribute most to the 
position of the points in the PCA plot were identified for each PC (Table 56 and 57). This 
was done by examining the loadings matrix from the PCA analysis. 
Table 56 - A list of MCI's contributing to most of the variance for each PC (Analysis 1 – 
Missing values ignored) 
PC1 PC2 
705 
479 
576 
416 
705 
385 
831 
392 
479 
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Table 57 - A list of MCI's contributing to most of the variance for each PC (Analysis 1 – 
Missing values replaced by zero) 
PC1 PC2 
416 
479 
705 
576 
 
479 
705 
385 
 
These results show that features 705 and 479 are very influential for both PC1 and PC2. 
Features 416 and 576 are significantly responsible for the variance displayed in PC1, while 
features 385, 831 and 392 are significantly responsible for the variation in PC2. This suggests 
that these features may warrant further investigation with regards to their impact on the 
circadian rhythm, as PC2 shows some distinction between the two groups of samples. For 
smaller datasets (i.e. smaller number of features) the dataset can be transposed to treat the 
different samples (A:E 9 and 12) as variables and treat the features as the samples to see if 
any grouping occurs between the features. If any distinct features are identified then these are 
likely to be the features responsible for the variance between the samples. 
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6.3 Partial Least Squares Discriminant Analysis (PLS-DA) 
Approaches such as Principal Component Analysis (PCA) simply identify the amount of 
variance a protein gives to total variation in a given dataset. Additionally they are both 
unsupervised explanatory techniques. This means that all the variables are treated in the same 
way and there is no distinction between explanatory and dependent variables. Alternatively 
PLS determines a threshold level for which proteins are significant in the classification of 
samples into various groups. The threshold value can then be set to identify those proteins or 
peptides which contribute to the differences between samples. PLS-DA is a supervised 
technique which is designed to identify the differences between defined groups. 
PLS-DA is a classification technique which classifies samples following consideration of its 
multivariate structure. PLS-DA is a supervised multivariate classification method which has 
been identified as a technique which can be used for the purpose of classification of data from 
proteomic experiments. It is a multivariate regression technique which can be used to identify 
relationships between one or more dependent variables (Y) and a group of descriptors (X). 
The group of descriptors (X) and the dependent variables are simultaneously modelled to 
discover the latent variables (LV) in X, which can be used to predict the latent variables in Y 
while concurrently identifying the largest possible information present in X. The Latent 
Variables (LV) are similar to the principal components (PCs) that are calculated from 
Principal Component Analysis (PCA), so the first LV accounts for the largest amount of 
maximum residual variance.  
6.3.1 Methodology of PLS-DA 
PLS-DA based classification techniques assign an object (x) to a class (g) where P(g/x) is at 
its maximum value where: 
       
        
        
 
Pg = prior probability of class g   Pk   prior probability of class k (k ≠ g) 
f(x|g) = probability density function of class g  f(x|k) = probability density function of class k 
Each class is derived by a Gaussian multivariate probability distribution obtained by the 
following formula.  
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Pg = prior probability of class g 
Sg = covariance matrix of class g 
Cg = centroid of class g 
p = number of descriptors 
In Linear Discrimination Analysis (LDA) the covariance matrix of each class is approximated 
with the pooled covariance matrix and all the classes are considered to have a common 
weighted average of the shape of the present class. The variables contained in the model 
which discriminate the classes can then be identified. This is achieved step-wise by iteratively 
choosing the most discriminating variables. 
Using the PLS-DA technique there are various options with regards to the identification of 
the group of features that are significantly responsible for the differences between groups. 
These techniques include jack-knife estimation and cross model validation. 
6.3.1.1 Partial Least Squares with Jack-Knife Estimation 
PLS has been used to extract data from 2D Gel Electrophoresis (2DGE) through the use of 
discrimination PLS with a variable selection (Jack-knife) procedure (Jessen et al, 2002). PLS 
allows the successful identification of the spots which can be characterised by a systematic 
variation. The Jack-knife procedure allows the identification of only the spots with actual 
relevant variations. PLS-DA can also be applied to identify differences between a number of 
proteomic datasets (Karp et al, 2005). 
Partial Least Squares (PLS) regression with Jack-knife estimation of significant regression 
coefficients can be calculated to identify significant variables (Grove et al, 2008). The idea 
behind this technique is to search for variables with a large variation across the sample 
groups. To avoid scaling down these variables and scaling up those variables displaying less 
variation, the group-scaling method is used to calculate a weight based on the variation 
between the groups while keeping out the variation between the peptides or proteins. These 
weights can be calculated based on the standard deviation for the protein in question with 
relation to the various sample groups.  The significance level for each variable is based on the 
stability of the estimated regression coefficients. Once the proteins or peptides with 
significant regression coefficients have been identified, a new PLS regression with Jack-
Knife is conducted using only these variables. This technique is repeated until the point of 
convergence (where all the variables are classed as significant).  
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6.3.1.2 The Cross Model Validation (CMV) 
This is a Partial Least Squares (PLS) analysis with the inclusion of an additional validation 
step. It involves the removal of one sample before the model is built based on the remaining 
samples. The model is built using PLS with Jack-Knife and full cross-validation. The 
eliminated sample is then classified using the results from the PLS analysis. The technique is 
repeated until all samples have been taken out of the analysis.  
6.3.2 Constraints to PLS-DA 
Although PLS based techniques provide a higher predictive accuracy and reduced chance of 
correlation compared to regression alone, there is an increased risk of neglecting the real 
correlations (Cramer, 1993). There is also an increased sensitivity to the relative scaling of 
the descriptor variables. 
6.3.3 PLS-DA in Biomarker Hunter 
Partial Least Squares Discriminant Analysis (PLS-DA) with jack-knifing can be conducted 
on the datasets using an R script separate to the Biomarker Hunter script. In a published study 
various statistical testing methods were conducted on 2D gel-based proteomic data to identify 
biomarkers (Grove et al, 2008). The methods compared were ANOVA, PLS with Jack-
knifing, Cross Model Validation, and the Power-PLS method. The reason for PLS-DA with 
jack-knifing being used as the preferred PLS-DA model is because besides ANOVA, PLS-
DA was seen to be the most complementary method to use as a multivariate technique. Due 
to the results of this study the jack-knifing procedure was applied in Biomarker Hunter to 
identify the biomarkers. 
The script conducts PLS-DA on the dataset, and then subsequent jack-knife analysis is 
conducted to return p-values for each peptide (feature). The features that are seen to show 
significant differences are then extracted into a new dataset where the PLS-DA and jack-
knife techniques are repeated until all the features are classed as significant. 
6.3.4 Biomarker Hunter - PLS-DA in use 
The Partial Least Squares – Discriminant Analysis (PLS-DA) was conducted on Dataset 3 
(Xenograft Pre-Clinical Project) which was provided by OBT which aims to compare four 
groups of samples. Once PLS-DA was conducted, jack-knifing was conducted to identify 
features with a p-value lower than 0.05. These features will be extracted into a new dataset, 
on which the process the PLS-DA and then jack-knifing procedure were repeated until the 
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point of convergence (all the features have a p-value lower than 0.05 for the jack-knifing). 
This follows the technique used for the identification of potential biomarkers from other 
studies (Grove et al, 2008).  
This resulted in a total of 57 features being identified as potential biomarkers (i.e. showing a 
statistically significant difference in expression) between the different sample groups (Table 
58). When compared to the list of potential biomarker candidates obtained using the 
univariate approach, it was found that all of the biomarkers identified using this technique 
were identified by the univariate tests. As far as the analysis of this dataset is concerned, the 
PLS-DA technique did not identify any potential biomarkers unique to this test. It can 
however be used as a technique to add confidence to those features identified using univariate 
techniques. 
Table 58 - A list of features identified as potential biomarkers using PLS-DA 
List of Features Identified as Potential Biomarkers 
1131 9303 8091 1250 1328 55 1677 
6113 6856 4020 97 764 1765 168 
8408 5433 9166 2122 983 2303 171 
588 7415 2769 9660 723 2509 1830 
6641 1538 6985 6794 1481 2183 
 5658 3778 3501 20081 3100 2652 
 6058 2781 2572 2187 3850 2670 
 1058 5752 2760 10383 3954 269 
 4582 4803 9253 10321 4232 2832 
 8995 4427 4784 794 4498 1554 
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7 Business Aspects of Proteomic Biomarker Discovery 
This chapter will outline the business opportunities that will be presented through quicker, 
more efficient discovery of biomarkers. An introduction to the sponsor company will be 
provided to give context to the industrial application of biomarker discovery. It will then 
discuss the clinical impact that biomarkers aim to deliver both in terms of health benefits to 
patients and economic benefits to organisations such as healthcare providers and drug 
manufacturers. A SWOT analysis describing the companies’ considerations when conducting 
such research is also presented as well as a review of existing software in the market.  
7.1 Sponsor Company - Oxford BioTherapeutics (OBT) 
OBT Previously OGS (Oxford Genome Services and Oxford GlycoSciences) are a leading 
organisation in the relatively immature field of proteomics. They aim to develop innovative 
and break-through cancer treatments through the discovery of novel diagnostic biomarkers 
and targets to improve disease management through tailored treatments. They specialise in 
personalised drugs, which are more effective for individuals due to the variety of genetic 
differences amongst individuals. Individualised medicine (also known as personalized 
medicine) focuses on differences between people and the potential for these differences to 
influence medical outcomes (Figure 67). This contrasts the trial-and-error (empiric) method 
previously used, and still frequently used today (Chapman, 2010). 
 
Figure 67 - The principle of individualised medicine as opposed to empiric medicine 
(Chapman, 2010). 
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OBT has experience in safety biomarker discovery research with the FDA and large 
pharmaceutical companies, such as Pfizer. The company’s strengths also include an 
expanding network of relevant alliances with key technology providers. OBT have access to 
the OGAP® proteomic data analysis and interpretation database. OGAP is one of the world’s 
largest databases of human proteins which allow an in-silico validation of biomarkers with 
human in-vivo data. It is built up from protein disease data which has been linked with 
genetic and clinical information. It contains information extracted from human tissues 
including samples from patients suffering from known diseases. It allows the identification of 
biomarkers which are useful for drug discovery and development. OGAP provides a unique 
source of qualified targets and biomarkers assisting in the transfer of determined markers to 
their clinical benefits. The database allows for re-profiling of existing targets in order to 
develop these further. The database also has a set of tools which can be used to analyse 
various proteomic data. 
 
 
 
 
 
 
 
 
 
 
Page | 190  © Cranfield University, 2011 
 
7.2 Commercial Impact of Biomarkers and Biomarker Hunter 
7.2.1 Commercial Aspects of Biomarker Hunter 
From a commercial perspective pharmaceutical companies would benefit from improving 
productivity in research & development through earlier application of biomarkers for safety 
and efficacy in the drug discovery process. Regulatory agencies interests lie in development 
of more predictable animal models and translatable biomarker approaches to take advantage 
of technological “omics” related advances.  
This software will aim to reduce the cost of conducting preclinical and clinical validation 
studies. This is based on the premise that it will lead to a decrease in the time, required to 
develop accurate biomarker assays within drug development programs, by the earlier 
indication of features (i.e. peptides or proteins) of interest. The realisation of these biomarker 
assays will lead to the earlier diagnosis of diseases in patients. The software will aim to lead 
to the determination of the mechanisms which drugs use to deliver their effect in a time 
effective manner due to the reduction in time and cost of the drug development process. 
In its current form Biomarker Hunter is an open source pipeline meaning it is freely available. 
While this is the case it is difficult to make a commercial impact because the software can not 
be sold for a profit. Firms have invested billions of dollars in developing open source 
software, which is freely available. This accounts for a number of jobs and revenue, which 
could be added to the economy (Ghosh, 2006). This represents Problems associated with 
open source are well documented and include: 
 The development and distribution of open source software is of a non-centralised 
nature. This reduces the chance of having someone to blame if things go wrong and 
introduce a degree of risk to the future development of individual applications. 
 There are hidden costs involved despite the non-existent acquisition costs. This may 
include, among other issues, staff retraining. 
 The lack of user friendly tools and documentation and neglect of the importance of 
intuitive user interfaces. 
 The rapid pace of changes to open source software, arising from the huge base of 
contributing programmers. 
 The risk of open source software stagnating due to developer distraction or loss of 
motivation or resources. 
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The market penetration of open source software is very high. A large share of private and 
public organisations report some use of open source software in most applicational domains 
(Ghosh, 2006). In the private sector, the adoption of open source software is driven by 
medium and large sized firms. As far as industries are concerned, open source software saves 
them over 36% in software research and development investments that can result in increased 
profits for them. These profits can be more usefully spent in further innovation. 
It is quite common in the software industry that great achievements can start from volunteer-
based projects (Phipps, 2010). This can work initially but eventually if the project becomes a 
threat to larger, controlled organisations that develop commercial software. At this point, for 
the sake of survival and competition, the project may have to fortify its position by fostering 
commercial involvement to enable the project to advance and compete. The 
commercialisation of a successful open source project is part of the projects natural lifecycle. 
In terms of the Biomarker Hunter software created by this project it is possible that 
commercial gain can be achieved from open source projects. Many independent software 
vendors use open source frameworks within their proprietary, for-profit products and 
services. As far as customers are concerned they may be willing to pay for additional services 
such as legal protection or high quality support that is typical of commercial software, on top 
of the independence that open source software provides. This commercial benefit is only 
likely to be achieved if there are a large number of users that rely on the software. The vast 
majority of commercial open source companies experience a conversion ratio well below 1% 
(Wheeler, 2006). Although commercialisation of open source software is difficult, it is by no 
means impossible. For example Red Hat and VA software are both open source companies 
that have gone public. There is also the opportunity for open source projects to be acquired 
by current public organisations. The other alternative would be to create a commercial 
version of Biomarker Hunter, but this would not be achieved in R. The code would have to be 
converted to a different programming platform. 
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7.2.2 Clinical Impact of Validated Biomarkers 
Biomarkers can be found in different biological systems including muscle, blood plasma or 
embryos. In the Proteomic field of biomarker discovery, the aim is to identify those proteins 
which can be utilised to explain a particular biological process. For example in drug 
discovery there is a need to identify the process of the disease as well as measure responses to 
drugs. The biomarker can also be used to diagnose a particular diseased state or condition. 
The identification of these proteins (biomarkers) is very important to pharmaceutical and 
biotechnology oriented companies. These companies need to have accurate measurements of 
responses to experimental treatments and new drugs. Some diseases require invasive 
techniques, such as biopsies, in order to diagnose patients. This can be uncomfortable for 
patients as well as increasing healthcare costs (Ludwig & Weinstein, 2005). 
The ability to identify and validate biomarkers linked to particular disease using a cost 
effective and non-invasive method could revolutionise current clinical trial practices (Soares 
& Shaw, 2010). This can be achieved through the development of a biomarker assay, which 
can be translated into a hand held point-of-care (POC) device that monitors these biomarkers 
in body fluids. Biomarkers could be very useful for doctors to make decisions on how to treat 
patients. If a biomarker can be developed that can identify whether a particular patient will 
respond to this therapy, it can reduce the costs. This is because there is less time and 
resources being wasted on patients which will not respond to the therapy. It also reduces risks 
of undesired side effects. This reduced cost will lead to increased profits and therefore better 
shareholder dividends. 
A number of drug development companies, as well as organisations that have been contracted 
to carry out research on their behalf, spend a considerably significant amount of time, energy 
and resources in biomarker discovery. These resources are spent to be able to discover, 
identify and measure novel biomarkers (Netterwald, 2010). One of the most important criteria 
for the biomarker discovery process is that no assumptions should be made about the 
biomarker to be discovered. 
The pharmaceutical industry desperately needs biomarkers to better target its drugs to its 
patients. This however presents a double-edged sword as a biomarker may keep a billion 
dollar drug development process from getting derailed by stratifying patients into responders 
and non-responders before entering clinical trials (Krueger, 2005). This is because successful 
validation of the markers would lead to more approvals as well as cheaper and earlier failure 
for non-promising drugs. A good example to outline this issue is the anti-inflammatory drug 
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Vioxx marketed by Merck & Co (Horton, 2004). This drug was withdrawn over safety 
concerns but only after it created 2.5 billion US Dollars in sales revenue for Merck & Co.  
Biomarkers are a very active area of research. This can be measured by the number of 
scientific or medical articles published on this topic (Figure 68). Between 1960 and 1989, 
approximately 42,000 peer reviewed articles were available on the PubMed database. This 
number more than doubled in the 1990s and nearly doubled again between 2000 and 2009. 
Another indicator of the growing interest in biomarkers is the existence of journals dedicated 
to the topic, such as Molecular Biomarkers. 
The FDA has regulatory oversight over all medical tests or test systems that are manufactured 
for commercial use in point-of-care settings. It is surprising that, despite this increasing 
interest in biomarkers, the number of clinical biomarker tests approved by the Food and Drug 
Administration (FDA) has not kept pace with this increased research (Figure 69) (Phillip et 
al, 2012). In fact, this number has actually decreased in the past decade, and few of the 
approved biomarkers have become standard practice (Chapman, 2010), Reasons for this 
include the time and cost of developing a new drug, from discovery to patient use, is 
constantly increasing.  
 
Figure 68 - A histogram showing the number of published scientific or medical articles 
related to biomarkers (Chapman, 2010). 
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Figure 69 - Although there has been increased interest in biomarkers this has not 
affected the number of validated biomarkers in clinical use (Chapman, 2010). 
 
There has been an obvious delay in the clinical impact that proteomic biomarker research has 
delivered. This can be exemplified by the fact that the first proteomics based in vitro 
diagnostic multivariate index assay (IVDMIA) for ovarian cancer was only recently approved 
by the FDA (Fung, 2010). This was the Vermillion’s OVA1 test which includes four novel 
protein biomarkers which were discovered and validated using the Surface-enhanced laser 
desorption/ionisation (SELDI) platform. SELDI is a high-throughput biomarker discovery 
and protein-profiling tool. The SELDI platform allowed Vermillion to conduct a 600 sample 
validation study in less than six months. Other technologies and approaches take the same 
time to screen 10-15 samples. 
When making payment decisions for new drugs and expensive interventions, cost-
effectiveness and cost-utility studies are used. These studies are relatively rare for the 
evaluation of cost-utility for clinical laboratory tests. As the medical costs increase along with 
decreased resources it is likely that new biomarkers may increasingly be scrutinised with 
respect to their economic benefits in addition to the clinical utility (Scott, 2010). This 
represents an additional struggle for routine use of new biomarkers, but prior to this the 
markers must still display clinical usefulness.  Thus a newly discovered marker will never 
make economic sense if it does not display clinical usefulness.  
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When both diagnostic accuracy and potential clinical usefulness have been established there 
are several types of economic studies that new biomarkers may undergo. The most common 
of these studies is the cost-utility study. This test estimates the ratio between the cost of the 
intervention or test and the benefit it produces. The benefit is usually measured in the number 
of years gained in full health by the patient. The ratio is measured in amount of money per 
quality adjusted life year (QALY) (Pai, 2012). 
The challenges associated with the discovery of biomarkers and the eventual development of 
biomarker-based clinical tests go hand-in-hand with the challenges facing other medical 
products. The US FDA issued several reports which explain why there has been a problem 
translating these scientific findings into medical products in clinical use (US-FDA, 2004). 
These issues include: 
 The current medical product development is becoming increasingly inefficient, costly 
and challenging. 
 The number of new drug and biological applications submitted to the FDA is 
significantly decreasing, as well as the number of innovative medical device 
applications. 
 Innovators focus their efforts on drugs and applications with a potentially high market 
return, due to increased costs of product development. 
 The applied sciences needed for medical product development has not kept pace with 
the tremendous advances in basic sciences.  
 Not enough applied scientific work has been done to create new tools to get 
fundamentally better answers about how the safety and effectiveness of new products 
can be demonstrated in a faster, more accurate and cheaper way. 
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7.3 SWOT Analysis 
The analysis is based on an existing project currently being carried out by the sponsoring 
organisation OBT, for which the software and outcomes of this EngD project will be utilised. 
Certain company names have been withheld to protect company and project anonymity. 
SWOT analysis (also known as the Internal-External Analysis) is a simple yet very useful 
tool to illustrate the strengths and weaknesses of a company or project with relevance to the 
study as well as the opportunities it will create and the possibility of external threats. It allows 
companies to identify good business opportunities, and be aware of the pitfalls so they can be 
managed in an appropriate manner. 
A SWOT analysis involves the study of both internal and external influences on a project 
(Figure 70). The Strengths and weaknesses identified are usually internal factors that can 
often be controlled by the organisation, whereas the opportunities and threats are external 
factors upon which organisations have limited control. 
 
Figure 70 - An illustrative explanation of a SWOT analysis 
 
Figure 71 in section 7.3.5 shows the overall SWOT analysis for this study, which is discussed 
in detail in the following sections.  
 
7.3.1 Strengths 
The strengths identify the advantages a business has that its competition does not necessarily 
possess, as well as the implied strengths that clients may see in the organisation. Strengths 
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cannot simply be tasks the company does, or a unique idea the organisation has had. These 
strengths are always relative to the competition, as in what this organisation does that its 
competitors do not offer. 
The strengths that OBT has over its competitors lie mainly within the fact that they have an 
established and robust technology platform for proteomic biomarker studies. They have 
collaborated with a number of the top ten pharmaceuticals organisations as well as the FDA 
and boast a history of successful studies and partnerships. These studies have often resulted 
in the discovery of novel biomarkers which have then been validated and translated into drug 
targets, which have positive impacts both for drug discovery and health services. Various 
biomarkers identified by OBT have been used for: 
 Efficacy and toxicological profiles of new drug candidates 
 Identification of disease biomarkers to result in the accurate testing for early signs of 
diseases 
 Determination of whether certain treatments are working, and if the patients are 
responding to them or not 
 Identifying new targets for therapeutics 
OBT are based in an industrial park in Oxford which has a number of companies who can 
carry out screening of compounds effects, using zebrafish embryos for OBT for a fee based 
service. The co-locality of the organisations make it an ideal partnership as they can both 
focus on the area they specialise in (i.e. OBT do not have to spend resources on becoming 
experts in screening), and it is easier for the organisations to transfer samples between each 
other. The location also allows the organisations to be able to hold meetings rather than only 
having telephone and email contact which results in better project co-ordination and 
management.  
Zebrafish are a good, inexpensive model to use in drug development research. They are 
vertebrates so are more closely related with humans than models based on invertebrates (e.g. 
Drosophila) without backbones. These models have more similar biological traits with the 
human model. They also reproduce in large numbers so often they are more cost effective, 
where a large number of samples are required.  
These studies usually use the zebrafish embryos (ZFE) and since these are produced outside 
the parent body they are easy to isolate. Zebrafish embryos develop very quickly, and usually 
take about 24 hours to become fish, whereas other species may take longer. This is especially 
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true when conducting studies using mice, which take up to 21 days to develop. The use of 
zebrafish embryos has been well established to screen drug candidates for possible 
toxicological effects based on morphologic and/or phenotypic observations (Nusslein-
Volhard, 2002). ZFEs display the majority of organ systems present in mammals, including 
the cardiovascular, nervous and digestive systems. Additional characteristics that make them 
advantageous for large-scale, high-throughput compound screening are their small size, 
transparency and their ability to absorb compounds through the water. The technique also 
benefits through economies of scale and reduced animal usage making ZFEs an even more 
attractive toxicology model if the toxicity biomarkers discovered can be translated into 
humans. There was significant overlap between biomarkers identified in ZFEs and those 
identified using the same hepatotoxins, in rats (Kurz et al, 2010). This suggests that ZFEs 
may represent a viable model organism to identify novel safety biomarkers. 
OBT also has a strategic alliance with Biosite, which is a specialist in the field of antibody 
development. Biosite use technologies such as Omniclonal which allow the generation of 
large numbers of antibodies in a high throughput manner. This allows OBT to obtain 
antibodies against their cancer targets with better-quality binding characteristics. 
Another primary strength of OBT is their staff off scientists who have immense experience in 
the field. Many of the scientist who currently run the organisation have remained from the 
previous version of the company OGS which was in 1998. Their track record and proficiency 
in this area of study give the organisation scientific credibility which is very important to 
potential clients who may be interested in using the services provided by OBT. As well as 
this they have links with proteomics experts in Cranfield University which further solidify 
their scientific credibility. Evidence of this credibility has been proven through grant support 
the Department of Trade and Industry (DTI) as well as potential interest being shown by the 
FDA in upcoming projects. 
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7.3.2 Weaknesses 
The weaknesses identify the improvements the organisation must make and anything that 
should be avoided. Any issues that may cause you to lose business should also be tackled. 
Even though the weaknesses are usually internal, as with the strengths, it is important to also 
focus on the external view of clients and partners, and what they may see as weaknesses in 
your organisation.  
A major weakness of these biomarker studies is that there is often not much confidence in the 
statistical methods applied. This lack of trust in the statistical analysis is necessary to justify 
the expenses brought by validation techniques. This means often the studies are not followed 
up and meaningful conclusions (i.e. identification of valid markers) are not made. This is a 
serious issue for many of the studies conducted by biomarker companies (Vora, 2011). 
Since OBT would be taking part in its first grant assisted project, this brings with it new 
territories not explored by OBT before. Previous biomarker studies conducted by OBT have 
been on a much smaller scale and the projects have usually been more specific. Projects 
involving the DTI grant will be large scale screening of a large list of compounds (i.e. several 
hundred) in order to discover the candidate biomarkers for hepatoxicity and nephrotoxicity. 
These will then be validated and a panel of biomarkers will be selected for use in a 
commercial assay for hepatoxicity, and another panel of biomarkers for a commercial assay 
for nephrotoxicity. Although OBT has plenty of experience working with large organisations 
and conducting biomarker studies, they have never experienced such a large scale project. 
Even the pilot study for the project is considerably larger than studies they have carried out 
before. 
Although OBT have experience using ordered peptide arrays, their experience is limited. 
They do not have robust Standard Operating Procedures (SOPs) set. This is an area that needs 
to be focused on and addressed. 
At this stage of the project there are no pharmaceutical company partnerships for this study. 
Usually in these large projects there is usually a potential client who is willing to fund the 
projects, who would exclusively have rights to the results from the study. As this is a 
government funded project the financial support is not an issue but a pharmaceutical client 
will need to be identified and secured in order for organisations involved in this project to 
make a commercial gain. 
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7.3.3 Opportunities 
This section identifies the business opportunities that can arise from these studies. These 
identify not only the business gain but also how the project may influence changes in 
technology and client organisations, as well as the effect on the public. It will identify 
whether the strengths of the organisation and the study will open up opportunities as well as 
how the weaknesses can be tackled to create new opportunities. 
These studies will allow the development of a FDA approved safety biomarker panel for 
hepatoxicity, which will lead the market in this field leading to a commercial assay for 
toxicity. These can be useful to pharmaceutical organisations and can create a potential 
market either as an ongoing service for these organisations or as an asset that can be sold.  
The collaborations involved in this study may create strong relationships for future studies. 
As stated before there is a company involved who specialise in the farming and research of 
ZFEs which will be useful for future studies, to reduce the need for in-house specialists. 
There are also collaborations with hardware technology vendors as a named technology 
partner. This will help in the form of contribution of equipment and possibly funding.  
Since the project involves the screening of such a large number of compounds it may 
possibly give rise to the potential for a database and software capabilities that can be 
marketed. These can also be utilised to attract future clients and help to obtain governmental 
grants for subsequent studies. There is also the potential opportunity to leverage the 
connections made through any potential pharmaceutical industry customers in order to raise 
the profile of OBT as well as any alliance company products, in order to promote sales. 
 
 
 
 
 
 
.  
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7.3.4 Threats 
The threats identify the potential obstacles faced by the organisation. This may include the 
activities being carried out by competitive organisations as well as effects this study may 
have on OBT. Outcomes of this project may affect quality standards and specifications for 
the company. Changing technologies may also have an impact on the position of OBT in the 
industry and these threats need to be identified before they adversely affect the business. 
The requirement for the DTI grant for a grant is that more than one Small or Medium 
Enterprise (SME) must be involved in the project. This project involves collaboration with 
another company which may cause potential relationship issues with regards to the people or 
companies involved.  
Another external issue that may occur is the time involved in these projects. Since these 
projects take several years, before useful results are obtained. It is possible that within this 
time competitive companies may develop an equivalent or superior panel of biomarker assays 
for hepatoxicity or nephrotoxicity before OBT. As this industry is very competitive, many 
organisations keep their research confidential so by the time other companies have developed 
their panel of biomarkers OBT may have already spent a lot of time and resources on this 
project. If this situation arises OBT may not be able to make any financial gain from the 
project, so the progress of this project is extremely time sensitive. 
The commercial potential for this study is dependent on the interest of pharmaceutical 
organisations wanting to invest in the panel of biomarkers. These clients were not identified 
prior to the start of the study; therefore the commercial success of this project is dependent on 
a pharmaceutical partner or client. Some companies have been approached but there was 
limited interest in the development of a safety biomarker discovery effort. Some 
pharmaceutical companies have been hesitant to be involved in studies using zebrafish as 
they have not previously used ZFE’s as a model. These threats however can be handled by 
stressing the involvement of the FDA in this project. 
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7.3.5 SWOT Diagram – How to Present SWOT in Meetings 
 
Figure 71 - A SWOT analysis of the OBT safety biomarker study (Dataset 1) as it would 
be presented in meetings, with succinct bullet points which are to be discussed during 
the meeting. 
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7.4 Existing Algorithms and Software 
This section reviews the existing tools which are available to users for the purpose of 
statistical analysis of data from biomarker experiments. The section will focus on the tools 
involved in the statistical analysis of data from biomarker experiments, or the statistical 
analysis components of larger pipelines. The section will discuss the available options for the 
user and state the benefits or limitations to using the particular software in comparison with 
Biomarker Hunter, the software created through this project. An overview of the software is 
presented in Table 59 at the end of the section. 
 
7.4.1 Commercial Software 
7.4.1.1 MarkerView Software 
The MarkerView software is a program , created by Applied Biosystems, which is designed 
for biomarker profiling workflows. It contains a range of statistical analysis and graphics 
tools (Applied-Biosystems, 2005). Its statistics capabilities include: 
 Principal Component Analysis 
o Offers various scaling algorithms such as Mean Centering and Autoscaling 
o Presents groupings in a scores plot 
o Allows review of the loading plot to identify variables that contribute to the 
clustering (i.e. potential biomarkers) 
 T-Tests 
The advantages of this software, as opposed to Biomarker Hunter, mainly lies in its ability to 
take in raw data and also conduct the spectral peak picking as well as being able to align mass 
and retention time values. However the statistical analysis of the data is restricted solely to 
the Principal Component Analysis and T-Tests. 
7.4.1.2 PDQuest 
This commercial software produced by Bio-Rad (BioRad, 2011) can be used for the imaging, 
analysing and the data-basing of data from proteomic biomarker experiments. It is however, 
limited to the field of 2D gels and does not deal with data from MS based techniques. As far 
as statistical analysis is concerned the software offers normalisation, and both differential and 
statistical analysis. The normalisation technique used is similar to the total spot normalisation 
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technique used in commercial software Progenesis produced by Non-Linear. However the 
PDQuest software also takes into account any pipetting errors.  
Differential analysis is also offered by PDQuest which simply gives a value relating to how 
much a certain protein is up or down regulated in various condition groups. This technique 
suggests that any protein which is up- or down-regulated between sample groups, with a 
minimum variation factor of ±2.0, may be a potential biomarker (Marengo et al, 2004). 
However if DIGE is used a lower variation factor can be accepted due to reduced variation 
between samples. With PDQuest only the proteins which display a variation factor above that 
of the minimum will qualify for the statistical analysis step. 
For the purpose of statistical analysis the PDQuest software uses the students T-test. Once the 
proteins which are differentially expressed have been identified these are analysed using the 
T-test. Those proteins with a p-value of 0.05 or lower are then identified as potential 
biomarkers.  
As with MarkerView the advantages of this package are that it provides options for image 
filtering and spot detection prior to statistical analysis. This however also means that it is 
unable to deal with data from Mass Spectrometry experiments. Also the statistical analysis is 
restricted to the students T-test which is not an ideal technique to employ for the data 
involved. The students T-test assumes the data is normally distributed and this is not usually 
the case. This requires the use of a Bartlett test to identify whether the data displays 
normality. Biomarker Hunter however utilises the Welch T-test which accounts for data that 
does not display non-normality. Biomarker Hunter also has an option allowing the user to 
decide whether they want to screen the dataset and only conduct statistical analysis on 
samples with a variation factor set by the user. 
7.4.1.3 Pipeline Pilot Biomarkers Toolkit 
Pipeline Pilot is a commercial biomarker toolkit created by Accelrys and is used to manage, 
integrate and analyse large datasets obtained from “omics” biomarker experiments (Accelyrs, 
2010). For its statistical analysis component it utilises the R statistical programming 
language.  
With regards to statistical analysis the software produces boxplots to allow users to 
graphically visualise the data as well as conducting ANOVA analysis to identify any 
differences between the means of different sample groups. The software is very useful in that 
it can deal with a variety of data and help to identify biomarkers of interest using various 
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techniques. However its statistical analysis is restricted to ANOVA and does not use any non-
parametric analysis. 
7.4.1.4 Progenesis LC-MS 
Progenesis LC-MS is an advanced proteomics based research tool (Non-Linear, 2010). It is 
commercially available and it allows analysis of data from label-free quantitative data. It can 
be used alongside most MS hardware and produces data with no missing values. This is 
achieved by automated detection and quantification of each peptide ion. The outline of a 
peptide ion in one run is found and consequently applied to all subsequent runs to provide a 
complete data set. This is illustrated in Figure 72 where the outline of the peptide ions has 
been marked in red and all peaks within this area are quantified. The software uses ion 
intensities rather that the traditional approach of spectral counting. These methods have been 
compared and the benefits of the ion intensity approach used by Progenesis outweigh those of 
spectral counting (Zhixiang, 2010). The statistical analysis options offered in this package are 
limited as far as univariate techniques are concerned as the only option offered is ANOVA. 
The software does offer more on the multivariate side as the software provides options for: 
 False Discovery Control 
 Principal Components Analysis 
 Correlation Analysis 
 Power Analysis 
 
Figure 72 - Progenesis LC-MS Quantifies peptides based on ion abundance (Non-
Linear, 2010) 
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The advantage this software has over Biomarker Hunter obviously lies in its ability to 
produce datasets with no missing values which is the biggest issue faced in this field of 
research. Although the statistical analysis is limited, the Progenesis software more than 
makes up for this by creating datasets with no missing values. Biomarker Hunter however is 
not a tool that creates datasets alongside MS hardware. Biomarker Hunter is only concerned 
with the analysis of data created from biomarker experiments. 
 
7.4.2 Freely Available Software 
7.4.2.1 MaxQuant 
MaxQuant is a freely available proteomics software package, which can be used for the 
analysis of large MS datasets. It is an analysis pipeline which offers: 
 Feature detection and quantification 
 Peptide mass correction 
 Peptide and protein identification 
 Protein Quantification 
The pipeline does offer statistical analysis options; however this is limited to the one way non 
parametric analysis in the form of the Wilcoxon-Mann Whitney test. There are no parametric 
alternatives or any group analysis such as the Kruskal-Wallis or ANOVA tests. The 
advantage that MaxQuant shares with Biomarker Hunter is that it is freely available, so it is 
readily accessible by all laboratories regardless of the budget available to them. 
7.4.2.2 QuiXoT 
QuiXoT is a software package produced by the Centro de biologica, based in Spain (Navarro, 
2009). It is created for the purpose of automated statistical analysis, and is used for high 
throughput quantitative proteomics data from experiments which incorporate stable isotope 
labelling.  
QuiXoT employs a novel multi-approach statistical model which deals with the various 
sources of variation individually and then allows accurate control of the outliers at the 
scanning stage and at the peptide level. This allows identifying proteins of interest among 
several stable isotopic labelling approaches. 
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7.4.2.3 The OpenMS Proteomics Pipeline (TOPP)  
TOPP is an open-source software pipeline based in the C++ programming language which is 
freely available from OpenMS (Malmstrom et al, 2011). It can be used for the management 
and analysis of data from LC-MS experiments. The pipeline encompasses a number of 
smaller applications which can be used to create an analysis pipeline. The tools fall into the 
following categories: 
 File Handling 
 Signal Processing and Pre-processing 
 Quantitation 
 Protein/Peptide Identification 
 Protein/Peptide Processing 
 Targeted Experiments 
 Peptide Property Prediction 
 Map Alignment 
 Graphical Tools 
Although this pipeline contains many algorithms, unfortunately it does not contain any 
statistical analysis tools which can be used for differential analysis. 
 
 
 
 
 
 
 
 
 
 
Page | 208  © Cranfield University, 2011 
 
Table 59 - An overview of currently available statistical analysis software reviewed for this study. 
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8 Discussions and Conclusions 
The following sections discuss the outcomes of the project aims outlined in section 1.4. These 
aims being: 
 Identification of suitable methods for dealing with missing values in the data from 
proteomic biomarker experiments (Section 8.1). This aim was only partially achieved. 
This was mainly due to the lack of information regarding which features were actual, 
validated biomarkers. Because this information was not available, it was not possible 
to make definitive statements regarding the most ideal or efficient approach to 
statistical analysis for proteomic biomarker data. As it was not possible to make actual 
conclusions about the ideal statistical approach, it was only possible to make 
prediction based on the analysis of one dataset.   
 The evaluation of the suggested statistical analysis methods for the discovery of 
biomarkers from proteomic experimental data (Section 8.2). This aim was  achieved; 
however it is not yet possible to determine whether the novel clustering algorithm is 
actually appropriate. This can only be determined once the results are compared with 
actual, validated biomarkers lists to see if the clustering has a positive impact on the 
nature of the data, as opposed to just reducing missing values by clustering together 
features which do not represent the same peptide or protein. Appropriate imputation 
methods to deal with missing values have been implemented, but this research was 
not conducted in this study. These methods were chosen based on existing literature 
(Albrecht et al, 2010). 
 The development of an R toolkit (i.e. Biomarker Hunter) for the identification of 
biomarkers from proteomic experimental data (Section 8.3). This aim was wholly 
achieved and an R script is presented in Appendix A as well as an executable file on 
the supplemental CD. This was used throughout the study and has been validated 
against existing software and manual calculations. However, it may be necessary to 
change some of the features based on comparison of this research with validated 
biomarkers. Currently this is presented as open source software, so can be pursued 
and developed as more information becomes available. 
 Researching the Business Opportunities for Biomarkers and Statistical Analysis 
Software (This was discussed previously in Chapter 7). 
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8.1 Identification of Suitable Methods for Dealing with Missing Values  
Imputation algorithms are methods that replace missing values with appropriate values using 
modelling techniques. The suggested method for imputation is selective imputation based on 
the feature presence (Albrecht et al, 2010). For features with a feature presence below 25% 
minimum value imputation (MIN) should be used. This replaces the missing values with a 
value of zero. For a high feature presence, above 75% KNN imputation is the ideal method. 
For the remaining features the REPMED technique should be implemented. This replaces the 
missing values with a median value of the actual values within the group. Although 
imputation allows the replacement of missing values based on models, it can cause 
misrepresentation of the data when large datasets have to be imputed. As the percentage of 
missing values increases, there is a higher proportion of them compared to actual values. 
This calls for the need of a novel algorithm which reduces the presence of missing values. 
The clustering algorithm ClusterFix was developed to identify features that have been 
incorrectly mismatched as different features. This option should be used to reduce the 
missing values prior to selective imputation, so there are fewer imputed values in the dataset 
compared to actual values. Although options were devised for the manipulation of missing 
values, as a list of validated biomarkers was not available, it was not possible to determine 
the effects of these techniques in terms of the quality of the potential biomarker candidates.  
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8.2 Recommendations for Statistical Analysis Methods for Biomarker 
Discovery 
This section outlines the recommendations for the statistical analysis of proteomic 
experimental data, as well as the suggested methods of data pre-treatment and post-hoc data 
treatment. These conclusions are made from both the statistical analysis conducted for this 
project as well as the extensive review of existing literature available in this field of research. 
Once again, as a list of actual, validated biomarkers was not available, it was not possible to 
determine the effects of these techniques in terms of the quality of the potential biomarker 
candidates. Because of this, the following suggestions are mainly based on the literature and 
may change, based on comparison of the results from this project with a list of actual, 
validated markers. 
8.2.1 Data Pre-Treatment Options 
If normalisation has not been conducted prior to analysis, it is strongly recommended that this 
is done. If the quantitative analysis approach used is subject to technical variation between 
samples then its effects need to be accounted for. This can be accounted for using the Total 
Intensity Normalisation option offered in Biomarker Hunter. This can be ignored for 
techniques which remove technical variation such as iTRAQ or 2D DIGE (difference gel 
electrophoresis). Additionally the statistical analysis can benefit from the use of data scaling 
techniques such as log transformation, or auto scaling and range scaling. This adds strength to 
the subsequent statistical analysis conducted on the data (Limpert et al, 2001).  
Ideally technical replicates should be left as individual samples within the groups as opposed 
to averaging them. This is because the inclusion of these technical replicates helps to limit the 
variability within the experiments by averaging it out. It also enables the statistical models to 
account for the subtle differences in the experimental technique. Additionally when the 
technical replicates are averaged the implied feature presence of the samples increases. This 
is because when only one of the technical replicates has an actual value the presence of the 
missing value is ignored. This increases the percentage of present values. This would lead to 
higher p-values in the univariate hypothesis test, which results in an increased probability of 
the inclusion of false positives. 
Chapter 5 discusses that selective imputation based on feature presence along with use of the 
clustering algorithm is the ideal technique for dealing with missing values. 
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8.2.2 Statistical Analysis 
The four univariate statistical methods conducted by Biomarker Hunter gave complementary 
results. A Venn diagram was created to identify the overlap between the different techniques. 
This shows that 139 features were identified as potential biomarkers by all four univariate 
methods prior to the application of multiple testing corrections. With the exception of the 
Kruskal-Wallis technique all the other techniques also identify unique potential biomarkers 
that the other techniques do not, especially the two pair-wise hypothesis tests (The Welch T-
test and the Wilcoxon Tests). 
The addition of multivariate tests can be used to answer further questions. PLS-DA with the 
jack-knifing procedure can be used to identify features that are significantly differentially 
expressed between groups. This technique is very stringent, therefore it doesn’t identify any 
unique features as opposed to the univariate analysis but the list can refine the list of potential 
biomarker candidates obtained by the other techniques. The PCA and HCA techniques can be 
used to detect relationships between samples. 
8.2.3 Post-Treatment Options 
The pipeline offers various methods of multiple testing corrections to reduce the occurrence 
of false positives. False positives are inevitable in large datasets due to the errors caused by 
the multiple hypothesis tests. The use of multiple testing corrections is strongly advised. This 
seriously reduces the number of biomarkers identified using the pipeline. This can be an 
advantage, as it means that fewer features need to be validated. Validation is a time and cost 
expensive procedure and can create a bottleneck in biomarker discovery. If the false positive 
occurrences are reduced then this speeds up the biomarker discovery process as well as bring 
cost reduction. This is often the case for academic studies where budgets are often restricted. 
MTC however does not apply to the multivariate tests and is ignored for these tests. 
There is however a downside to multiple testing corrections. Due to the large number of 
features (peptides or proteins) the number of statistical tests is also very high. Since the 
multiple testing algorithms are based on the number of tests these methods are usually very 
stringent. These methods significantly reduce the p-values obtained from the tests as seen in 
the univariate results following multiple testing corrections presented in section 4.2.1.3. This 
significantly reduced the number of potential biomarker candidates identified as well as the 
number of tests in which the features are seen as significant. For Dataset 3 the Welch T-tests 
only returned one feature with a p-value below 0.05 following corrections (Feature 540). The 
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stringency of these tests couple with the large number of features can create a high proportion 
of false negative errors (i.e. features that are potential biomarkers being incorrectly classed as 
a non-marker). This is the reason that the Benjamini-Hochberg is suggested by the available 
literature on this topic (Shaffer, 1995). This theory also agrees with the results of the multiple 
testing corrections conducted on Dataset 2 which showed that the Benjamini-Hochberg 
algorithm retained six markers, while all the others retained only two.  
Multiple testing corrections can be ignored if the user would like to retain as many potential 
biomarkers as possible at the expense of the inclusion of potential false positive conclusions. 
This may occasionally be the case for biomarker studies conducted by large organisations 
with larger budgets and resources, especially in the pharmaceutical industry. The drug 
biomarker industry is an internationally competitive business (Hampel et al, 2010). Since the 
time taken for biomarker discovery and validation is usually long the projects are usually 
long-term contracts so companies are always competing for an edge. This may mean the 
ability to identify biomarker assays of a higher quality (i.e. identifying a higher number of 
actual biomarkers that other companies are not able to provide due to time and cost 
bottlenecks). In these cases the company may be willing to sacrifice the resources to give 
them a competitive edge.  
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8.3 An R Toolkit for Biomarker Discovery from Proteomic Data 
Using the R statistical programming language a user friendly statistical pipeline, “Biomarker 
Hunter”, was developed. The R script for this software is presented in Appendix A. As well 
as this a copy of the program has been provided on the supplemental CD and the user manual 
as shown in Appendix B. This software allows the statistical analysis of large proteomic 
datasets for the identification of features (peptides and proteins) that are differentially 
expressed between different groups of samples. These features are expected to be diagnostic 
of the physiological differences between the sample groups.  
This software can be used by researchers who have quantified the proteomic composition of 
physiologically different samples, using gel or MS based technologies. It allows the user to 
employ the various data treatment methods, described in this thesis, giving them control over 
the nature of this analysis.  
8.3.1 The Current State of the Biomarker Hunter Pipeline Software 
Datasets can be pre-treated using normalisation, replicate averaging, missing value 
imputation as well as the novel clustering algorithm to reduce missing data. It conducts four 
univariate statistical techniques in the form of the Welch T-test, Wilcoxon test, Group-wise 
ANOVA and the Kruskal-Wallis. The stable version of Biomarker Hunter provided also 
performs multivariate analysis in the form of PCA and HCA. The PLS-DA multivariate 
analysis however had to be presented as a separate piece of software. This is because memory 
issues in R are created when conducting PLS-DA. The portion of R code conducting the PLS-
DA is presented in Appendix C. Following the statistical analysis, the user can implement 
various methods of multiple testing corrections to reduce the occurrence of false positives in 
the univariate analysis. The user is then presented with the output of results described in 
section 2.2.4 as well as the ability to create boxplots for features of interest. This software has 
been used to create lists of biomarkers for datasets for the sponsor company. This pipeline 
has been used to create all the results presented in this thesis. 
8.3.2 Capabilities of the Biomarker Hunter Pipeline Software 
The advantage this software can bring to the field of proteomic lie primarily in the 
automation of the statistical analysis tasks that need to be conducted subsequent to the 
quantitative analysis of proteomic samples. This leads to the decrease in the time that is 
required to develop accurate biomarker assays. This can be used for a range of studies 
involving the need to identify peptides or proteins responsible for the differences between 
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divergent groups of samples. Compared to the statistical software alternatives, both 
commercially and freely available, the range of statistical analysis algorithms offered in 
Biomarker Hunter is much wider (Section 7.4).  
Additional to this the user has better control and understanding of the inner workings of the 
statistical analysis compared to the commercial black-box statistical tools. This allows 
organisations to conduct statistical analysis with better understanding and transparency of the 
analysis and processing steps conducted, providing open source traceable statistical analysis. 
This means the analysis can be adjusted based on the requirements of the researcher. For 
example if the user would like to retain as many potential biomarkers, at the expense of false 
negative identifications, it is possible to skip the multiple testing corrections step. 
The reduction in time as well as the fact that Biomarker Hunter is freely available software, 
also leads to a reduction in the costs involved in biomarker discovery. This can assist 
proteomic biomarker studies especially for organisations with limited budgets. This pipeline 
eliminates the need for expensive commercial statistical analysis options such as GeneSpring 
MS. There is also potential for the extension of this pipeline as a tool for the identification of 
biomarkers outside of proteomics (e.g. genomics and metabolomics). As the software created 
is open-source it is available to researchers in the field to analyse data from their biomarker 
experiments. If this is used for a study, where the researchers have an appropriate budget to 
validate these markers there is further potential for the evaluation of the optimal strategies for 
biomarker identification from proteomic biomarker discovery data. 
8.3.3 Future Work for Biomarker Hunter 
Following the statistical analysis stage the biomarkers are validated using techniques such as 
Multiple Reaction Monitoring (MRM). As the nature of the studies conducted is sensitive, the 
identity of the features has been kept confidential. Unfortunately the author has not been 
provided with the list of the validated markers in order to evaluate the quality of the list of 
biomarkers obtained using the software pipeline Biomarker Hunter. Comparison of the list of 
biomarkers provided by the pipeline software with the list of validated markers would enable 
the evaluation of Biomarker Hunter as a viable tool for the purpose of biomarker 
identification. Ideally all the features identified by Biomarker Hunter should undergo MRM 
in order to be able to evaluate the amount of false positive identifications by Biomarker 
Hunter. A list of the actual biomarkers would also help evaluate the ideal data treatment 
options to identify the suggested strategy to implement for the evaluation of biomarkers. 
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As datasets from proteomic biomarker experiments are generally very large, univariate 
calculations can lead to longer computational times for analysis. This has been constantly 
addressed through the development of the software pipeline. Currently the software takes less 
than one hour for even large datasets (i.e. over 90,000 features) if clustering is not required to 
reduce missing values. The computation time for clustering however can take a long time on 
very large datasets. This can take over 24 hours in some cases (i.e. over 90,000 features). 
Relatively, this is not a large problem as the actual quantitative analysis may take months to 
conduct in the first place. However the implementation of parallel processing could reduce 
this time for extremely time sensitive studies. Parallel frame works have been developed in R 
which could be used alongside High-Performance Computing (HPC) to reduce processing 
times for biological computing such as the SPRINT package (Hill et al, 2008). If time 
sensitivity is an issue then the script can be updated to implement the use of these parallel 
frameworks.  
Once the list of actual, validated biomarkers is available, the various functions of the pipeline 
may need to be changed. This may include inclusion or removal of statistical analysis tests, or 
development of the ClusterFix algorithm amongst other features. Additionally as not all 
researchers are familiar with the R programming language, it would be useful to implement a 
user-friendly GUI front-end to Biomarker Hunter. It would also be useful to produce a web-
based interface for Biomarker Hunter. This would make the software more likely to be used 
by more researchers and improve the potential economic impact this software can bring. If, 
following additional research, it is discovered that this pipeline is likely to have widespread 
usage; it may make sense to develop a commercial version of the software using these 
algorithms. This would lead to better chance of having an economic benefit of the pipeline.   
Due to memory issues it was not possible to implement the PLS-DA in the pipeline so it is 
presented as a separate piece of software. Other researchers have come across this problem 
when dealing with large datasets, and solutions are constantly being developed. These could 
be implemented to create one full pipeline. 
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8.4 Concluding Remarks 
It is extremely disappointing that it was not possible to obtain information about the features 
that the analyses in this thesis have indicated to be potential biomarkers. Contrary to 
expectations, the identities of the peptides and proteins to which the features relate are not 
available, nor any indication as to which features proved to be real biomarkers during 
experimental validation. Without knowing the “correct answers” it is impossible to make 
robust recommendations as to which of the many statistical workflows should be used. 
However, it has been possible to evaluate the relative differences between the output of the 
various workflows in terms of the level of agreement or difference between them. The 
Biomarker Hunter software produced during this project is to be released into the public 
domain, allowing others to easily take the next step to establish the most appropriate 
workflow when such data is available. The obvious area of future work for this project is to 
compare the results from the tests conducted in this project with a list of actual, validated 
biomarkers. Alternatively the statistical analysis can be repeated using data from a project for 
which a list of actual, validated biomarkers is available.  
It should be noted that the development of data processing algorithms in the absence of 
known answers is widely accepted within proteome informatics. All the crucial early work on 
peptide and protein identification from LC-MS/MS was done using samples of unknown 
composition, and algorithms for quantitation using in vivo labelling methods such as SILAC 
can only ever be evaluated on samples containing proteins of unknown abundance.  
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APPENDIX A – BiomarkerHunter.r 
#clear console 
rm(list=ls()) 
#calls for the impute library (needs to be done each time for some reason) 
library(impute) 
#create project name to idntify output files 
ProjectName <- readline(prompt = "Enter the Project name to identify Output Files:") 
 
########## Stage 1 ################################ 
##### Data Set importing and Initial Manipulation## 
#Allows user to choose the file 
DataFile <- choose.files(default = "AKTESTDATA.csv", caption = "Select the file containing the data", multi = 
FALSE, filters = "csv") 
#prompts user for the syntax given to missing values 
NAsyntax <- readline(prompt = "Enter the syntax given to NA values:") 
#Creates an instance of the dataset 
zz <- read.csv(DataFile, strip.white = TRUE, na.strings = NAsyntax) 
#Allows the user to choose or create a file to store results outputs 
results.dir <- choose.dir(default = "F:/Apr2010 Pr9549", caption = "Select the folder in which to store 
Clustering Results :") 
setwd(results.dir)   
 
############# Stage 2 ############################# 
########## Group Data Structure ################### 
#Removes additional rows by asking user for first data row 
head(zz[,1:2]) 
DataStartPoint <- readline(prompt = "Which row contains the first set of data values?:") 
#asks user for total number of samples 
TotalNumberofSamples <- readline(prompt = "Enter the total number of samples in the dataset :") 
TotalNumberofSamples <- as.numeric(TotalNumberofSamples) 
#asks user for total number of Groups 
cat("Enter the number of different groups being compared :") 
NumberofGroups <- scan(file = "", what = integer(0),nlines = 1) 
#for Looping purposes 
groupcolumns <-  NumberofGroups + 1  
#Creates an instance of the data without additional rows 
zzData <- zz[DataStartPoint:length(zz[,1]),] 
SampleNames <- colnames(zzData) 
#Creates expected feature presence 
FeaturePresenceExpected <- zzData[1,1:NumberofGroups] 
FeaturePresenceExpected [1:NumberofGroups] = 0 
#Use groupscript? 
DataEntryCheck <- readline(prompt = "Would you like to enter data 1)Manually or 2)Using Grouping script:") 
#The following for loops create vectors with the column numbers of the data in each group 
GroupSeparator <- list() 
#implements groupscript if chosen 
    if (DataEntryCheck == 2){ 
    #choose groupscript datafile 
      GroupDataFile <- choose.files(default = "AKTESTDATA.csv", caption = "Select the file containing the 
Grouping data", multi = FALSE, filters = "csv") 
      GroupingCSV <- read.csv(GroupDataFile, strip.white = TRUE, na.strings = NAsyntax) 
      #creates a table of unique groups 
      Group_Table <- table(GroupingCSV) 
         for (i in 1:NumberofGroups) { 
          Groupname <- row.names(Group_Table)[i] 
          GroupSeparator[[i]] <- as.vector(which(Group_Table[i,] == 1)) 
          GroupSeparator[[i]] <-  GroupSeparator[[i]] + 1 
          FeaturePresenceExpected [i] <-  length(GroupSeparator[[i]]) 
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          } 
        }else{  
          for (i in 1:NumberofGroups) { 
            #For every group the user is prompted for the number of samples in the group 
            Groupname <- paste("Group", i, sep = " ", collapse = NULL) 
            GroupText <- paste("Enter the number of samples in", Groupname, ":" , sep = " ", collapse = NULL) 
            GroupsampleNumber <- as.numeric(readline(prompt = GroupText)) 
            #imputs expected feature presence 
            FeaturePresenceExpected [i] <-   GroupsampleNumber 
            #Creates a blank vector to be used for the imoputation of col numbers 
            Group <- rep(NA, GroupsampleNumber) 
            GroupHeaders <- rep(NA, GroupsampleNumber) 
            GroupColumnNumbers <- GroupText 
            #allows the user to dteremine greoup structure 
              for (j in 1:GroupsampleNumber) { 
                GroupSampleName <- paste("Group", i, "- Sample", j, sep = " ", collapse = NULL) 
                GroupSampleText <- paste("Enter column number containing", GroupSampleName, ":"  , sep = " ", 
collapse = NULL) 
                datacolumn <- as.numeric(readline(prompt = GroupSampleText)) 
                Group[j] <- as.numeric(datacolumn) 
                GroupHeaders[j] = GroupSampleName 
                GroupColumnNumbers <- c(GroupColumnNumbers, datacolumn) 
                } 
              GroupSeparator[[i]] <- GroupColumnNumbers[-1]     
              } 
            } 
             
########## Stage 3 ################################ 
########## Options ################################ 
#checks if the data is logged (As this affects the calculations that need to be done) 
LogsCheck <- readline(prompt = "Are the data natural logarithms ? (y/n)[Case sensitive]:") 
#Offers TSN as normaliusation method 
NormalisationCheck <- readline(prompt = "Normalise the data using TSN (Total Spot Normalisation)? 
(y/n)[Case sensitive]:") 
#checks if the user wants to average technical replicates 
AverageCheck <- readline(prompt = "Would you like to average technical replicates? (y/n):")     
#Asks the user whether they would like to use Clusterfix   
ClusterAlgorithmCheck <- readline(prompt = "Use Clusterfix to reduce missing values? (y/n):")     
  if (ClusterAlgorithmCheck  == "y"){ 
    #Collects additional information needed for clusterfix 
    MassColumn <- readline(prompt = "Which column contains the Mass data?:") 
    RTColumn <- readline(prompt = "Which column contains the Retention Time (RT) data?:") 
    MassTolerance <- as.numeric(readline(prompt = "Mass tolerance level (+/-) you would like to use?:")) 
    RTTolerance <- as.numeric(readline(prompt = "Retention time tolerance level (+/-) you would like to use?:")) 
    MassColumn <-as.numeric(MassColumn) 
    RTColumn <- as.numeric(RTColumn) 
    #Creates vectors of the mass and RTdata 
    MassData <- as.vector(zzData[,MassColumn]) 
    RTData <- as.vector(zzData[,RTColumn]) 
    } 
#Asks the user whether Mutliple testing Correction is required 
MultipleTestingCheck <- readline(prompt = "Implement Multiple Testing Correction methods? (y/n):") 
  if (MultipleTestingCheck == "y"){ 
    #Asks the user for MTC method 
    cat("1(holm), 2(hochberg), 3(hommel), 4(bonferroni), 5(BH), 6(BY) \n") 
    MultipleTestingMethod <- as.numeric(readline(prompt = "Which Multiple Testing method to apply?")) 
    }  
#checks if Imutation is required 
MissingValueImputationCheck <- readline(prompt = "Impute missing values using selective Imputation? 
(y/n):")     
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  #If imputation isnt rquired then asks the user if MIN imputation is required 
  if (MissingValueImputationCheck == "n"){ 
    MissingValuesCheck <- readline(prompt = "Replace missing values (NA) with an arbitrary value? (y/n)[Case 
sensitive]:") 
      #asks the user for the value to use for MIN imputation  
      if (MissingValuesCheck == "y"){ 
        ReplacementNAsyntax <- readline(prompt = "Syntax You want to give to all NA values:") 
        ReplacementNAsyntax <- as.numeric(ReplacementNAsyntax) 
        } 
      } 
#Checks if Multivariate analysis is required 
MultivariateCheck <-  readline(prompt = "Conduct Multivariate analysis? (y/n):")   
#Removes additional columns 
zzData <- zzData[,1:(TotalNumberofSamples +1)] 
#Creates Vector of identifiers 
PCIList <- as.vector(zzData[,1]) 
#Aberages the data if required 
  if (AverageCheck  == "y"){ 
    #creates a sequence of 20 groups of 2   starting from the second column  
    ix <- seq(from=2,to=(TotalNumberofSamples +1), by=2) 
    #creates an average for each pair of values 
    A <- zz[,ix] 
    B <- zz[, ix+1] 
    Ave <- (A + B)/2 
    Asub <- is.na(B) & !is.na(A) 
    Bsub <- !is.na(B) & is.na(A) 
    Ave[Asub] <- A[Asub] 
    Ave[Bsub] <- B[Bsub] 
    averagedResults <-  cbind(zz[,1],Ave ) 
    zzData <- averagedResults  
    SampleNames <- colnames(zzData) 
#re-enter the group structure following averaging 
  TotalNumberofSamples <- readline(prompt = "Enter the total number of samples in the dataset :") 
  TotalNumberofSamples <- as.numeric(TotalNumberofSamples) 
  #asks user for total number of Groups 
  cat("Enter the number of different groups being compared :") 
  NumberofGroups <- scan(file = "", what = integer(0),nlines = 1) 
  #for Looping purposes 
  groupcolumns <-  NumberofGroups + 1  
  #Creates an instance of the data without additional rows 
  zzData <- zz[DataStartPoint:length(zz[,1]),] 
  SampleNames <- colnames(zzData) 
  #Creates expected feature presence 
  FeaturePresenceExpected <- zzData[1,1:NumberofGroups] 
  FeaturePresenceExpected [1:NumberofGroups] = 0 
   
  DataEntryCheck <- readline(prompt = "Would you like to enter data 1)Manually or 2)Using Grouping script:")  
      #### sample grouping needs to be redone 
      GroupSeparator <- list() 
      if (DataEntryCheck == 2){ 
        GroupDataFile <- choose.files(default = "AKTESTDATA.csv", caption = "Select the file containing the 
Grouping data", multi = FALSE, filters = "csv") 
        GroupingCSV <- read.csv(GroupDataFile, strip.white = TRUE, na.strings = NAsyntax) 
        #creates a table of unique groups 
        Group_Table <- table(GroupingCSV) 
           for (i in 1:NumberofGroups) { 
            Groupname <- row.names(Group_Table)[i] 
            GroupSeparator[[i]] <- as.vector(which(Group_Table[i,] == 1)) 
            GroupSeparator[[i]] <-  GroupSeparator[[i]] + 1 
            FeaturePresenceExpected [i] <-  length(GroupSeparator[[i]]) 
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            } 
          }else{  
            for (i in 1:NumberofGroups) { 
              #For every group the user is prompted for the number of samples in the group 
              Groupname <- paste("Group", i, sep = " ", collapse = NULL) 
              GroupText <- paste("Enter the number of samples in", Groupname, ":" , sep = " ", collapse = NULL) 
              GroupsampleNumber <- as.numeric(readline(prompt = GroupText)) 
              #imputs expected feature presence 
              FeaturePresenceExpected [i] <-   GroupsampleNumber 
              #Creates a blank vector to be used for the imoputation of col numbers 
              Group <- rep(NA, GroupsampleNumber) 
              GroupHeaders <- rep(NA, GroupsampleNumber) 
              GroupColumnNumbers <- GroupText 
                for (j in 1:GroupsampleNumber) { 
                  GroupSampleName <- paste("Group", i, "- Sample", j, sep = " ", collapse = NULL) 
                  GroupSampleText <- paste("Enter column number containing", GroupSampleName, ":"  , sep = " ", 
collapse = NULL) 
                  datacolumn <- as.numeric(readline(prompt = GroupSampleText)) 
                  Group[j] <- as.numeric(datacolumn) 
                  GroupHeaders[j] = GroupSampleName 
                  GroupColumnNumbers <- c(GroupColumnNumbers, datacolumn) 
                  } 
                GroupSeparator[[i]] <- GroupColumnNumbers[-1]     
                } 
              }       
      } 
       
########## Stage 4 (Optional) ##################### 
######### TSN Normalisation ####################### 
  if (LogsCheck == "n"){ 
    if (NormalisationCheck  == "y"){ 
      zzData_noMCI = zzData[,-1] 
      zzData_noMCI <- apply(zzData_noMCI, 2, as.numeric) 
      # Normalised volume = volume spot n/total volume of all spots * scaling factor 
      col_sums <- colSums (zzData_noMCI, na.rm = TRUE, dims = 1) #Creates a vector of sums of each colum 
      data_norm <- scale(zzData_noMCI, scale=col_sums, center=FALSE) 
      data_norm = data_norm*1000000 
      zzData <- cbind(PCIList, data_norm) 
      } 
    } 
 
########## Stage 5 ################################ 
####Create Feature Presence Matrix ################ 
FeaturePresenceresult <- zzData[,1:2] 
FeaturePresenceresult[,2] = 0 
FeaturePresenceMatrix <- zzData[,-1] 
FeaturePresenceMatrix <- as.matrix(FeaturePresenceMatrix) 
FeaturePresenceMatrix[ is.na(FeaturePresenceMatrix)] <- as.numeric(0) 
FeaturePresenceMatrix[FeaturePresenceMatrix != 0] = as.numeric(1) 
rownames(FeaturePresenceMatrix) <- PCIList 
FeaturePresenceMatrix <- apply(FeaturePresenceMatrix, 2, as.numeric) 
FeaturePresenceresult[,2] <- as.numeric(rowSums(FeaturePresenceMatrix, na.rm = TRUE)) 
FeaturePresenceresult <- apply(FeaturePresenceresult, 2, as.numeric) 
colnames(FeaturePresenceresult)[2] = "Total Feature Presence" 
TotalFeaturePresenceExpected <- sum(FeaturePresenceExpected) 
FeaturePresenceExpected <- c(FeaturePresenceExpected, TotalFeaturePresenceExpected) 
#Calculates initial Feature Presence statistics To compare against clustered results 
InitialNumberofPCI <- length(zzData[,1]) 
InitialNoneNA <- sum(FeaturePresenceresult[,2]) 
InitialTotalNumberofValues <-  InitialNumberofPCI * TotalNumberofSamples 
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InitialPercentageofNA <- (InitialNoneNA/InitialTotalNumberofValues)*100 
zzData <- apply(zzData,2,as.numeric)  
    
########## Stage 6 (Optional) ##################### 
############CLUSTERFIX ############################ 
  if (ClusterAlgorithmCheck  == "y"){ 
    cat("Using Clusterfix") 
    #Prompts the user for the columns with the mass and RT data  
    MassData <- as.vector(MassData) 
    RTData <- as.vector(RTData) 
#Create Cluster Output File  
    ClusterInfo <- as.matrix(zzData[,1:21]) 
    ClusterInfo[,2:21] = 0 
    colnames(ClusterInfo)[1] <- "Primary PCI" 
    colnames(ClusterInfo)[2] <- "Status" 
    colnames(ClusterInfo)[3] <- "No of potential Matches" 
    colnames(ClusterInfo)[4] <- "Clustered (as secondary) with PCI" 
    colnames(ClusterInfo)[5:21] <- "Potential Secondary Matches" 
    ####### Preparation for Loop    ##################### 
    #Allows the user to set Mass and Retention time tolerance levels 
    ClusterMatchCheck <- as.matrix(zzData[,1:2]) 
    ClusterMatchCheck[,2] = 0 
    ClusteredData <- as.matrix(zzData[,-1]) 
    MassRTToleranceMultiplyingFactor <- as.numeric(RTTolerance/MassTolerance) 
#k is the row number for the primary PCI (This for loop Is iterated for each PCI 
      for (k in 1:length(FeaturePresenceresult[,1])) { 
        cat(paste(k, "\n", sep = " ", collapse = NULL)) 
#this if/else loop rejects PCI's which have no missing values 
          if (FeaturePresenceresult[k,2] == TotalNumberofSamples){ 
            cat("No Missing Values") 
          ClusterInfo[k,2] <- "100% Actual Feature Presence" 
          ClusterMatchCheck[k,2] <- as.numeric(1) 
          }else 
          { 
#Excludes PCI's which have already been matched 
          if (ClusterMatchCheck[k,2] != 1) { 
           #Creates Mass and RT Windows 
           PCIMass <- as.numeric(MassData[k]) 
           PCIRT <- as.numeric(RTData[k]) 
           MassUpperLimit <- PCIMass + MassTolerance 
           MassLowerLimit <- PCIMass - MassTolerance 
           RTUpperLimit <- PCIRT + RTTolerance 
           RTLowerLimit <- PCIRT - RTTolerance  
#creates a vector called rowlist to access the correct rows of information during clustering 
           rowlist <- as.vector(k) 
#this for loop  searches all other PCI's to find potential matches (Secondary PCI's) 
                for (p in 1:length(FeaturePresenceresult[,1])) { 
#Excludes the Primary PCI 
                  if (p != k) { 
#Excludes PCI's which have already been matched 
                if (ClusterMatchCheck[p,2] != 1) { 
#Excludes samples outside of the Mass and RT windows 
                 if ((as.numeric(MassData[p]) <= MassUpperLimit) && 
(as.numeric(MassData[p]) >= MassLowerLimit) && 
                      (as.numeric(RTData[p]) <= RTUpperLimit) && (as.numeric(RTData[p]) >= RTLowerLimit)) { 
#Excludes PCI's where the total Feature Presence of both Primary and matching PCI is above that of total 
sample size 
                  if ((FeaturePresenceresult[k,2] + 
FeaturePresenceresult[p,2]) <= TotalNumberofSamples) { 
#Primary and secondary count are the respective rows from feature presence matrix 
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#This if/else statement checks that there are no overlaps between PCI's  
#by calculating sums of Feature Presence Matrix 
                   PrimaryCount <- FeaturePresenceMatrix[k,] 
                   SecondaryCount <- FeaturePresenceMatrix[p,] 
                   PrimaryMinusSecondary <- PrimaryCount - 
SecondaryCount 
                   PrimaryPlusSecondary <- PrimaryCount + 
SecondaryCount 
                       #This if/else statement checks that there are no overlaps 
between PCI's 
                            if(all(PrimaryPlusSecondary < 2)) { 
                              rowlist <- c(rowlist, p) 
                              } 
                            } 
                        } 
                      } 
                    } 
                  }#closes the loop for searching through secondary PCI's 
#Creates a Feature Presence matrix of the primary PCI and all possible matches  
#and corresponding rownames and values from zzData 
              PatternMatchMatrix <- FeaturePresenceMatrix[rowlist,] 
              PatternMatchMatrixRownames <- PCIList[rowlist] 
              MatchedValues <- zzData[rowlist,] 
#This if/else statement skips the next stages if there are no potential matches 
                if (length(rowlist) == 1){ 
                  cat("No Matches") 
                  ClusterInfo[k,2] <- "No Potential Secondary Matches" 
                  }else 
                  { 
                  MatchedValues <- as.matrix(MatchedValues[,-1]) 
                  PatternMatchMatrixColumnSums <- colSums(PatternMatchMatrix) 
#This if/else statement checks that there are no overlaps between secondary PCI's 
#If there are any conflicts this if statement identifies the closest match 
                    if(any(PatternMatchMatrixColumnSums >= 2)){ 
                      ClusterInfo[k, 2] <- "CONFLICTING matches" 
                      cat("CONFLICT") 
                      ConflictingSampleLocation <- as.numeric(which.max(PatternMatchMatrixColumnSums)) 
                      ConflictingPCIsRowPatternMatchMatrix <- 
which(PatternMatchMatrix[,ConflictingSampleLocation] == 1) 
                      ConflictingPatternMatchMatrix <- PatternMatchMatrix[ConflictingPCIsRowPatternMatchMatrix,] 
                      ConflictingMassValues <- 
as.numeric(MassData[rowlist[ConflictingPCIsRowPatternMatchMatrix]]) 
                      ConflictingRTValues <- as.numeric(RTData[rowlist[ConflictingPCIsRowPatternMatchMatrix]]) 
#Calculates the Differences in Mass and RT from the primary PCI 
                      ConflictingMassDifference <- abs(ConflictingMassValues - PCIMass) 
                      ConflictingRTDifference <- abs(ConflictingRTValues - PCIRT) 
                      ConflictingMassDifference <- ConflictingMassDifference * MassRTToleranceMultiplyingFactor 
                      TotalDifference <- ConflictingMassDifference  + ConflictingRTDifference 
#Identifies the location of the Closest Neighbour 
                      ClosestNeighbour <- which.min(TotalDifference) 
#Removes the false Matches 
                      ConflictingPCIsRowPatternMatchMatrix <- ConflictingPCIsRowPatternMatchMatrix[-
ClosestNeighbour] 
     
#remove conflicting rows from PatternMatch Matrix , rownames, rowlist and matched values 
                      PatternMatchMatrix <- PatternMatchMatrix[-ConflictingPCIsRowPatternMatchMatrix,] 
                      PatternMatchMatrixRownames <- PatternMatchMatrixRownames[-
ConflictingPCIsRowPatternMatchMatrix] 
                      MatchedValues <-  MatchedValues[-ConflictingPCIsRowPatternMatchMatrix,] 
                      rowlist <- rowlist[-ConflictingPCIsRowPatternMatchMatrix] 
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                      } 
####### Cluster the Matches into Primary ############ 
#This for loop goes through each value in the primary PCI to see if there are any missing values 
                  for (Value in 1:length(PatternMatchMatrix[1,])) { 
                    if(PatternMatchMatrix[1,Value] == 1) { 
                      }else 
                      { 
#If there are any missing values this for loop searches for a replacement value in the other PCI's 
                      for (Value2 in 2:length(PatternMatchMatrix[,1])) { 
                        if(PatternMatchMatrix[Value2,Value] == 1) { 
#SecondaryValue <- rowlist[Value2] 
                          ClusteredData[k,Value] <- as.numeric(MatchedValues[Value2,Value]) 
                          } 
                        } 
                      } 
                    } 
#The following lines of code enter the relevant columns of teh clusterinfo putput file 
                ClusterMatchCheck[k,2] <- 1 
                ClusterInfo[k,2] <- "Clustered as Primary" 
                  for (secondary in 2:length(rowlist)){ 
                    MatchedPCI <- rowlist[secondary] 
                    ClusterMatchCheck[MatchedPCI,2] <- as.numeric(1) 
                    ClusterInfo[MatchedPCI, 4] <- PCIList[k] 
                    ClusterInfo[MatchedPCI, 2] <- "Matched" 
                    ClusteredData[MatchedPCI,]  <- paste("Clustered with PCI", PatternMatchMatrixRownames[k], 
sep = " ", collapse = NULL) 
                    ClusterInfoColumn <- as.numeric(4) 
                      for (SecondaryMatches in 2:length(rowlist)){ 
                        ClusterInfoColumn <- as.numeric(ClusterInfoColumn +1) 
                        ClusterInfo[k,ClusterInfoColumn] <- PCIList[rowlist[SecondaryMatches]] 
                        ClusterInfo[k,3] <- length(PatternMatchMatrixRownames) - 1 
                        } 
                    cat(PCIList[rowlist]) 
                    cat("Clustered\n") 
                    } 
                  } 
              } 
            } 
        } 
     ClusterInfo[,4:21][ ClusterInfo[,4:21] == 0] = "NA" 
#Creates new Clustered Feature Presence Matrix  
    ClusteredRows <- grep("Clustered", ClusteredData[,1]) 
    ClusteredDataReduced <- ClusteredData[-ClusteredRows,] 
    PCIListReduced <- PCIList[-ClusteredRows] 
    rownames(ClusteredDataReduced) <- PCIListReduced    
    FeaturePresenceMatrix2 <- as.matrix(ClusteredDataReduced) 
    FeaturePresenceMatrix2[ is.na(FeaturePresenceMatrix2)] <- as.numeric(0) 
    FeaturePresenceMatrix2[FeaturePresenceMatrix2 != 0] = as.numeric(1) 
    rownames(FeaturePresenceMatrix2) <- PCIListReduced 
    FeaturePresenceMatrix2 <- apply(FeaturePresenceMatrix2, 2, as.numeric) 
    colnames(FeaturePresenceMatrix2)[2] = "Total Feature Presence" 
    #Calculates Post Clustering Feature Presence statistics 
    PostNumberofPCI <- length(ClusteredDataReduced[,1]) 
    FeaturePresenceresult2 <- zzData[1:PostNumberofPCI,1:2] 
    FeaturePresenceresult2[,2] = 0 
    FeaturePresenceresult2[,2] <- rowSums(FeaturePresenceMatrix2, na.rm = TRUE) 
    FeaturePresenceresult2[,1] <- PCIListReduced 
    FeaturePresenceresult2 <- apply(FeaturePresenceresult2,2,as.numeric) 
    PostNoneNA <- sum(as.numeric(FeaturePresenceresult2[,2])) 
    PostTotalNumberofValues <-  PostNumberofPCI * TotalNumberofSamples 
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    PostPercentageofNA <- (PostNoneNA/PostTotalNumberofValues)*100 
    #creates the clustered comparison file 
    ClusteredComparisonFile <- matrix(nrow = 4, ncol = 2, byrow = FALSE, dimnames = list(c("Number of 
PCI", "Total Possible Values", "None NA Values", "Percentage of None missing Values"),c("Initial", "Post-
Clustering"))) 
    ClusteredComparisonFile[,1] <- c(InitialNumberofPCI, InitialTotalNumberofValues, InitialNoneNA, 
InitialPercentageofNA) 
    ClusteredComparisonFile[,2] <- c(PostNumberofPCI, PostTotalNumberofValues, PostNoneNA, 
PostPercentageofNA) 
    #Creates Filenames for output files 
    ClusteredDataFileName <- paste(ProjectName, "_ClusteredData.csv", sep = "") 
    ClusterInfoFileName <- paste(ProjectName, "_ClusteringInformaftion.csv", sep = "") 
    ClusterComparisonFileName <- paste(ProjectName, "_ClusterComparison.csv", sep = "") 
    #Creates csv files of clustrered data, Clusterinfo file and the Cluster comparison data 
    write.csv(ClusteredDataReduced, file = ClusteredDataFileName, row.names = TRUE) 
    write.csv(ClusterInfo, file = ClusterInfoFileName, row.names = FALSE) 
    write.csv(ClusteredComparisonFile, file = ClusterComparisonFileName, row.names = TRUE) 
    zzData <- cbind(row.names(ClusteredDataReduced), ClusteredDataReduced)  
    }else 
    { 
    #Removes additional columns 
    zzData <- zzData[,1:(TotalNumberofSamples +1)] 
#Clustered Feature Presence Matrix  
    FeaturePresenceMatrix2 <- as.matrix(zzData) 
    FeaturePresenceMatrix2[ is.na(FeaturePresenceMatrix2)] <- as.numeric(0) 
    FeaturePresenceMatrix2[FeaturePresenceMatrix2 != 0] = as.numeric(1) 
    rownames(FeaturePresenceMatrix2) <- PCIList 
    FeaturePresenceMatrix2 <- apply(FeaturePresenceMatrix2, 2, as.numeric) 
    colnames(FeaturePresenceMatrix2)[2] = "Total Feature Presence" 
    FeaturePresenceresult2 <- zzData[,1:2] 
    FeaturePresenceresult2[,2] = 0 
    FeaturePresenceresult2[,2] <- rowSums(FeaturePresenceMatrix2, na.rm = TRUE) 
    FeaturePresenceresult2[,1] <- PCIList 
    FeaturePresenceresult2 <- apply(FeaturePresenceresult2,2,as.numeric) 
    } 
     
########## Stage 7 (Optional) ##################### 
######### IMPUTE MISSING VALUES ################### 
zzData <- apply(zzData,2,as.numeric) 
  if (MissingValueImputationCheck  == "y"){ 
    MissingValuesCheck <- "n" 
    cat("Imputing Missing Values") 
    #calculates the feature presence cut-off points for various methods of imputation 
    FPBelow <- ceiling(TotalNumberofSamples * 0.25) 
    FPAbove <- floor(TotalNumberofSamples * 0.75) 
    #creates 3 different lists of PCI's to extract from dataset  
    FPBelowlist <- which(FeaturePresenceresult2[,2] <= FPBelow) 
    FPAbovelist <- which(FeaturePresenceresult2[,2] >= FPAbove) 
    #extracts partial dataset into 3 lists for imputation 
   FPBelowData <- zzData[FPBelowlist,] 
   FPAboveData <- zzData[FPAbovelist,] 
   FPMiddlelist <- c(FPBelowlist, FPAbovelist) 
   FPMiddleData <- zzData[-FPMiddlelist,] 
   ####### KNN ################################# 
    if(exists(".Random.seed")) rm(.Random.seed) 
   KNNImputedData <- impute.knn(FPAboveData[,-1] ,k = 10, rowmax = 0.9, colmax = 0.96, maxp = 
length(FPAboveData[,1])) 
   #KNNImputedData <- KNNImputed$data 
   KNNData <- cbind(FPAboveData[,1], KNNImputedData)                                   
    ######## Minimal Value imputation MIN ############ 
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    FPBelowData [ is.na(FPBelowData)] <- as.numeric(0) 
    MINImputedData <- FPBelowData 
    ######### REPMED ############################## 
      for (i in 1:NumberofGroups) { 
        MiddleGroupData <-  FPMiddleData[,as.numeric(GroupSeparator[[i]])] 
        RowMedian <- as.numeric(apply(MiddleGroupData, 1, median, na.rm = TRUE)) 
          for (j in 1:length(RowMedian)) { 
            MiddleGroupData[j,][ is.na( MiddleGroupData[j,])] <- as.numeric(RowMedian[j]) 
            } 
        FPMiddleData[,as.numeric(GroupSeparator[[i]])] <-  MiddleGroupData[j,] 
        }  
      zzData  <- rbind(KNNData, FPMiddleData, MINImputedData)   
      PCIList <- zzData[,1] 
      }               
 
########## Stage 8 (Optional) ##################### 
######### Multivariate Analysis ################### 
  if (MultivariateCheck == "y"){ 
    require(reshape) 
    MultivariateData <- zzData 
    MultivariateData[is.na(MultivariateData)] <- 0 
    ###########  PCA  #################################### 
    result = prcomp(MultivariateData, center=FALSE) 
    #obtain scores matrix 
    scores=result$rotation 
    #PC1 vs PC2 plot 
    PCAFileName <- paste(ProjectName, "_PCAPlot.wmf", sep = "")  
    plot(scores[,1], scores[,2], xlab="PC1", ylab="PC2") 
    text((scores[,1]+0.0015),(scores[,2]+0.003), colnames(MultivariateData)[2:length(zz[1,])]) 
    dev.copy(win.metafile ,PCAFileName) 
    dev.off() 
    #Print summary of variance 
    print(summary(result)) 
    ###########  HCA  #################################### 
    #Dendrogram with Choice of distance and agglomeration methods 
    cat("1(euclidean), 2(maximum), 3(manhattan), 4(canberra), 5(binary), 6(minkowski) \n") 
    HCADistanceMethod <- as.numeric(readline(prompt = "Which Distance meausure would you like to 
apply?(1-6)")) 
    cat("1(ward), 2(single), 3(complete), 4(average), 5(mcquitty), 6(median), 7(centroid) \n") 
    HCAagglomerationMethod <- as.numeric(readline(prompt = "Which Agglomeration method would you like 
to apply?(1-7)")) 
    #Define distance method 
     if (HCAagglomerationMethod == 1){ 
      HCAagglomerationMethod <- "euclidean" 
      }else 
      if (HCAagglomerationMethod == 2){ 
       HCAagglomerationMethod <- "maximum" 
       }else 
       if (HCAagglomerationMethod == 3){ 
        HCAagglomerationMethod <- "manhattan" 
        }else 
        if (HCAagglomerationMethod == 4){ 
         HCAagglomerationMethod <- "canberra" 
         } 
         else 
         if (HCAagglomerationMethod == 5){ 
          HCAagglomerationMethod <- "binary" 
          }else 
          if (HCAagglomerationMethod == 6){ 
           HCAagglomerationMethod <- "minkowski" 
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           }   
    #Define Agglomeration method 
     if (HCADistanceMethod == 1){ 
      HCADistanceMethod <- "ward" 
      }else 
      if (HCADistanceMethod == 2){ 
       HCADistanceMethod <- "single" 
       }else 
       if (HCADistanceMethod == 3){ 
        HCADistanceMethod <- "complete" 
        }else 
        if (HCADistanceMethod == 4){ 
         HCADistanceMethod <- "average" 
         } 
         else 
         if (HCADistanceMethod == 5){ 
          HCADistanceMethod <- "mcquitty" 
          }else 
          if (HCADistanceMethod == 6){ 
           HCADistanceMethod <- "median" 
           }else 
            if (HCADistanceMethod == 7){ 
            HCADistanceMethod <- "centroid" 
            } 
    HCAFileName <- paste(ProjectName, "_HCAPlot.wmf", sep = "")      
   
    HCAData <- dist(t(MultivariateData), method = HCADistanceMethod) 
    dendrogram <-hclust(t(HCAData), method = HCAagglomerationMethod, members = NULL) 
    plot (dendrogram) 
    dev.copy(win.metafile ,HCAFileName) 
    dev.off() 
    } 
     
################ Stage 9 ############################ 
####### Create Analysis Data Groups ################# 
Grouplist <- list() 
Naresult <- zzData[,1:groupcolumns] 
Naresult[,2:groupcolumns] = as.numeric(0) 
Meanresult <- zzData[,1:groupcolumns] 
Meanresult[,2:groupcolumns] = as.numeric(0) 
FeaturePresenceresult <- zzData[,1:(groupcolumns+1)] 
SampleNamesRow <- names(zzData[2:(TotalNumberofSamples+1)]) 
FeaturePresenceresult <- zzData[,1:(groupcolumns+1)] 
FeaturePresenceresult[,2:(groupcolumns+1)] = as.numeric(0) 
zzDataGrouped <- zzData[,1] 
PCIList <- as.vector(zzData[,1]) 
####### DEFINING GROUPS LOOPS ####################### 
  for (i in 1:NumberofGroups) { 
    Grouplist[[i]] <- zzData[,as.numeric(GroupSeparator[[i]])] 
    zzDataGrouped  <- cbind(zzDataGrouped, zzData[,as.numeric(GroupSeparator[[i]])])  
    cat("Processing Group Sample and Statistics...... PLEASE WAIT\n") 
    Samp <- data.matrix(Grouplist[[i]]) 
    Samp <- apply(Samp,2,as.numeric) 
      if (LogsCheck == "y"){ 
        expSamp <- exp(Samp) 
        }else 
        { 
        expSamp <- Samp 
        }  
# GROUP STATS ################################# 
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##calculates AND ENTERS MEANS 
    cat("Calculating Group Stats (Means and Feature Presence...... PLEASE WAIT\n") 
    Meanresult[,i+1] <- rowMeans(expSamp, na.rm = TRUE) 
    colnames(Meanresult)[i+1] = paste("Mean - Group ", i) 
    colnames(FeaturePresenceresult)[i+1] = paste("Feature Presence Group ", i) 
    ##calculates AND ENTERS Feature Presence 
    GroupFeaturePresence <- Samp 
    GroupFeaturePresence[ is.na(GroupFeaturePresence)] <- as.numeric(0) 
    GroupFeaturePresence[GroupFeaturePresence != 0] = as.numeric(1) 
    FeaturePresenceresult[,(i+1)] <- as.numeric(rowSums(GroupFeaturePresence, na.rm = TRUE)) 
      if (MissingValuesCheck == "y"){ 
          Samp[is.na(Samp)] <- ReplacementNAsyntax 
          Grouplist[[i]] <- Samp 
        }   
    #rename(Group, Groupname) 
    AnalysisVariable <- paste("Group", i, sep = "", collapse = NULL) 
    assign(AnalysisVariable, Samp) 
    } 
colnames(FeaturePresenceresult)[groupcolumns+1] = "Total Feature Presence " 
ForRowSumming <- FeaturePresenceresult[,2:groupcolumns] 
ForRowSumming <- apply(ForRowSumming,2,as.numeric) 
RowsumsforTotalFP <- rowSums(ForRowSumming) 
FeaturePresenceresult[,groupcolumns+1] <-  RowsumsforTotalFP 
FeaturePresenceresult <- apply(FeaturePresenceresult,2,as.numeric) 
 
################ Stage 10############################ 
####### COMPARITIVE ANALYSIS lOOP ################### 
FoldChange <- PCIList 
FoldChangeTemp <- zzData[,1:2] 
FoldChangeTemp[,2] = 0  
FoldChangeHead <- "PCI" 
TTestHead <- "PCI" 
WilcoxHead <- "PCI" 
TTestresult <- zzData[,1]  
TTestresultTemp <- zzData[,1:2] 
TTestresultTemp[,2] = 0  
Wilcoxresult <- zzData[,1]  
WilcoxresultTemp <- zzData[,1:2] 
WilcoxresultTemp[,2] = 0 
groupsminusone <- NumberofGroups - 1  
  for (k in (1:groupsminusone)) { 
    #GetGroupName <- paste("Samp", k, sep = "")  
    #SampleDenom <- eval(as.name(GetGroupName)) 
    cat(paste("Group ", k, " Analysis ...... PLEASE WAIT\n" , sep = " ", collapse = NULL)) 
    GroupAnalysisDenominator <- as.data.frame(Grouplist[k])  
      for (l in (k+1):NumberofGroups)  { 
        cat(paste("Group ", k, "vs" , l, " Analysis ...... PLEASE WAIT\n", sep = " ", collapse = NULL)) 
        GroupAnalysisNumerator <- as.data.frame(Grouplist[l])  
        FoldChangeTemp[,2] <- as.numeric(Meanresult[,l+1]) / as.numeric(Meanresult[,k+1]) 
        for (p in 1:length(zzData[,1])) { 
          SampleDenominator <- as.vector(GroupAnalysisDenominator[p,])  
          SampleNumerator <- as.vector(GroupAnalysisNumerator[p,])  
          SampleDenominatorTranspose <- t(GroupAnalysisDenominator[p,])  
          SampleNumeratorTranspose <- t(GroupAnalysisNumerator[p,])      
            if (p == length(zzData[,1])/4) { 
              cat("25% Completed.............\n") 
              }  
            if (p == length(zzData[,1])/2) { 
              cat("50% Completed.............\n") 
              }  
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            if (p == length(zzData[,1])/1.5) { 
              cat("75% Completed.............\n") 
              }       
            if (FeaturePresenceresult[p, (k+1)]  < 2 | FeaturePresenceresult[p,l+1] < 2) { 
              TTestresultTemp[p,2] <- NA  
              WilcoxresultTemp[p,2] <- NA 
              }else  
              { 
              TTestresultTemp[p,2] <- t.test(SampleNumerator, SampleDenominator, na.rm=TRUE, var.equal = 
FALSE, paired=FALSE, conf.level=0.95)$p.value 
              WilcoxresultTemp[p,2]  <- wilcox.test(SampleNumeratorTranspose, SampleDenominatorTranspose, 
na.rm=TRUE, paired=FALSE, conf.level=0.95)$p.value 
              } 
            } 
        FCHead <- paste("Fold Change (", l, " / ", k, ")") 
        TTHead <- paste("Welch T Test (", l, " / ", k, ")") 
        WilcHead <- paste("Wilcoxon Mann Whitney Test (", l, " / ", k, ")") 
        FoldChangeHead <- c(FoldChangeHead, FCHead) 
        TTestHead <- c(TTestHead, TTHead) 
        WilcoxHead <- c(WilcoxHead, WilcHead) 
        FoldChange <- cbind(FoldChange, FoldChangeTemp[,2])  
        TTestresult <- cbind(TTestresult, TTestresultTemp[,2]) 
        Wilcoxresult <- cbind(Wilcoxresult, WilcoxresultTemp[,2]) 
        cat("Analysis 100% Completed\n") 
        } 
      } 
colnames(FoldChange) <-  FoldChangeHead 
colnames(TTestresult) <-  TTestHead 
colnames(Wilcoxresult) <- WilcoxHead 
 
#################### Stage 11 ########################## 
###################  Groupwise Analysis################# 
ANOVAresult <- zzData[,1:6] 
ANOVAresult[,2:6] = 0  
colnames(ANOVAresult)[2] = "ANOVA NA p-value" 
colnames(ANOVAresult)[3] = "ANOVA NA (groups as.numeric) p-value" 
colnames(ANOVAresult)[4] = "ANOVA -4.60517 p-value" 
colnames(ANOVAresult)[5] = "ANOVA -4.60517 (groups as.numeric) p-value" 
colnames(ANOVAresult)[6] = "oneway test -4.60517 p-value" 
KRUSKALresult <- zzData[,1:2] 
KRUSKALresult[,2] = 0  
colnames(KRUSKALresult)[2] = "Kruskall Wallis p-value" 
TotalIntensityList <- zzData[,1] 
GroupingList <- c() 
LabelsList <- c() 
  for (q in (1:NumberofGroups)) { 
    cat("Creating ANOVA list structure.........Please Wait\n")  
  UnlistedGroupData <- as.data.frame(Grouplist[q]) 
  TotalIntensityList <- cbind(TotalIntensityList, UnlistedGroupData) 
  GroupingListTemp <-  c()  
  GroupSize <- as.numeric(FeaturePresenceExpected[q]) 
    for (grp in 1:GroupSize) { 
     GroupingListTemp <-  c(GroupingListTemp, q)  
       } 
  GroupingList <- c(GroupingList, GroupingListTemp) 
  LabelTemp<- paste("Group", q, sep = "", collapse = NULL) 
  LabelsList <- c(LabelsList, LabelTemp) 
    } 
RownameList <- c() 
  for (r in (1:TotalNumberofSamples)){ 
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    RownameList <- c(RownameList, r) 
    } 
ANOVATukeyresult <- TTestresult 
ANOVATukeyresult[,2:length(ANOVATukeyresult[1,])] = 0  
TotalIntensityList <- TotalIntensityList[,-1] 
###################   ANOVA TUKEY Header ############################ 
#Searches for Row with best Feature Presence 
BFP <- which.max(FeaturePresenceresult[,(groupcolumns+1)]) 
datalist <-  vector(mode = "numeric") 
  for (vec in 1:TotalNumberofSamples){ 
    datalist[vec] <- TotalIntensityList[BFP,vec] 
    } 
  if (MissingValuesCheck == "y"){ 
    datalist[ is.na(datalist) ] <- ReplacementNAsyntax 
    }  
"zzzanova" <- structure(list(Intensity = datalist,  
        Group = structure(GroupingList, .Label = LabelsList, class = "factor"),  
        Sample = structure(as.numeric(1:TotalNumberofSamples))) 
        , .Names = c("Intensity", "Group", "Sample"),  
        row.names = RownameList, class = "data.frame")    
#Conducts the ANOVA for that PCI 
zzz.aov <- aov(Intensity ~ Group, data = zzzanova) 
#TUKEY 
zzz.aov.tk <- TukeyHSD(zzz.aov)  
colnames(ANOVATukeyresult)[2:length(ANOVATukeyresult[1,])] <- rownames(zzz.aov.tk[[1]]) 
ANOVATukeyHead <- c("PCI", rownames(zzz.aov.tk[[1]])) 
TotalIntensityList <- zzData[,1] 
 for(sampleclusters in 1:NumberofGroups){ 
  TotalIntensityList <- cbind(TotalIntensityList, Grouplist [[sampleclusters]]) 
  } 
TotalIntensityList <- TotalIntensityList[,-1] 
TotalIntensityList <- apply(TotalIntensityList,2,as.numeric) 
  cat("Conducting ANOVA........Please Wait\n") 
 ###################   ANOVA Row wise Loop ############################ 
  for(s in 1:length(zzData[,1])) { 
    if (s == length(zzData[,1])/4) { 
      cat("25% Completed.............\n") 
      }  
    if (s == length(zzData[,1])/2) { 
      cat("50% Completed.............\n") 
      }  
    if (s == length(zzData[,1])/1.5) {                                                     
      cat("75% Completed.............\n") 
      }  
    ##Does a check to ensure that at least 2 samples are present in each group 
  if(any(FeaturePresenceresult[s,-1] < 2)){   
    ANOVAresult[s,2:6] <- NA 
    KRUSKALresult[s,2] <- NA 
    cat("Not enough Samples\n") 
    }else  
      { 
      cat("ANOVA\n") 
      #Create a list which can be analysed by ANOVA 
      datalist <-  vector(mode = "numeric") 
        for (vec in 1:TotalNumberofSamples){ 
          datalist[vec] <- TotalIntensityList[s,vec] 
          } 
    if (MissingValuesCheck == "y"){ 
      datalist[ is.na(datalist) ] <- ReplacementNAsyntax 
      }  
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    "zzzanova" <- structure(list(Intensity = datalist,  
        Group = structure(GroupingList, .Label = LabelsList, class = "factor"),  
        Sample = structure(1:TotalNumberofSamples)) 
        , .Names = c("Intensity", "Group", "Sample"),  
        row.names = RownameList, class = "data.frame") 
    zzz.aov <- aov(Intensity ~ Group, data = zzzanova) 
    sum<-summary(zzz.aov) 
    #retreive p-value 
    ANOVAresult[s,2] <- unlist(sum)["Pr(>F)1"] 
    sum <- summary(aov(Intensity ~ as.numeric(zzzanova$Group), data = zzzanova))   
    ANOVAresult[s,3] <- unlist(sum)["Pr(>F)1"] 
    #Conducts the ANOVA for that PCI 
    zzz.aov <- aov(Intensity ~ Group, data = zzzanova) 
    #Assign the summary to an object 
    sum<-summary(zzz.aov) 
    #retreive p-value 
    ANOVAresult[s,4] <- unlist(sum)["Pr(>F)1"] 
    sum <- summary(aov(Intensity ~ as.numeric(zzzanova$Group), data = zzzanova)) 
    ANOVAresult[s,5] <- unlist(sum)["Pr(>F)1"] 
    ANOVAresult[s,6] <- oneway.test(Intensity ~ Group, data = zzzanova, var.equal = FALSE)$p.value 
    KRUSKALresult[s,2] <- kruskal.test(Intensity ~ Group, data = zzzanova)$p.value 
    #TUKEY   
    zzz.aov.tk <- TukeyHSD(zzz.aov)  
    TukeyGroups <- c("PCI", rownames(zzz.aov.tk[[1]])) 
  for (tkrow in 2:length(TukeyGroups)) { 
   for (tkcol in 2:length(ANOVATukeyHead)) { 
    if (TukeyGroups[tkrow] == ANOVATukeyHead[tkcol]) { 
     ANOVATukeyresult[s,tkcol] <- zzz.aov.tk[[1]][(tkrow-1),4] 
    }   
   } 
  }      
        } 
      }   
ANOVATukeyHead <- paste("ANOVA Tukey ", ANOVATukeyHead) 
colnames(ANOVATukeyresult) <- ANOVATukeyHead 
colnames(ANOVAresult)[6] <- "Overall ANOVA P-Value" 
cat("ANOVA Analysis 100% Completed\n") 
 
################ Stage 12 ########################### 
######### Create output files   ##################### 
FullPValues <- cbind(TTestresult, ANOVAresult[,6], ANOVATukeyresult[,-1], KRUSKALresult[,2], 
Wilcoxresult[,-1]) 
FullPValuesColumnNames <- c(colnames(TTestresult), colnames(ANOVAresult)[6], 
colnames(ANOVATukeyresult[,-1]), colnames(KRUSKALresult)[2], colnames(Wilcoxresult[,-1])) 
FullPValues <- apply(FullPValues,2,as.numeric) 
colnames(FullPValues) <- FullPValuesColumnNames  
colnames(FullPValues)[1] = "Feature Identifier" 
FullOutput <- cbind(Meanresult, FeaturePresenceresult[,-1], FoldChange[,-1], FullPValues[,-1]) 
OutputFileName <- paste(ProjectName, "_FullOutput.csv", sep = "") 
write.csv(FullOutput, file = OutputFileName, row.names = FALSE) 
 
################ Stage 13 ######################### 
######## Multiple Testing Correction ############## 
MultipleTestingData <- FullPValues 
MultipleTestingData[,2:(length(MultipleTestingData[1,]))] = 0  
if (MultipleTestingCheck == "y"){ 
 if (MultipleTestingMethod == 1){ 
  MultipleTestingMethod <- "holm" 
  colnames(MultipleTestingData) <- paste("Holm", colnames(FullPValues), sep = "_")  
  }else 
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  { 
  if (MultipleTestingMethod == 2){ 
   MultipleTestingMethod <- "hochberg" 
   colnames(MultipleTestingData) <- paste("Hochberg", colnames(FullPValues), sep = 
"_")  
   }else 
   { 
   if (MultipleTestingMethod == 3){ 
    MultipleTestingMethod <- "hommel" 
    colnames(MultipleTestingData) <- paste("Hommel", 
colnames(FullPValues), sep = "_")  
    }else 
    { 
    if (MultipleTestingMethod == 4){ 
     MultipleTestingMethod <- "bonferroni" 
     colnames(MultipleTestingData) <- paste("Bonferroni", 
colnames(FullPValues), sep = "_")  
     } 
     else 
     { 
     if (MultipleTestingMethod == 5){ 
      MultipleTestingMethod <- "BH" 
      colnames(MultipleTestingData) <- paste("Benjamini-
Hochberg", colnames(FullPValues), sep = "_")  
      }else 
      { 
      if (MultipleTestingMethod == 6){ 
       MultipleTestingMethod <- "BY" 
       colnames(MultipleTestingData) <- 
paste("Benjamini-Yekutieli", colnames(FullPValues), sep = "_")  
       } 
      } 
     } 
    } 
   } 
  } 
      for (pvaltests in 2:length(MultipleTestingData[1,])) { 
         CurrentMTCData <-  as.numeric(FullPValues[,pvaltests]) 
       MultipleTestingData[,pvaltests] <- p.adjust(CurrentMTCData, method = 
MultipleTestingMethod) 
        } 
  CorrectedFullOutput <- cbind(Meanresult, FeaturePresenceresult[,-1], FoldChange[,-1], 
MultipleTestingData[,-1]) 
  FullPValues <- MultipleTestingData 
  CorrectedOutputFileName <- paste(ProjectName, "_", MultipleTestingMethod, "_CorrectedOutput.csv", sep = 
"") 
  write.csv(CorrectedFullOutput, file = CorrectedOutputFileName, row.names = FALSE) 
 } 
 
################ Stage 14 ########################### 
#Create Options File       
 
OptionsFile <- mat.or.vec(8, 2) 
OptionsFile[1,1] <- "Biomarker Hunter Options" 
OptionsFile[2,1] <- "Is the data natural logs?" 
OptionsFile[3,1] <- "Clusterfix used?" 
OptionsFile[4,1] <- "Is Multiple Testing implemented?" 
OptionsFile[5,1] <- "Multiple Testing Method?" 
OptionsFile[6,1] <- "Missing data imputed?" 
OptionsFile[7,1] <- "User defined Minimal Value Imputation used?" 
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OptionsFile[1,2] <- paste("Filename:", DataFile, sep = "") 
OptionsFile[2,2] <- LogsCheck 
OptionsFile[3,2] <- ClusterAlgorithmCheck 
OptionsFile[4,2] <- MultipleTestingCheck 
  if (MultipleTestingCheck == "y"){ 
    OptionsFile[5,2] <- MultipleTestingMethod 
    } 
  if (MultipleTestingCheck == "n"){ 
    OptionsFile[5,2] <- "NA"   
    } 
OptionsFile[6,2] <- MissingValueImputationCheck 
  if (MissingValueImputationCheck == "n"){ 
    OptionsFile[7,2] <- MissingValuesCheck 
      if (MissingValuesCheck == "y"){ 
        OptionsFile[7,2] <- paste(MissingValuesCheck, "(",ReplacementNAsyntax, ")", sep = "") 
        } 
    } 
OptionsFile[8,1] <- "Total Spot Normalisation?"     
OptionsFile[8,2] <- NormalisationCheck 
OptionsFileName <- paste(ProjectName, "_OptionsFile.csv", sep = "") 
write.csv(OptionsFile, file = OptionsFileName, row.names = FALSE) 
 
################ Stage 15 ########################### 
######### Significant biomarkers List ############### 
FullPValues[FullPValues == 0] = "ZERO" 
PotentialBiomarkerList <- FullPValues 
NumberOfMarkers <- "Number of Biomarkers" 
PotentialBiomarkerList[,2:length(PotentialBiomarkerList[1,])] <- "NA"  
PotentialBiomarkerList <-cbind(PotentialBiomarkerList, 
PotentialBiomarkerList[,2:length(PotentialBiomarkerList[1,])]) 
PBListColNumber <- 1 
FullBiomarkerList = NULL 
  for (tests in 2:length(FullPValues[1,])) {  
    SignificantMarkers <- which(FullPValues[,tests] <= 0.05) 
    PBListColNumber <- PBListColNumber + 1 
    colnames(PotentialBiomarkerList) [PBListColNumber] =  colnames(FullPValues)[tests] 
    colnames(PotentialBiomarkerList) [PBListColNumber+1]   = "P-Value" 
      if (length(SignificantMarkers) == 0){ 
        cat("No Potential Biomarkers!\n") 
        NumberOfMarkers <- c(NumberOfMarkers, 0)       
        PotentialBiomarkerList[1,PBListColNumber] <- "No Potential Biomarkers" 
        PBListColNumber <- PBListColNumber + 1 
        PotentialBiomarkerList[1,PBListColNumber] <- "NA" 
        }else 
        { 
        cat("Biomarkers Found!\n") 
        NumberOfMarkers <- c(NumberOfMarkers, length(SignificantMarkers)) 
        SignificantMarkersList <- FullPValues[SignificantMarkers,1] 
        FullBiomarkerList <- c(FullBiomarkerList, SignificantMarkersList) 
        SignificantPValues <- FullPValues[SignificantMarkers, tests]  
        PotentialBiomarkerList[(1:length(SignificantMarkersList)),PBListColNumber] <-SignificantMarkersList 
        PBListColNumber <- PBListColNumber + 1 
        PotentialBiomarkerList[(1:length(SignificantMarkersList)),PBListColNumber] <- SignificantPValues 
        } 
    }  
NumberOfMarkers <-  as.numeric(NumberOfMarkers) 
PotentialBiomarkerList <- PotentialBiomarkerList[1:max(NumberOfMarkers[-1]),-1] 
rownames(PotentialBiomarkerList) <- 1:max(NumberOfMarkers[-1]) 
#Creates a list of significant PCI and their occurence in each test 
FreqOfOccur <-as.data.frame(table(FullBiomarkerList)) 
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colnames(FreqOfOccur)<-c("PCI","Count")  
FreqOfOccur_Sort <- FreqOfOccur[order(-FreqOfOccur$Count, na.last = TRUE) , ] 
colnames(FreqOfOccur_Sort)<-c("Feature Identifier","Positive Tests Count") 
BiomarkerFileName <- paste(ProjectName, "_BiomarkerList.csv", sep = "")  
BiomarkerListFileName  <- paste(ProjectName, "_BiomarkerOccurence.csv", sep = "")  
write.csv(PotentialBiomarkerList, file = BiomarkerFileName, row.names = FALSE) 
write.csv(FreqOfOccur_Sort, file = BiomarkerListFileName, row.names = FALSE) 
# GroupList       
GrouplistFileName <- paste(ProjectName, "_GroupList.csv", sep = "")  
write.csv(GroupSeparator, file = GrouplistFileName, row.names = FALSE) 
GrouplistFile <- read.csv(GrouplistFileName, strip.white = TRUE, na.strings = NA) 
GrouplistColnames <- paste("Group" ,c(1:NumberofGroups)) 
colnames(GrouplistFile) <- GrouplistColnames 
write.csv(GrouplistFile, file = GrouplistFileName, row.names = FALSE) 
 
################ Stage 16 ########################### 
#########             BoxPlots        ############### 
BoxplotsCheck <- readline(prompt = "Would you like to create boxplots for any Feature? (y/n):") 
library(fields) 
  while (BoxplotsCheck  == "y"){ 
    BoxplotsFeature <- readline(prompt = "Which Feature would you like to create a Boxplot for?:") 
    BoxplotsFeature <- as.numeric(BoxplotsFeature) 
    BoxplotsData <- as.numeric(which(PCIList == BoxplotsFeature)) 
    BoxplotsData <- TotalIntensityList[BoxplotsData,] 
    BoxplotsData[which( BoxplotsData == 0 )] <- "NA" 
    BoxplotsData <- as.numeric(BoxplotsData[-1]) 
    BoxplotsHeading <- paste("Tukey boxplot (including outliers) for PCI ", BoxplotsFeature , sep = "") 
    bplot(as.numeric(BoxplotsData), GroupingList, style = "tukey", outlier = TRUE,  
  col="red", main = BoxplotsHeading, 
    xlab = "Groups", ylab = "Intensity", plot = TRUE) 
    BoxplotsFilename <- paste(BoxplotsFeature, "_Boxplot", sep = "") 
    savePlot(filename = "BoxplotsFilename", type = "jpeg", device = dev.cur(), restoreConsole = TRUE) 
    BoxplotsCheck <- readline(prompt = "Create another boxplot for any Feature? (y/n):") 
    } 
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APPENDIX B - Biomarker Hunter – A User Guide  
(All screenshots are from Microsoft Windows XP and will differ on other operating systems) 
Biomarker Hunter is a reliable pipeline software solution, based in the statistical 
programming platform R, which will be utilized for the identification of biomarkers through 
the use of statistical analysis of experimental datasets. It can be used to identify peptides or 
proteins which are differentially expressed following various treatments in order to identify 
the effects of the treatment. This was created as part of an EngD Project undertaken at 
Cranfield University (Patel A. , Bioinformatics Solutions for the Development and 
Evaluation of Statistical Approaches in Proteomic Biomarker Discovery, 2011). For detailed 
discussion about the development of this software package please refer to the thesis. Figure 
73 shows an overview of the Biomarker Hunter pipeline software.  
 
Figure 73 - An overview of the Biomarker Hunter pipeline software. 
 
The pipeline allows the user to analyse data from proteomic biomarker experimental data. It 
offers a variety of data pre-processing options including normalisation, replicate averaging, 
missing value imputation as well as the novel clustering algorithm (ClusterFix) to reduce 
missing data, prior to statistical analysis. The software offers a variety of univariate and 
multivariate statistical analysis methods to analyse the proteomic datasets. Following the 
statistical analysis, the user can implement various methods of multiple testing corrections to 
reduce the occurrence of false positives in the univariate analysis.  
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The user is then presented with the output of results which will be described in this user 
manual. Biomarker Hunter offers a number of data pre-processing options including: 
 Normalisation of technical variance 
 Averaging of technical replicates 
 Missing value treatment  
o Missing value imputation 
o The novel clustering algorithm “ClusterFix”  
Biomarker Hunter offers a range of statistical analysis options: 
 Univariate Analysis (Figure 74) 
 
Figure 74 - An outline of the univariate hypothesis tests implemented for Biomarker 
Hunter showing the parametric and non-parametric alternatives for both one-way and 
group-wise analysis 
 Multivariate Analysis 
o Principal Component Analysis (PCA) 
o Hierarchical Cluster Analysis (HCA) 
 
Subsequent to the analysis, the user has the option to implement multiple testing corrections 
to allow for the error of a large number of statistical tests. These methods are: 
 Bonferroni (Bland & Altman, 1995) 
 Holm (Holm, 1979) 
 Hochberg (Hochberg, 1988) 
 Hommel (Hommel, 1988) 
 Benjamini Hochberg (Benjamini et al, 1995) 
Once this is completed the following files will be available in the results directory 
 ProjectName_FullOutput.csv (Contains the following univariate results) 
o (Mean) Mean value of intensities for each Group 
o FeaturePresence (Number of none NA samples in each group and overall for 
each identifier(PCI, MCI) 
o Foldchange (Fold change between each group) 
o TTest  (Welch T-test p-values between each group) 
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o Wilcox  (Wilcoxon Mann Whitney test p-values between each group) 
o ANOVA (Welch Anova p-values) including Post-hoc Tukey p-values  
o Kruskall (Kruskall Wallis p-values between all groups) 
o ProjectName_BiomarkerList.csv (A list of feature identifiers with a p-value 
below 0.05 for each test conducted) 
o ProjectName_OptionsFile.csv (A table presenting the used options for the 
software) 
o ProjectName_BiomarkerOccurence.csv (The occurrence of features identified 
as biomarkers between the univariate tests) 
 
IF THE CLUSTERFIX OPTION IS USED THEN THE FOLLOWING FILES WILL ALSO 
BE AVAILABLE 
 ProjectName_ClusteredData.csv (A copy of the dataset after the clustering has been 
conducted) 
 ProjectName_ClusteringInformaftion.csv (A output file which identifies which PCI’s 
are clustered with which others) 
 ProjectName_ClusterComparison.csv (Statistics illustrating the effectiveness of the 
clustering algorithm) 
 
IF THE MULTIVARIATE OPTION IS USED THEN THE FOLLOWING FILES WILL 
ALSO BE AVAILABLE 
 ProjectName_PCA.jpg (A PCA plot) 
 ProjectName_HCA.jpg (A HCA dendrogram) 
 
 
 
 
 
 
 
 
Step by Step Guide 
1. To use the Biomarker Hunter pipeline software the machine must first have the 
statistical programming language R installed. If this is not the case R can be installed 
from one of the CRAN mirrors found at (http://www.r-project.org/). 
 
2. Once R is installed, an instance of the R console needs to be opened which should 
look like Figure 75: 
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Figure 75 - R Console 
3.  Using the commands – File>Change dir.....  set the working directory to the 
directory in which the software file named BiomarkerHunter.r is stored. 
4. In the R console now type the command  
> source("BiomarkerHunter.r") 
 
5. You will then be prompted to enter a project name which will then be used to identify 
any output files. This may contain any valid filename characters (i.e. You can't use 
any of the following characters in a file name: \ / ? : * " > < |) 
Enter the Project name to identify Output Files: 
 
6. Select the file containing the dataset you would like to analyse using Biomarker 
Hunter using the pop up browser (Figure 76): 
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Figure 76 - Data file pop-up selection box 
 
The software package contains a file which can be used for test purposes named 
BHTestdataset.csv. The dataset must be in a comma separated file format which, if 
not available, can easily be created using excel or a similar spreadsheet solution. The 
first column should be an identifier for each feature (protein, peptide or gene etc.). 
The following columns should contain the abundance of each protein for each sample. 
If the dataset contains mass and retention time data, these columns should be placed 
after the sample intensity columns. The samples do not necessarily have to be in a 
particular order as the data will be sorted by the software. Additional rows of 
information above the data are allowed which can be removed using this software.  
Table 60 shows an outline of how an acceptable dataset should be structured. 
Takeda2_all_files
AKTestdataset2.csv
1 2 X
PCI Sample 1 Sample 2 Sample X Mass data RT Data
1 Intensity S1 Intensity S2 Intensity SX Mass PCI 1 RT PCI 1
2 Intensity S1 Intensity S2 Intensity SX Mass PCI 2 RT PCI 2
3 Intensity S1 Intensity S2 Intensity SX Mass PCI 3 RT PCI 3
4 Intensity S1 Intensity S2 Intensity SX Mass PCI 4 RT PCI 4  
Table 60 - Outline of an acceptable dataset .csv file (Mass and RT columns are optional) 
7. You will then be asked to identify the missing values in the dataset by imputing the 
syntax given to the missing values (i.e. NA, N/A, 0 or other minimal values). (Use 
“0” for BHTestdataset.csv) 
Enter the code given to NA values: 
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8. The following prompt allows the user to remove any additional rows above the actual 
data by asking for the row number of the first row of data. IF YOU ARE VIEWING 
THE FILE IN EXCEL, ONE ROW WILL BE USED AS A HEADER SO YOU 
SHOLD USE (ROW NUMBER – 1). (Use “6” for BHTestdataset.csv (In excel the 
first data row is contained in row 7))  
Which row contains the first set of data values?: 
 
9. You will then be prompted for the total number of samples being analysed with the 
prompt below: (Use “24” for BHTestdataset.csv) 
Enter the total number of samples in the dataset : 
 
10. You will then be prompted for the number of different sample groups: (Use “4” for 
BHTestdataset.csv) 
Enter the number of different groups being compared: 
 
11. You will be presented with two options for the extraction of samples into their 
respective groups. This can either be done manually or using a grouping file. 
 
Would you like to enter data 1)Manually or 2)Using Grouping script: 
 
If Option 1 is used you would be asked for the number of samples in each group as 
well the corresponding column numbers for each sample in the group  (each column 
number must be entered individually):  
Enter the number of samples in Group 1: 
Enter column number containing Group 1 - Sample 1: 
For BHTestdataset.csv, each group has 6 samples, with the columns assigned as 
specified below (note that column 1 is the identifier). 
 Group 1 : 2, 3, 4, 5, 6, 7 
 Group 2 : 8, 9, 10, 11, 12, 13 
 Group 3 : 14, 15, 16, 17, 18, 19 
 Group 4 : 20, 21, 22, 23, 24, 25 
 
If Option 2 is used you can provide the location of a grouping file. A grouping file is a 
.csv file with two columns with column headers (Figure 77). The first column will 
state the group identifier (A name or number referencing the group, which will be the 
same for each sample in the group). The second column will identify the column 
numbers of the samples in all the groups. 
 
 
Group 
Identifier 
Column 
Number 
A 2 
B 3 
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C 4 
A 5 
B 6 
C 7 
Figure 77 - An example of a grouping file 
12. You will be prompted (Figure 78) to specify the folder in which to store results: 
Ideally a newly created folder should be used. 
 
Figure 78 - Results folder pop-up selection box 
13. If the data has been normalised previously using natural logarithms (log) then this 
needs to be specified. (Use “n” for BHTestdataset.csv) 
Are the data natural logarithms ? (y/n)[Case sensitive]: 
 
14. If normalisation is required, the software offers normalisation through the Total Spot 
Normalisation (TSN). (Use “y” for BHTestdataset.csv) 
This involves using the formula: 
 
NInt =   Intensity of PCI n 
TOTInt =  Total Intensity of all the PCI’s in the sample(column) 
Scaling = A factor by which all values are multiplied to allow for extremely 
small numbers 
Normalise the data using TSN (Total Spot Normalisation)? (y/n)[Case sensitive]: 
15. The aim of the Clusterfix Option is to reduce the number of missing values. It aims to 
achieve this by searching for PCIs which lie within user-specified mass and retention 
time windows and share a similar pattern with regards to missing values. This requires 
mass and retention time data. (Use “y” for BHTestdataset.csv) 
Use Clusterfix to reduce missing values? (y/n):  
If Clusterfix is used then you will be asked for the columns with the mass and 
retention time (RT) data. (Use “26” = mass and “27” = RT for BHTestdataset.csv). 
Which column contains the Mass data?: 
Which column contains the Retention Time (RT) data?: 
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You will then be asked for the tolerance levels for mass and retention time. (Use 
“0.1” = mass and “0.5” = RT for BHTestdataset.csv). 
Mass tolerance level (+/-) you would like to use?: 
Retention time tolerance level (+/-) you would like to use?: 
 
16. The Biomarker Hunter pipeline software offers six methods for multiple testing 
corrections. Implement Multiple Testing Correction methods? (y/n)Case sensitive: 
(Use “y” for BHTestdataset.csv). If Multiple Testing will be used then you will be 
asked for the number relating to the method to be used. 
1(holm), 2(hochberg), 3(hommel), 4(bonferroni), 5(BH), 6(BY) 
Which Multiple Testing method to apply? 
 
17. The Biomarker Hunter software allows the imputation of missing values that cannot 
be fixed using the Clusterfix option. The imputation method depends on the feature 
presence of the PCI. These methods are explained in detail in the thesis. 
Low feature presence (i.e below 26%) -> Minimal Value Imputation (MIN) 
Feature presence between 26% and 74% -> Repeated Median (REPMED) 
High feature presence (i.e. above 74%) -> k-nearest neighbours (KNN) 
 (Use “y” for BHTestdataset.csv) 
Impute missing values? (y/n): 
If Imputation is not chosen then it is possible for the user to choose a minimal value to 
replace all NA values. 
Replace missing values (NA) with an arbitrary value? (y/n)[Case sensitive]: 
(if (y) then -> Syntax You want to give to all NA values: 
 
18. Once the final column number has been entered the first stage of the analysis (Welch 
T-Test and Wilcoxon test) will begin. The R display will keep you updated as to 
which stage of the analysis is being conducted, like this: 
Calculating Group Means...... PLEASE WAIT 
Calculating Feature Presence...... PLEASE WAIT 
Group  1  Analysis ...... PLEASE WAIT 
Group  1 vs 2  Analysis ...... PLEASE WAIT 
25% Completed............. 
50% Completed............. 
75% Completed............. 
Analysis 100% Completed 
This will continue until each group has been compared with every other group and the 
user will then be informed that certain files are now available in their set results 
directory. 
19. The second stage (ANOVA and Kruskall Wallis) of the analysis will then be 
conducted while the user is presented with the progress: 
Conducting ANOVA........Please Wait 
25% Completed............. 
50% Completed............. 
75% Completed............. 
ANOVA Analysis 100% Completed 
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20. Once this is completed the files described earlier will be available in the results 
directory. 
 
21. Biomarker Hunter gives the user the option to create boxplots for features of interest 
following the statistical analysis. Boxplots are a good method for displaying groups of 
data for visual comparison. An illustration of the principle of boxplots is shown in  
Figure 79. 
 
Figure 79 - An example of a boxplot illustrating what the various points of the boxplot 
represent. 
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APPENDIX C – PLSDA Portion of Biomarker Hunter 
########## Stage 7  ############################### 
######### Do PLS######## ################### 
###################################################     
PLSdata <- data.frame(GroupingList = GroupingList, PCIList = I(FullDataListTrans)) 
#PLS_BigData <- big.matrix(data.frame(GroupingList = GroupingList, PCIList = I(FullDataListTrans))) 
 
#BHPLS1 <- plsr(GroupingList ~ PCIList, ncomp = 10, data = PLSdata, jackknife = False, validation = "LOO") 
#do plsr , enable jackknife 
BHPLS1 <- plsr(GroupingList ~ PCIList, ncomp = 10, data = PLSdata, jackknife = TRUE, validation = "LOO") 
#conduct jack knife on plsr result 
BHPLS1_Jackknife <- jack.test(BHPLS1,ncomp = BHPLS1$ncomp, use.mean = TRUE) 
#BHPLS1_Jackknife <- jack.test(BHPLS1, P.values = TRUE,ncomp = BHPLS1$ncomp, use.mean = TRUE) 
#extract pvalues from jackknife result 
BHPLS1_Pvalues <- BHPLS1_Jackknife$pvalues 
 
NewDataList <- FullDataListTrans 
CurrentPCIList <- PCIList 
#Now to create a loop to repeat until point of convergence 
  while (any(BHPLS1_Pvalues >= 0.05)) { 
  SignificantPCI_Columns <- which(BHPLS1_Pvalues <= 0.05) 
  CurrentPCIList <- CurrentPCIList[SignificantPCI_Columns] 
  NewDataList <-  NewDataList[,SignificantPCI_Columns] 
  NewPLSdata <- data.frame(GroupingList = GroupingList, PCIList = I(NewDataList)) 
  BHPLS1 <- plsr(GroupingList ~ PCIList, ncomp = 10, data = NewPLSdata, jackknife = TRUE, validation = 
"LOO") 
  #conduct jack knife on plsr result 
  BHPLS1_Jackknife <- jack.test(BHPLS1,ncomp = BHPLS1$ncomp, use.mean = TRUE) 
  #extract pvalues from jackknife result 
  BHPLS1_Pvalues <- BHPLS1_Jackknife$pvalues 
  } 
Potential_Biomarkers <- cbind(CurrentPCIList,BHPLS1_Pvalues)   
    #identify p-values which are considered significant 
 
Page | XL  © Cranfield University, 2011 
 
APPENDIX D – Statistical Reference Tables 
Student's t-Table 
(Obtained from www.statsoft.com) 
 
The Shape of the Student's t distribution is determined by the degrees of freedom. As shown 
in the animation above, its shape changes as the degrees of freedom increases. For more 
information on how this distribution is used in hypothesis testing, see t-test for independent 
samples and t-test for dependent samples in the chapter on Basic Statistics and Tables. See 
also, Student's t Distribution. As indicated by the chart below, the areas given at the top of 
this table are the right tail areas for the t-value inside the table. To determine the 0.05 critical 
value from the t-distribution with 6 degrees of freedom, look in the 0.05 column at the 6 row: 
t(.05,6) = 1.943180.  
 
 
 
 
 
 
 
 
 
 
 
 
t-table (normal distribution) http://davidmlane.com/hyperstat/t_table.html 
t table with right tail probabilities 
 
df\p 0.40  0.25  0.10  0.05  0.025  0.01  0.005  0.0005  
1  0.324920 1.000000 3.077684 6.313752 12.70620 31.82052 63.65674 636.6192 
2  0.288675 0.816497 1.885618 2.919986 4.30265 6.96456 9.92484 31.5991 
3  0.276671 0.764892 1.637744 2.353363 3.18245 4.54070 5.84091 12.9240 
4  0.270722 0.740697 1.533206 2.131847 2.77645 3.74695 4.60409 8.6103 
5  0.267181 0.726687 1.475884 2.015048 2.57058 3.36493 4.03214 6.8688 
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z-table 
Obtained from http://www.intmath.com/Counting-probability/z-table.php 
The following z-Table indicates the area to the right of the vertical centre-line of the z-curve 
(or standard normal curve) for different standard deviations. 
Example 
The green shaded area in the diagram below represents 1.45 standard deviations from the 
mean (which is 0). The area of this shaded portion is 0.4265 (or 42.65% of the total area 
under the curve). 
To get this area, we read down the left side of the table for the standard deviation's first 2 
digits (the whole number and the first number after the decimal point, in this case 1.4), then 
we read across the table for the "0.05" part (the top row represents the 2nd decimal place of 
the standard deviation that we are interested in.)  
z 0.00 0.01 0.02 0.03 0.04 0.05 0.06 
1.4 0.4192 0.4207 0.4222 0.4236 0.4251 0.4265 0.4279 
We have: 
(left column) 1.4 + (top row) 0.05 = 1.45 standard deviations 
The area represented by 1.45 standard deviations to the right of the mean is shaded in green 
in the following standard normal curve. 
 
You can see how to find the appropriate value in the full z-table below. 
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z 0.00 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 
0.0 0.0000 0.0040 0.0080 0.0120 0.0160 0.0199 0.0239 0.0279 0.0319 0.0359 
0.1 0.0398 0.0438 0.0478 0.0517 0.0557 0.0596 0.0636 0.0675 0.0714 0.0753 
0.2 0.0793 0.0832 0.0871 0.0910 0.0948 0.0987 0.1026 0.1064 0.1103 0.1141 
0.3 0.1179 0.1217 0.1255 0.1293 0.1331 0.1368 0.1406 0.1443 0.1480 0.1517 
0.4 0.1554 0.1591 0.1628 0.1664 0.1700 0.1736 0.1772 0.1808 0.1844 0.1879 
0.5 0.1915 0.1950 0.1985 0.2019 0.2054 0.2088 0.2123 0.2157 0.2190 0.2224 
0.6 0.2257 0.2291 0.2324 0.2357 0.2389 0.2422 0.2454 0.2486 0.2517 0.2549 
0.7 0.2580 0.2611 0.2642 0.2673 0.2704 0.2734 0.2764 0.2794 0.2823 0.2852 
0.8 0.2881 0.2910 0.2939 0.2967 0.2995 0.3023 0.3051 0.3078 0.3106 0.3133 
0.9 0.3159 0.3186 0.3212 0.3238 0.3264 0.3289 0.3315 0.3304 0.3365 0.3389 
1.0 0.3413 0.3438 0.3461 0.3485 0.3508 0.3531 0.3554 0.3577 0.3599 0.3621 
1.1 0.3643 0.3665 0.3686 0.3708 0.3729 0.3749 0.3770 0.3790 0.3810 0.3830 
1.2 0.3849 0.3869 0.3888 0.3907 0.3925 0.3944 0.3962 0.3980 0.3997 0.4015 
1.3 0.4032 0.4049 0.4066 0.4082 0.4099 0.4115 0.4131 0.4147 0.4162 0.4177 
 
